

BENZO[1,2,5]THIADIAZOLE COMPOUNDS

159159

Field of the Invention

There is provided by the present invention compounds that are CCK2
5 receptor modulators. More particularly, there is provided by the present
invention benzo[1,2,5]thiadiazoles that are CCK2 receptor modulators useful
for the treatment of disease states mediated by CCK2 receptor activity.

Background of the Invention

10 This invention relates to gastrin and cholecystokinin (CCK) receptor
ligands. The invention also relates to methods for preparing such ligands and
to compounds that are useful intermediates in such methods. The invention
further relates to pharmaceutical compositions comprising such ligands and
methods for preparing such pharmaceutical compositions.

15 The gastrins and cholecystokinins are structurally related neuropeptides
that exist in gastrointestinal tissue, gastrinomas and, in the case of the
cholecystokinins, the central nervous system (J.H. Walsh, *Gastrointestinal
Hormones*, L.R. Johnson, ed., Raven Press, New York, 1994, p. 1).

Several forms of gastrin are found including 34-, 17- and 14-amino acid
20 species with the minimum active fragment being the C-terminal tetrapeptide
(TrpMetAspPhe-NH₂), which is reported in the literature to have full
pharmacological activity (H.J. Tracy and R.A. Gregory, *Nature (London)*, 1964,
204:935-938). Much effort has been devoted to the synthesis of analogs of this
tetrapeptide (and the N-protected derivative Boc-TrpMetAspPhe-NH₂) in an
25 attempt to elucidate the relationship between structure and activity.

Natural cholecystokinin is a 33 amino acid peptide (CCK-33), the C-
terminal 5 amino acids of which are identical to those of gastrin. Also found
naturally is the C-terminal octapeptide (CCK-8) of CCK-33. A review of CCK
receptors, ligands and the activities thereof may be found in P. de Tullio et al.
30 (*Exp. Opin. Invest. Drugs*, 2000, 9(1):129-146).

Gastrin and cholecystokinin are key regulators of gastrointestinal
function. In addition, cholecystokinin is a neurotransmitter in the brain. Gastrin
is one of the three primary stimulants of gastric acid secretion. In addition to



the acute stimulation of gastric acid, gastrin has a trophic effect on the gastrointestinal mucosa and is implicated as a trophic hormone of several adenocarcinomas, including pancreatic, colorectal, esophageal and small cell lung.

5 Cholecystokinin stimulates intestinal motility, gallbladder contraction and pancreatic enzyme secretion, and is known to have trophic actions on the pancreas thus increasing, inter alia, pancreatic enzyme production.

Cholecystokinin also inhibits gastric emptying and has various effects in the central nervous system, including regulation of appetite and pain.

10 Gastrin acts on CCK2 (otherwise known as gastrin/CCK-B receptors) whereas cholecystokinin acts on both CCK2 and CCK1 receptors (otherwise known as cholecystokinin/CCK-A receptors). Compounds that bind to cholecystokinin and/or gastrin receptors are important because of their potential pharmaceutical use as antagonists of the natural peptides or mimetics,
15 of the natural peptides acting as partial or full agonists at the cholecystokinin and/or gastrin receptors. A selective gastrin receptor antagonist has not yet been marketed. However, several are currently undergoing clinical evaluation. JB95008 (gastrazole) is being developed by The James Black Foundation and Johnson & Johnson Pharmaceutical Research and Development LLC for the
20 potential treatment of advanced pancreatic cancer (pancreatic adenocarcinoma), and is currently in Phase II clinical trials. ML Laboratories and Panos are developing L-365,260 (Colycade), which is in Phase II clinical trials for pain. Other potential indications included eating disorders and cancer. YF-476 (formerly YM-220), under joint development by Yamanouchi and
25 Ferring Research Institute, is in Phase I clinical trials for gastro-esophageal reflux disease (GERD). In Phase I trials, Zeria Pharmaceutical is investigating Z-360, an orally available 1,5-benzodiazepine derivative (WO-09825911), as a potential treatment for gastroduodenal ulcers and reflux esophagitis. CR 2945 (itriglumide), an orally active anthranilic acid derivative, has been investigated
30 by Rotta in Phase I trials for anxiety disorders, cancer (particularly colon cancer) and peptic ulcer.


Gastrimmune, Apton Corporation's anti-gastrin vaccine, which works by chemical neutralization of the hormone, is undergoing late stage clinical trials for cancer indications, in particular, pancreatic and gastric tumors.

In addition to those indications described above, gastrin (CCK2) antagonists have been proposed for the following gastrin-related disorders: gastrointestinal ulcers, Barrett's esophagus, antral G cell hyperplasia, pernicious anaemia, Zollinger-Ellison syndrome and other conditions in which lower gastrin activity or lower acid secretion is desirable.

Cholecystokinin (CCK1) receptors have been shown to mediate cholecystokinin-stimulated gallbladder contraction, pancreatic enzyme secretion, satiety, gastric emptying inhibition and regulation of peristalsis, indicating a key role in the integrated physiological gastrointestinal response to a meal. In addition, there is evidence that cholecystokinin receptors mediate a mitogenic action of cholecystokinin on some adenocarcinomas. Consequently, selective cholecystokinin receptor antagonists, for example, devazepide (Merck), lorglumide (Rotta), 2-NAP (JBF), dexloxiglumide (Rotta) and lintitript (Sanofi) have been examined in the clinic for potential applications in, inter alia, irritable bowel syndrome, chronic constipation, non-ulcer dyspepsia, acute and chronic pancreatitis, biliary disease and pancreatic cancer. Additional roles of cholecystokinin receptors include the regulation of appetite and metabolism, indicating potential therapeutic applications in the treatment of disorders such as obesity and anorexia nervosa. Other possible uses are in the potentiation of opiate (for example, morphine) analgesia and in the treatment of cancers, especially of the pancreas. Moreover, ligands for cholecystokinin/gastrin receptors in the brain have been claimed to possess anxiolytic activity, and gastrin receptor antagonists would be expected to act as neurological agents towards the relief of anxiety and related neuroses and psychoses.

Summary of the Invention

The invention features a compound of formula (I):



wherein

R^1 and R^2 are each independently selected from the group consisting of

a) H, C_{1-7} alkyl, C_{2-7} alkenyl, C_{2-7} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl, benzo-fused C_{4-7} cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C_{3-7} cycloalkyl C_{1-7} alkyl,

b) naphthyl- (CR^s_2) -, benzoyl C_{0-3} alkyl- (CR^s_2) -, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f , phenyl- (CR^s_2) -, said phenyl optionally fused at two adjacent carbon atoms to R^f ,

R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

c) Ar^6 -(CR^s_2)-, where Ar^6 is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused or pyrido fused,

d) Ar^5 -(CR^s_2)-, where Ar^5 is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC $_{1-4}$ alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzo fused or pyrido fused,

e) Ar^{6-6} -(CR^s_2)-, where Ar^{6-6} is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are -N=,

f) Ar^{6-5} -(CR^s_2)-, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC $_{1-4}$ alkyl and having 0 or 1 additional heteroatom member which is -N=,

g) C₁₋₄alkylO- and HSC₁₋₄alkyl,

where R¹ and R² are not simultaneously H and, except in positions where

R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q,

R^q is independently selected from the group consisting of C₁₋₄alkyl,

5 hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl,
C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO-C₁₋₄alkyl,
C₁₋₄alkylO-C₁₋₄alkyl, HS-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy and
C₁₋₄alkylS-,

R^s is independently selected from the group consisting of hydrogen,

10 C₁₋₄alkyl, trifluoromethyl, aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl,
diC₁₋₄alkylaminoC₁₋₄alkyl, HO-C₁₋₄alkyl, HS-C₁₋₄alkyl, C₁₋₄alkylS-
C₁₋₄alkyl and phenyl;

or, alternatively,

R¹ and R² may be taken together with the nitrogen to which they are attached

15 and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.0^{2,6}]dec-4-yl, optionally mono- or
di-substituted with R^p,

R^p is independently selected from the group consisting of hydroxy,

20 C₁₋₄alkyl, hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted
phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1
additional heteroatom members separated from the nitrogen of
attachment by at least one carbon member and selected from O, S,
-N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1
25 or 2 carbon members which is a carbonyl, optionally having one
carbon member which forms a bridge and having 0, 1 or 2
substituents R^p,

iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring
having 0 or 1 additional heteroatom members separated from the
30 nitrogen of attachment by at least one carbon member and selected
from O, S, -N=, >NH or >NR^p, having 0 or 1 additional unsaturated
bonds, having 0, 1 or 2 carbon members which is a carbonyl, having

0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R^p ,

iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^p ;

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^p ;

R^a is, independently, selected from the group consisting of -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC₁₋₆alkyl, -SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO₂, -N(R^y)R^z (wherein R^y and R^z are independently selected from H, C₁₋₄alkyl or C₁₋₆cycloalkylC₁₋₄alkyl), -(C=O)C₁₋₄alkyl, -SCF₃, halo, -CF₃, -OCF₃, and -COOC₁₋₄alkyl, or, alternatively, two adjacent R^a , may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R^b is, independently, selected from the group consisting of -C₁₋₄alkyl and halogen;

and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

The invention also features pharmaceutical compositions containing such compounds and methods of using such compositions in the treatment or prevention of disease states mediated by CCK2 receptor activity.

Detailed Description

Preferably, R¹ and R² are, independently, selected from the group consisting of

- 5 a) H, C₁₋₇alkyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl, cyclobutylC₁₋₄alkyl, cyclopentylC₁₋₄alkyl, cyclohexylC₁₋₄alkyl, cycloheptylC₁₋₄alkyl,
- 10 b) phenyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-yl, optionally 5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3 or 4-yl, optionally 5,6,7 or 8 oxo substituted, benzyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-ylmethyl, optionally 5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3 or 4-ylmethyl, optionally 5,6,7 or 8 oxo substituted,
- 15 substituted, 1-phenyleth-1-yl, benzhydryl, naphthylmethyl, benzoylmethyl, 1-benzoyleth-1-yl,
- c) pyridylmethyl, pyrazinylmethyl, pyrimidinylmethyl, pyridazinylmethyl, quinolin-2,3 or 4-ylmethyl, isoquinolin-1,3 or 4-ylmethyl, quinazolin-2 or 4-ylmethyl, quinoxalin-2 or 3-ylmethyl,
- 20 d) furanylmethyl, thiophenylmethyl, 1-(H or C₁₋₄alkyl)pyrrolylmethyl, oxazolylmethyl, thiazolylmethyl, pyrazolylmethyl, imidazolylmethyl, isoxazolylmethyl, isothiazolylmethyl, benzofuran-2 or 3-ylmethyl, benzothiophen-2 or 3-ylmethyl, 1-(H or C₁₋₄alkyl)-1H-indol-2 or 3-ylmethyl, 1-(H or C₁₋₄alkyl)-1H-benzimidazol-2-ylmethyl, benzooxazol-2-ylmethyl,
- 25 benzothiazol-2-ylmethyl,
- e) quinolin-5,6,7 or 8-ylmethyl, isoquinolin-5,6,7 or 8-ylmethyl, quinazolin-5,6,7 or 8-ylmethyl, quinoxalin-5,6,7 or 8-ylmethyl,
- f) benzofuran-4,5,6 or 7-ylmethyl, benzothiophen-4,5,6 or 7-ylmethyl, 1-(H or C₁₋₄alkyl)-1H-indol-4,5,6 or 7-ylmethyl, 1-(H or C₁₋₄alkyl)-1H-benzimidazol-4,5,6 or 7-ylmethyl, benzooxazol-4,5,6 or 7-ylmethyl, benzothiazol-4,5,6 or 7-ylmethyl,
- 30 g) C₁₋₄alkylo- and HSC₁₋₄alkyl,


where each of a) to g) is substituted with 0, 1, 2, or 3 of R^q.

Most preferably, R^1 and R^2 are, independently, selected from the group consisting of hydrogen, methyl, ethyl, butyl, hexyl, phenyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl, optionally 5,6,7,8 or 9 oxo substituted, benzyl, 1-phenyleth-1-yl, furanylmethyl, benzoylethyl, 1-benzoyleth-1-yl, methylO-,
 5 cyclohexyl, cyclohexylmethyl, pyridylmethyl, naphthylmethyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, benzhydryl, where each member is substituted with 0, 1, 2, or 3 of R^q .

Specific R^1 and R^2 are, independently, selected from the group consisting of hydrogen, methyl, ethyl, butyl, phenyl, benzyl, 2-bromobenzyl,
 10 2-chlorobenzyl, 4-chlorobenzyl, 2,4-dichlorobenzyl, 3,4-dichlorobenzyl, 2,6-dichlorobenzyl, 2,4,6-trichlorobenzyl, 2-fluorobenzyl, 4-fluorobenzyl, 2,4-difluorobenzyl, 2,6-difluorobenzyl, 2,4,6-trifluorobenzyl, 2-chloro-4-fluorobenzyl, 2-fluoro-4-bromobenzyl, 2-fluoro-4-chlorobenzyl, 2-methylbenzyl, 2-methylsulfanylbzyl, 2-trifluoromethylbenzyl,
 15 1-phenyleth-1-yl, 1-phenylprop-1-yl, 1-(4-bromophenyl)eth-1-yl, 1-(4-fluorophenyl)eth-1-yl, 1-(2,4-dibromophenyl)eth-1-yl, 1-(2,4-dichlorophenyl)eth-1-yl, 1-(3,4-dichlorophenyl)eth-1-yl, 1-(2,4-difluorophenyl)eth-1-yl, 1-(4-methylphenyl)eth-1-yl, 1-methyl-1-phenyleth-1-yl, 1-phenyl-2-dimethylaminoeth-1-yl, 1-benzoyleth-1-yl,
 20 cyclohexyl, 1-cyclohexyleth-1-yl, furan-2-ylmethyl, naphth-1-ylmethyl, methoxy, methylthioethyl, 6-methyl-6-hydroxyhept-2-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 1-phenyl-2-hydroxyeth-1-yl, benzhydryl, 4-hydroxymethylpiperidin-1-yl, and --9-oxo-6;7;8,9-tetrahydro-5H-benzocyclohepten-2-yl.

It is preferred that one of R^1 and R^2 is H or C_{1-4} alkyl where the other is
 25 not H or C_{1-4} alkyl. It is also preferred that one of R^1 and R^2 is H, methyl or ethyl.

In another preferred embodiment, at least one of R^1 and R^2 are selected from the groups consisting of



where R^s is not hydrogen, said phenyl is optionally fused at two adjacent carbon atoms to R^f and, except in positions where R^s is indicated, each member is substituted with 0, 1, 2, or 3 of R^q .

Preferably, R^f is selected from the group consisting of $-CH_2CH_2CH_2-$,
 5 $-CH_2CH_2CH_2CH_2CH_2-$ and $-(C=O)CH_2CH_2CH_2-$.

Preferably, R^s is selected from the group consisting of hydrogen, methyl, ethyl, propyl, trifluoromethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, methoxymethyl, thiomethyl, methylthiomethyl and phenyl.

10 Most preferably, R^s is selected from the group consisting of H, methyl, ethyl, hydroxymethyl and dimethylaminomethyl.

Preferably, R^q is selected from the group consisting of methyl, ethyl, propyl, t-butyl, hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl,
 15 methoxymethyl, thiomethyl, methylthiomethyl, methoxy, ethoxy, methylmercapto and ethylmercapto.

Most preferably, R^q is selected from the group consisting of methyl, hydroxy, fluoro, chloro, bromo, iodo and trifluoromethyl.

Preferably, R^1 and R^2 taken together with the nitrogen to which they are
 20 attached are selected from the group consisting of

- i) 10-Oxa-4-aza-tricyclo[5.2.1.0^{2,6}]dec-4-yl,
- ii) 2-pyrrolin-1-yl, 3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl, 3-(H or R^p)imidazolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 3-(H or R^p)piperazin-1-yl, azepan-1-yl, thiazolidin-3-yl, oxazolidin-3-yl, 2,5-dihydro-
 25 pyrrol-1-yl, azetidin-1-yl, where each member of ii) in each ring has 0 or 1 unsaturated bond and has 0, 1 or 2 carbon members which is a carbonyl,
- iii) 3,4-dihydro-2H-quinolin-1-yl, 3,4-dihydro-2H-quinolin-2-yl, 2,3-dihydro-indol-1-yl, 1,3-dihydro-isoindol-2-yl, 1-oxo-1,3-dihydro-isoindol-2-yl, tetrahydro-benzo[b, c or d]azepin-1-yl, where each member of iii) in each ring
 30 has 0 or 1 unsaturated bond and has 0, 1 or 2 carbon members which are a carbonyl,

iv) decahydro-quinolin-1-yl, octahydro-isoquinolin-2-yl, octahydro-[1 or 2]pyrindin-1 or 2-yl, octahydro-indol-1-yl, octahydro-isoindol-2-yl, hexahydro-

cyclopenta[b]pyrrol-1-yl, hexahydro-cyclopenta[c]pyrrol-2-yl, (5,6,7 or 8-H or R^P)-decahydro-[1,5 or 1,6 or 1,7 or 1,8]naphthyridin-1-yl, (5,6,7 or 8-H or R^P)-decahydro-[2,5 or 2,6 or 2,7 or 2,8]naphthyridin-2-yl, 1-H or R^P-octahydro-pyrrolo[2,3-c]pyridin-6-yl, 2-H or R^P-octahydro-pyrrolo[3,4-c]pyridin-5-yl, 1-H or
 5 R^P-octahydro-pyrrolo[3,2-c]pyridin-5-yl, 1-H or R^P-octahydro-pyrrolo[2,3-b]pyridin-7-yl, 6-H or R^P-octahydro-pyrrolo[3,4-b]pyridin-1-yl, 1-H or R^P-octahydro-pyrrolo[3,2-b]pyridin-4-yl, 5-H or R^P-octahydro-pyrrolo[3,4-c]pyridin-2-yl, 6-H or R^P-octahydro-pyrrolo[2,3-c]pyridin-1-yl, 1-H or R^P-octahydro-pyrrolo[3,4-b]pyridin-6-yl, 7-H or R^P-octahydro-pyrrolo[2,3-b]pyridin-1-yl,
 10 octahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, where each member of iv) in each ring has 0, 1 or 2 carbon members which is a carbonyl, each ring of attachment has 0 or 1 unsaturated bonds and each secondary ring has 0, 1 or 2 unsaturated bonds,

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,
 15 where each member of i), ii), iii), iv) or v) is further substituted with 0, 1 or 2 of R^P.

Most preferably, R¹ and R² taken together with the nitrogen to which they are attached are selected from the group consisting of 10-oxa-4-azatricyclo[5.2.1.0^{2,6}]dec-4-yl, 2-pyrrolin-1-yl, 3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl, imidazolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl, azepan-1-yl, thiazolidin-3-yl, oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl, 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, azetidin-1-yl, octahydro-quinolin-1-yl, 3,4-dihydro-2H-quinolin-1-yl, 3,4-dihydro-2H-quinolin-2-yl, where each member is further substituted with 0, 1 or 2 of R^P.
 25

Specific R¹ and R² taken together with the nitrogen to which they are attached are selected from the group consisting of 1-methyl-10-oxa-4-azatricyclo[5.2.1.0^{2,6}]dec-4-yl, azetidin-1-yl, pyrrolidin-1-yl,
 30 2-hydroxymethylpyrrolidin-1-yl, 2,4-dimethyl-3-ethylpyrrolidin-1-yl, piperidin-1-yl, 2-methylpiperidin-1-yl, 4-hydroxymethylpiperidin-1-yl, 4-phenylpiperidin-1-yl, azepan-1-yl, 4-(2-hydroxyphenyl)piperazin-1-yl, morpholin-4-yl, octahydro-isoquinolin-2-yl, decahydro-quinolin-1-yl, thiazolidin-3-yl, 2,5-dimethyl-2,5-

dihydro-pyrrol-1-yl, 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl and 3,4-dihydro-2H-quinolin-2-yl.

Preferably, R^p is selected from the group consisting of hydroxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, phenyl, p-halophenyl, m-halophenyl, o-halophenyl, and p-hydroxyphenyl.

Most preferably, R^p is selected from the group consisting of hydroxy, methyl, ethyl, hydroxymethyl, hydroxyethyl, phenyl, mono-fluorosubstituted phenyl and mono-chlorosubstituted phenyl.

Preferably, R^a is selected from the group consisting of methyl, ethyl, propyl, ethenyl, propenyl, cyclopropyl, cyclobutyl, phenyl, furanyl, thienyl, pyrrol-1-yl, benzyl, hydroxy, methoxy, ethoxy, propoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, phenoxy, benzoxy, -SH, -Smethyl, -Sethyl, -S-t-butyl, -Scyclopropyl, -Sphenyl, -Sbenzyl, -NO₂, -CN, amino, dimethylamino, (cyclohexylmethyl)amino, acetyl, -SCF₃, I, F, Cl, Br, -CF₃, -OCF₃ and carboxymethyl.

Preferably, there is one R^a . More preferably, there is one R^a positioned on the ring para to the amide substituent.

Preferably, where two adjacent R^a are taken together with the carbons of attachment to form a fused ring, the fused ring is benzo.

Most preferably, R^a is selected from the group consisting of nitro, F, Cl, Br, fused benzo, I, CF₃, methoxy, ethoxy, propoxy, i-propoxy, ethenyl, cyclopentoxy, 2-propenyl, phenyl, furanyl, thienyl, amino, pyrrol-1-yl, dimethylamino, (cyclohexylmethyl)amino, -Smethyl, -Sethyl, -S-t-butyl, -Sbenzyl, -SCF₃, i-propyl and methyl.

Preferably, R^b is absent or selected from the group consisting of methyl, ethyl, I, F, Cl and Br.

Most preferably, R^b is absent.

Pharmaceutically acceptable salts include amino addition salts that are pharmacologically effective. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, trifluoroacetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate. See

example, S.M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977, 66:1-19, which is incorporated herein by reference.

Preferred compounds, where R¹ and R² taken together with the nitrogen to which they are attached form a heterocyclic ring structure, as defined in groups i)–v) above, are made according to the synthetic methods outlined in Schemes A and B and are selected from the group consisting of:

EX	Compound
1	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide;
2	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-nitro-2-(piperidine-1-carbonyl)-phenyl]-amide;
3	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
4	Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-(piperidine-1-carbonyl)-naphthalen-2-yl]-amide;
5	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
6	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(piperidine-1-carbonyl)-phenyl]-amide;
10	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methoxy-2-(piperidine-1-carbonyl)-phenyl]-amide;
11	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethoxy-2-(piperidine-1-carbonyl)-phenyl]-amide;
12	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propoxy-phenyl]-amide;
13	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropoxy-2-(piperidine-1-carbonyl)-phenyl]-amide;
14	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-cyclopentyloxy-2-(piperidine-1-carbonyl)-phenyl]-amide;
15	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-vinyl-phenyl]-amide;

16	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-allyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
17	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
18	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propyl-phenyl]-amide;
19	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-(piperidine-1-carbonyl)-biphenyl-3-yl]-amide;
20	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-2-yl-2-(piperidine-1-carbonyl)-phenyl]-amide;
21	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-3-yl-2-(piperidine-1-carbonyl)-phenyl]-amide;
22	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-2-yl-phenyl]-amide;
23	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-3-yl-phenyl]-amide;
24	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-amino-2-(piperidine-1-carbonyl)-phenyl]-amide;
25	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-pyrrol-1-yl-phenyl]-amide;
26	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-dimethylamino-2-(piperidine-1-carbonyl)-phenyl]-amide;
27	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-(cyclohexylmethyl-amino)-2-(piperidine-1-carbonyl)-phenyl]-amide;
28	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
29	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
30	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isobutylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
31	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-benzylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;

32	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-trifluoromethyl-phenyl]-amide;
33	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-fluoro-2-(piperidine-1-carbonyl)-phenyl]-amide;
34	Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide;
35	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dibromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
36	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dichloro-2-(piperidine-1-carbonyl)-phenyl]-amide;
37	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
44	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
54	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1-methyl-10-oxa-4-aza-tricyclo[5.2.1.0 ^{2,6}]decane-4-carbonyl)-phenyl]-amide;
60	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(pyrrolidine-1-carbonyl)-phenyl]-amide;
62	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-hydroxymethyl-piperidine-1-carbonyl)-phenyl]-amide;
63	Benzo[1,2,5]thiadiazole-4-sulfonic acid {5-chloro-2-[4-(2-hydroxy-phenyl)-piperazine-1-carbonyl]-phenyl}-amide;
64	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-phenyl]-amide;
66	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-2,5-dihydro-pyrrole-1-carbonyl)-phenyl]-amide;
68	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azepane-1-carbonyl)-5-chloro-phenyl]-amide;
70	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-methyl-piperidine-1-carbonyl)-phenyl]-amide;
71	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-isoquinoline-2-carbonyl)-phenyl]-amide;

72	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(3-ethyl-2,4-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide;
73	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-phenyl-piperidine-1-carbonyl)-phenyl]-amide;
75	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-quinoline-1-carbonyl)-phenyl]-amide;
78	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azetidine-1-carbonyl)-5-chloro-phenyl]-amide;
79	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(thiazolidine-3-carbonyl)-phenyl]-amide;
80	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-phenyl]-amide;
89	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine-3-carbonyl)-phenyl]-amide;
90	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide;
91	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(morpholine-4-carbonyl)-phenyl]-amide;
137	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(morpholine-4-carbonyl)-phenyl]-amide;
138	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide;
139	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(morpholine-4-carbonyl)-phenyl]-amide;
140	7-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
177	5-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
178	7-Bromo-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide; and

182	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide.
-----	--

Still further preferred compounds, where R¹ and R² are each independently selected from groups a)–g), as defined above, are made according to the synthetic methods outlined in Schemes A and B and are

5 selected from the group consisting of:

EX	Compound
7	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-methyl-benzamide;
8	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-bromo-N-methyl-benzamide;
9	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-iodo-N-methyl-benzamide;
38	3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid (4-fluoro-benzyl)-methanamide;
39	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-4-trifluoromethylbenzamide;
40	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-4-fluorobenzamide;
41	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-benzamide;
42	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichlorophenyl)-ethyl]-4-methylbenzamide;
43	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-dichlorophenyl)-ethyl]-benzamide;
45	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chlorobenzyl)-benzamide;
46	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-(5-hydroxy-1,5-dimethylhexyl)benzamide;
47	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methylsulfanyl-benzyl)benzamide;

48	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-dimethylamino-1-phenyl-ethyl)-N-methylbenzamide TFA salt;
49	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-ethylbenzamide;
50	N-Benzhydryl-2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methylbenzamide;
51	(S) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide;
52	(R) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide;
53	(R) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-ethyl)-benzamide;
55	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-2-fluorobenzyl)-4-chloro-benzamide;
56	(R) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-bromo-phenyl)-ethyl]-4-chloro-benzamide;
57	(R) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-p-tolylethyl)-benzamide;
58	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-phenylbenzamide;
59	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-butyl-4-chlorobenzamide;
61	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluorophenyl)-ethyl]-benzamide;
65	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N,N-diethylbenzamide;
67	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-furan-2-ylmethyl-N-methylbenzamide;
69	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-naphthalen-1-ylmethylbenzamide;
74	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-cyclohexyl-N-methylbenzamide;

76	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-cyclohexyl-ethyl)-benzamide;
77	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-benzamide;
81	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluorobenzyl)-benzamide;
82	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-fluorobenzyl)-benzamide;
83	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichlorobenzyl)-benzamide;
84	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(3,4-dichlorobenzyl)-benzamide;
85	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chlorobenzyl)-benzamide;
86	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluorobenzyl)-benzamide;
87	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1,2,3,4-tetrahydro-naphthalen-1-yl)-benzamide;
88	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3,4-dichlorophenyl)-ethyl]-benzamide;
92	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-2-fluorobenzyl)-benzamide;
93	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluorobenzyl)-benzamide;
94	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-trifluoromethyl-benzyl)-benzamide;
95	(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydroxy-1-phenyl-ethyl)-benzamide;
96	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-benzyl)-4-chloro-benzamide;
97	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-propyl)-benzamide;

98	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methyl-benzyl)-benzamide;
99	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-bromo-benzyl)-4-chloro-benzamide;
100	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-methyl-N-(1-phenyl-ethyl)-benzamide;
101	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methyl-N-(1-phenyl-ethyl)-benzamide;
102	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-benzamide;
103	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-N-methyl-benzamide;
104	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-N-methyl-benzamide;
105	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4-iodo-N-methyl-benzamide;
106	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-iodo-N-methyl-benzamide;
107	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;
108	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
109	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
110	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
111	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
112	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide;
113	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;

114	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-benzamide;
115	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(1-phenyl-ethyl)-benzamide;
116	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-phenyl-ethyl)-benzamide;
117	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methoxy-N-methyl-benzamide;
118	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide;
119	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-benzamide;
120	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-methyl-benzamide;
121	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-benzamide;
122	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;
123	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4,N-dimethyl-benzamide;
124	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;
125	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
126	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
127	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4,N-dimethyl-benzamide;
128	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
129	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluorophenyl)-ethyl]-N-methyl-benzamide;

130	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(4-fluorophenyl)-ethyl]-N-methyl-benzamide;
131	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluorobenzyl)-benzamide;
132	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluorobenzyl)-4-iodo-benzamide;
133	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluorobenzyl)-4-methyl-benzamide;
134	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluorobenzyl)-benzamide;
135	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-benzamide;
136	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4,N-dimethyl-benzamide;
141	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-difluorobenzyl)-benzamide;
142	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-dichlorobenzyl)-benzamide;
143	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trifluorobenzyl)-benzamide;
144	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trichlorobenzyl)-benzamide;
145	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-methyl-1-phenyl-ethyl)-benzamide;
146	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide;
147	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide;
148	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-difluorobenzyl)-benzamide;
149	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-dichlorobenzyl)-benzamide;

150	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trifluoro-benzyl)-benzamide;
151	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trichloro-benzyl)-benzamide;
152	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-benzamide;
153	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-methyl-1-phenyl-ethyl)-benzamide;
154	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide;
155	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide;
156	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trifluoro-benzyl)-benzamide;
157	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trichloro-benzyl)-benzamide;
158	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-iodo-benzamide;
159	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-iodo-benzamide;
160	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-iodo-benzamide;
161	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-benzamide;
162	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4,6-trifluoro-benzyl)-benzamide;
163	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-benzamide;
164	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trifluoro-benzyl)-benzamide;
165	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trichloro-benzyl)-benzamide;

166	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-methyl-benzamide;
167	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-methyl-benzamide;
168	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluoro-benzyl)-benzamide;
169	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide;
170	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,N-dimethyl-N-(1-phenyl-ethyl)-benzamide;
171	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
172	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4,N-dimethyl-benzamide;
173	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide;
174	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4,N-dimethyl-benzamide;
175	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-benzamide;
176	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-5-chloro-N-methyl-benzamide;
180	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluoro-benzyl)-N-methyl-benzamide;
181	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-benzyl)-N-methyl-benzamide;
183	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-benzamide;
184	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-fluoro-benzyl)-N-methyl-benzamide;
185	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-chloro-benzyl)-N-methyl-benzamide;

186	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-4-iodo-benzamide;
187	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-chloro-phenyl)-ethyl]-4-iodo-benzamide;
188	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-4-iodo-N-methyl-benzamide;
189	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-4-iodo-N-methyl-benzamide;
190	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-trifluoromethyl-benzamide;
191	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-4-trifluoromethyl-benzamide;
192	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-N-methyl-4-trifluoromethyl-benzamide;
193	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-N-methyl-4-trifluoromethyl-benzamide;
194	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-4-trifluoromethyl-benzamide;
195	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-methyl-N-(1-phenyl-ethyl)-4-trifluoromethyl-benzamide;
196	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-fluoro-benzamide;
197	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-fluoro-N-methyl-benzamide; and
198	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluoro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide.

Although all the compounds of formula I are novel for the uses and in the formulations taught herein, not all compounds of formula I are novel as such. Therefore, broadly, the invention may not include compounds in which:

- 5 A) one or both of R¹ and R² is phenyl substituted with 0, 1, 2, or 3 of R^q, or
 B) R¹ and R² taken together with the nitrogen to which they are attached is a 4-7 membered heterocyclic ring said heterocyclic ring having 0

or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds and having 0, 1 or 2 substituents R^p and R^a is nonexistent or there is a single R^a at the meta position of benzamide.

More specifically, the invention may not include compounds in which:

A) one or both of R¹ and R² is phenyl substituted with 0, 1, 2, or 3 of halo, or


B) R¹ and R² taken together with the nitrogen to which they are attached is a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O and having 0, 1 or 2 substituents R^p and R^a is nonexistent or there is a single R^a at the meta position of benzamide.

Even more specifically, the invention may not include compounds in which:

A) one or both of R¹ and R² is phenyl substituted with 1, 2, or 3 of halo, or

B) R¹ and R² taken together with the nitrogen to which they are attached is a 6 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O and R^a is nonexistent or there is a single R^a at the meta position of benzamide.

Most specifically, the invention does not include compounds in category B) of the formula:




The features and advantages of the invention are apparent to

one of ordinary skill in the art. Based on this disclosure, including the summary, detailed description, background, examples, and claims, one of ordinary skill in the art will be able to make modifications and adaptations to various conditions and usages. Publications described herein are incorporated by reference in their entirety.


Compounds of the present invention may be produced according to two broadly described reaction schemes. In Scheme A, sulfonylation is the final step of the process and in Scheme B, sulfonylation is the initial step of the process. Persons skilled in the art will recognize that certain compounds are more advantageously produced by one scheme as compared to the other.

Scheme A



Referring to Scheme A, commercially available aminonaphthoic acid A1 is reacted with triphosgene and Hünig's base to produce the benzofused isatoic anhydride species of the genus A2. Various isatoic anhydrides A2 are available commercially. An amine is acylated with the isatoic anhydride A2 to produce a benzamide A5. Benzamide A5 may also be obtained from commercially available anthranilic acid A3 through peptide coupling. Benzamide A5 may additionally be obtained from commercially available nitrobenzoic acid A4 through peptide coupling followed by reduction of the nitro group. Benzamide A5 is sulfonylated with the sulfonyl chloride to produce active compounds A6. Where R^a or R^b is a primary or secondary amine or hydroxy, they can be protected with common protecting groups. In the case of the primary or secondary amine, there can be employed Boc or Cbz. In the case of hydroxy, there can be employed TBS, TES or benzyl. Of course, a precursor substituent may be employed in the reaction steps and later transformed into the desired substituent. For example, where A6 is produced with R^a as nitro, the nitro may be reduced to the amine, and the amine may be, for example, alkylated, acylated, diazotized, etc.

Scheme B



5 Referring to Scheme B, methyl anthranilate B1 is sulfonlated to sulfonamide B2. The methyl ester is hydrolyzed to the acid B3. Acid B3 undergoes peptide coupling under standard conditions with an amine to produce active compounds B4. Where R^a or R^b is a primary or secondary amine or hydroxy, it can be protected with common protecting groups. In the case of the primary or secondary amine, there can be employed Boc or Cbz.

10 In the case of hydroxy, there can be employed TBS, TES or benzyl. Of course, a precursor substituent may be employed in the reaction steps and later transformed into the desired substituent. For example, where B4 is produced with R^a as nitro, the nitro may be reduced to the amine and the amine may be,

15 for example, alkylated, acylated, diazotized, etc.

The compounds of the present invention are CCK2 modulators and, as disclosed herein, many are demonstrated CCK2 antagonists. As such, the compounds are useful in the treatment of CCK2 mediated disease states. Particularly, the compounds may be used in the treatment or prevention of

20 pancreatic adenocarcinoma, pain, eating disorders, gastro-esophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors, gastric tumors, Barrett's esophagus, antral G

cell hyperplasia, pernicious anaemia and Zollinger-Ellison syndrome.

Particularly, CCK2 antagonists are now in development for the treatment or prevention of pancreatic adenocarcinoma, pain, gastro-esophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors and gastric tumors.

It is anticipated that the compounds of the invention can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical administration, and inhalation.

For oral administration, the compounds of the invention will generally be

provided in the form of tablets or capsules or as an aqueous solution or suspension. Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include

sodium and calcium carbonate, sodium and calcium phosphate and lactose.

Cornstarch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be

coated with a material such as glyceryl monostearate or glyceryl distearate, to

delay absorption in the gastrointestinal tract. Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil. For intramuscular,

intraperitoneal, subcutaneous and intravenous use, the compounds of the

invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles

include Ringer's solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a

wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n- propyl p- hydroxybenzoate.

Effective doses of the compounds of the present invention may be ascertained by conventional methods. The specific dosage level required for

any particular patient will depend on a number of factors, including severity of the condition being treated, the route of administration and the weight of the patient. In general, however, it is anticipated that the daily dose (whether administered as a single dose or as divided doses) will be in the range 0.01 to 1000 mg per day, more usually from 1 to 500 mg per day, and most usually from 10 to 200 mg per day. Expressed as dosage per unit body weight, a typical dose will be expected to be between 0.0001 mg/kg and 15 mg/kg, especially between 0.01 mg/kg and 7 mg/kg, and most especially between 0.15 mg/kg and 2.5 mg/kg.

10

EXAMPLES

In order to illustrate the invention, the following examples are included. These examples do not limit the invention. They are only meant to suggest a method of practicing the invention. Those skilled in the art may find other methods of practicing the invention, which are obvious to them. However, those methods are deemed to be within the scope of this invention.

15

Protocol for Preparative Reversed-Phase HPLC

Gilson®

20 Column: YMC-Pack ODS-A, 5 μ m, 75x30 mm

Flow rate: 10 mL/min

Detection: λ = 220 & 254 nm

Gradient (acetonitrile/water, 0.05% trifluoroacetic acid)

1) 0.0 min 20% acetonitrile/80% water

25 2) 20.0 min 99% acetonitrile/1% water

Protocol for HPLC (Reversed-Phase)

Hewlett Packard Series 1100

Column: Agilent ZORBAX® C8, 5 μ m, 4.6x150 mm

30 Flow rate: 1 mL/min

Detection: λ = 220 & 254 nm


Gradient (acetonitrile/water, 0.05% trifluoroacetic acid)

- 1) 0.0 min 1% acetonitrile/99% water
- 2) 8.0 min 99% acetonitrile/1% water

5 Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in either positive or negative modes as indicated.

NMR spectra were obtained on either a Bruker model DPX400 (400 MHz) or DPX500 (500 MHz) spectrometer. The format of the ^1H NMR data below is: chemical shift in ppm down field of the tetramethylsilane reference
10 (multiplicity, coupling constant J in Hz, integration).

EXAMPLE 1




15 Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide.

A. 2-Amino-4-chlorobenzoic acid piperidine amide. To a solution of 4-chloroisatoic anhydride (3.0 g, 15.2 mmol) in dimethylformamide (DMF) (60 mL) was added piperidine (1.5 mL, 15.2 mmol) followed by 4-dimethylaminopyridine (DMAP) (183 mg, 1.5 mmol). The mixture was allowed
20 to stir at ambient temperature overnight and concentrated *in vacuo*. The dark brown residue was purified by silica gel chromatography (hexanes/EtOAc) to provide the amide as a white solid (3.01 g, 83%). MS (ESI): m/z 239 $[\text{M}+\text{H}]^+$, 261 $[\text{M}+\text{Na}]^+$. ^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 7.00 (d, J = 8.2 Hz, 1H), 6.78 (d, J = 1.9 Hz, 1H), 6.72 (dd, J = 8.2, 1.9 Hz, 1H), 5.20–4.10
25 (bs, 2H), 3.80–3.30 (bs, 4H), 1.73–1.42 (bm, 6H).

B. Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide. 2-Amino-4-chlorobenzoic acid piperidine amide (0.059 g, 0.25 mmol) was dissolved in 1,2-dichloroethane (1 mL) and treated with pyridine

- (0.030 mL, 0.38 mmol) followed by a solution of 4-chlorosulfonyl-2,1,3-benzothiadiazole (61 mg, 0.26 mmol) in a mixture of 1,2-dichloroethane (0.45 mL) and DMF (0.05 mL). The reaction mixture was shaken overnight at ambient temperature. Solid-supported liquid-liquid extraction was performed.
- 5 A column (~1x3 cm) of Hydromatrix coarse diatomaceous earth was prepared and wetted with 1 N HCl (1.25 mL). The crude reaction mixture was passed through the column. The Hydromatrix was rinsed with dichloromethane (DCM) (1 mL), DMF (1 mL), and then DCM again (1 mL), and the combined washes were concentrated *in vacuo*. The crude product was redissolved in DMF (~1
- 10 mL) and purified by preparative reversed-phase HPLC to provide the sulfonamide as a solid (31 mg, 28%). HPLC (reversed-phase): $R_T = 9.63$ min (single peak). MS (ESI): m/z 437 $[M+H]^+$, 459 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.01 (s, 1H), 8.17 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.13 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.59 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.56 (dd, $J = 1.5,$
- 15 0.6 Hz, 1H), 6.89 (abx, $J = 8.0, 1.5, 0.6$ Hz, 2H), 3.70–2.70 (bs, 4H), 1.70–1.30 (bm, 6H).

EXAMPLE 2




- 20 Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-nitro-2-(piperidine-1-carbonyl)-phenyl]-amide.

- A. 2-Amino-4-nitrobenzoic acid piperidine amide. This compound was prepared in analogy to EXAMPLE 1 using 4-nitroisatoic anhydride (2.5 g, 12.0 mmol), piperidine (1.2 mL, 12.0 mmol), and DMAP (0.146 g, 1.2 mmol). The
- 25 title compound was obtained as a yellow solid (1.86 g, 62%). MS (ESI): m/z 250 $[M+H]^+$, 272 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 7.63 (dd, $J = 1.9, 0.2$ Hz, 1H), 7.61 (dd, $J = 8.2, 2.2$ Hz, 1H), 7.25 (dd, $J = 8.2, 0.2$ Hz, 1H), 4.49 (bs, 2H), 3.90–3.10 (bm, 4H), 1.75–1.38 (bm, 6H).

B. Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-nitro-2-(piperidine-1-carbonyl)-phenyl]-amide. This compound was prepared in analogy to EXAMPLE 1 using 2-amino-4-nitrobenzoic acid piperidine amide (0.062 g, 0.25 mmol), pyridine (0.030 mL, 0.038 mmol), and 4-chlorosulfonyl-2,1,3-benzothiadiazole (61 mg, 0.26 mmol). The title sulfonamide was obtained as a solid (6 mg, 5%). HPLC (reversed-phase): R_T = 9.11 min (single peak). MS (ESI): m/z 448 $[M+H]^+$, 470 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.90 (s, 1H), 8.48 (d, J = 2.2 Hz, 1H), 8.38 (dd, J = 7.0, 1.0 Hz, 1H), 8.27 (dd J = 8.8, 1.0 Hz, 1H), 7.88 (dd, J = 8.4, 2.2 Hz, 1H), 7.75 (dd, J = 8.8, 7.0 Hz, 1H), 7.25 (d, J = 8.4 Hz, 1H), 3.80–3.30 (bm, 2H), 3.30–2.80 (bm, 2H), 1.75–1.40 (bm, 6H).

EXAMPLE 3



Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide.

A. 2-Amino-5-bromobenzoic acid piperidine amide. To a stirred solution of 5-bromoisatoic anhydride (2.88 g, 11.9 mmol) in DMF (20 mL) was added piperidine (1.20 mL, 11.9 mmol) and DMAP (0.14 g, 1.19 mmol). The reaction mixture was stirred 15 h at ambient temperature, poured into water, and extracted with DCM (4x). The combined organic extracts were washed with 1:1 water/brine (3x), dried ($MgSO_4$), and concentrated. The residue was dissolved in 1:1 Et_2O / $EtOAc$ and washed with water (5x) to remove DMF. The organic layer was dried ($MgSO_4$) and concentrated. The residue was triturated with a mixture of Et_2O and hexanes and allowed to stand at 0 °C overnight. The solid product was collected by suction filtration and air-dried to give the desired amide as a tan solid (1.65 g, 49%). mp = 93–95 °C. MS (ESI): m/z 283 $[M+H]^+$, 305 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 7.23

(dd, $J = 8.6, 2.3$ Hz, 1H), 7.18 (d, $J = 2.3$ Hz, 1H), 6.59 (d, $J = 8.6$ Hz, 1H), 4.90–4.00 (bs, 2H), 3.90–2.90 (bm, 4H), 1.90–1.10 (bm, 6H).

B. Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide. This compound was prepared in analogy to EXAMPLE 1 using


- 5 2-amino-5-bromobenzoic acid piperidine amide (0.071 g, 0.25 mmol), pyridine (0.031 mL, 0.38 mmol), and 4-chlorosulfonyl-2,1,3-benzothiadiazole (61 mg, 0.26 mmol). The title sulfonamide was obtained as a solid (30 mg, 25%).

HPLC (reversed-phase): $R_T = 9.67$ min (single peak). MS (ESI): m/z 481

- 10 $[M+H]^+$, 503 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.67 (s, 1H), 8.23 (dd, $J = 8.8, 1.1$ Hz, 1H), 8.21 (dd $J = 7.0, 1.1$ Hz, 1H), 7.67 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.53 (d, $J = 8.8$ Hz, 1H), 7.40 (dd, $J = 8.8, 2.3$ Hz, 1H), 7.17 (d, $J = 2.3$ Hz, 1H), 3.75–2.65 (bm, 4H), 1.90–1.30 (bm, 6H). Elemental analysis: calculated for $C_{18}H_{17}BrN_4O_3S_2$, C 44.91, H 3.56, N 11.64; found C 44.83, H 3.39, N 11.48.

15

EXAMPLE 4



Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-(piperidine-1-carbonyl)-naphthalen-2-yl]-amide.

- 20 A. 3-Amino-2-naphthoic acid piperidine amide. To a solution of 3-amino-2-naphthoic acid (0.30 g, 1.6 mmol) in tetrahydrofuran (THF) (40 mL) at ambient temperature was added triphosgene (0.158 g, 0.53 mmol). After stirring 2 h at room temperature, Hünig's base (0.56 mL, 3.2 mmol) was added. The reaction mixture was stirred 1 h, and piperidine (0.64 mL, 6.4 mmol) was added. After
- 25 2 h, the mixture was poured into 0.5 M HCl (100 mL) and extracted with DCM (2x50 mL). The combined organic layers were dried (Na_2SO_4) and concentrated. The crude residue was purified by flash chromatography (hexanes/EtOAc) to afford the title compound as a pale orange solid (263 mg,

65%). MS (ESI): m/z 255 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 7.66 (dd, $J = 8.1, 1.0$ Hz, 1H), 7.57 (s, 1H), 7.54 (dd, $J = 8.3, 1.0$ Hz, 1H), 7.36 (ddd, $J = 8.1, 8.0, 1.0$ Hz, 1H), 7.22 (ddd, $J = 8.3, 8.0, 1.0$ Hz, 1H), 7.00 (s, 1H), 4.60–4.20 (bs, 2H), 3.90–3.20 (bm, 4H), 1.80–1.40 (bm, 6H).


5

B. Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-(piperidine-1-carbonyl)-naphthalen-2-yl]-amide.

3-Amino-2-naphthoic acid piperidine amide (263 mg, 1.03 mmol), 4-chlorosulfonyl-2,1,3-benzothiadiazole (295 mg, 1.24 mmol), and pyridine (0.242 mL, 3 mmol) were added to DCM (10 mL) and allowed to stir at ambient temperature overnight. The reaction mixture was poured into 1 N HCl and extracted twice with DCM. The combined organic extracts were dried (Na_2SO_4) and concentrated *in vacuo*. The crude residue was purified by flash chromatography (hexanes/EtOAc) to afford the desired product as a slightly impure orange solid. Trituration and stirring with methanol at ambient temperature overnight provided the title sulfonamide as a white powder, which was collected by suction filtration and air-dried (308 mg, 66%). MS (ESI): m/z 453 $[M+H]^+$, 475 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.88 (s, 1H), 8.26 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.19 (dd, $J = 8.8, 1.0$ Hz, 1H), 8.04 (s, 1H), 7.76 (d, $J = 8.2$ Hz, 1H), 7.67 (d, $J = 8.0$ Hz, 1H), 7.64 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.49 (arom m, 1H), 7.41 (arom m, 1H), 7.26 (s, 1H), 3.70–2.70 (bm, 4H), 1.80–1.30 (bm, 6H). Elemental analysis: calculated for $C_{22}H_{20}N_4O_3S_2$, C 58.39, H 4.45, N 12.38; found C 58.66, H 4.57, N 12.49.

20

EXAMPLE 5



25


Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide.

- A. 4-Bromo-2-nitrobenzoic acid. A mixture of 4-bromo-2-nitrotoluene (5.0 g, 23 mmol), KMnO_4 (10.9 g, 69 mmol), and water (250 mL) was heated at reflux overnight in a 1 L round-bottom flask fitted with a reflux condenser. The brown suspended MnO_2 was removed by filtration through a pad of diatomaceous earth. The filter cake was washed with water. The basic filtrate was acidified to pH $\sim$ 1 with concentrated HCl and extracted with EtOAc (3x300 mL). The combined organic layers were dried (MgSO_4) and concentrated *in vacuo* to provide pure benzoic acid (1.22 g, 22%). ^1H NMR (400 MHz, CD_3OD): 8.07 (d, J = 1.9 Hz, 1H), 7.85 (dd, J = 8.2, 1.9 Hz, 1H), 7.65 (d, J = 8.2 Hz, 1H). MS (ESI): neg. ion m/z 244 $[\text{M}-\text{H}]^-$.
- B. 4-Bromo-2-nitrobenzoic acid piperidine amide. A suspension of 4-bromo-2-nitrobenzoic acid (0.60 g, 2.44 mmol) in thionyl chloride (8 mL) was heated to reflux for 2 h. The reaction mixture became homogeneous. The mixture was cooled and concentrated *in vacuo* to give 4-bromo-2-nitrobenzoyl chloride as a white solid, which was used immediately in the following reaction. ^1H NMR (400 MHz, CDCl_3): 8.20 (d, J = 1.9 Hz, 1H), 7.92 (dd, J = 8.2, 1.9 Hz, 1H), 7.65 (d, J = 8.2 Hz, 1H). To a solution of 4-bromo-2-nitrobenzoyl chloride (2.44 mmol) in DCM (15 mL) at ambient temperature was added piperidine (1.2 mL, 12.2 mmol). The reaction mixture was stirred for 3 h then poured into water and extracted with DCM (2x). The combined organic extracts were washed with brine, dried (MgSO_4), and concentrated *in vacuo*. The residue was purified by flash chromatography (hexanes/EtOAc) to afford the title amide as a white solid (0.52 g, 76%). MS (ESI): m/z 313 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 8.33 (d, J = 1.9 Hz, 1H), 7.82 (dd, J = 8.1, 1.9 Hz, 1H), 7.27 (d, J = 8.1 Hz, 1H), 3.82–3.65 (bm, 2H), 3.16 (t, J = 5.6 Hz, 2H), 1.90–1.35 (bm, 6H).
- C. 4-Bromo-2-aminobenzoic acid piperidine amide. A solution of 4-bromo-2-nitrobenzoic acid piperidine amide (0.206 g, .66 mmol) in 1:1 EtOAc/DCM (10 mL) was treated with solid $\text{SnCl}_2 \cdot 2 \text{H}_2\text{O}$ (0.595 g, 2.6 mmol). The mixture was stirred at ambient temperature for 4 h then poured into saturated aqueous NaHCO_3 resulting in formation of a gelatinous emulsion. The emulsion was extracted with DCM (2x). The combined organic extracts were dried (MgSO_4) and concentrated *in vacuo*. The residue was purified by flash chromatography

(hexanes/EtOAc) to provide the desired aniline as a white solid (0.16 g, 86%).
 MS (ESI): m/z 283 $[M+H]^+$, 305 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$):
 (rotameric broadening) 6.72 (d, $J = 8.1$ Hz, 1H), 6.67 (d, $J = 1.8$ Hz, 1H), 6.62
 (dd, $J = 8.1, 1.8$ Hz, 1H), 4.90–3.90 (bs, 2H), 3.70–3.30 (bm, 4H), 1.75–1.45
 5 (bm, 6H).

D. Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide. To a solution of 4-bromo-2-aminobenzoic acid piperidine
 amide (0.145 g, 0.51 mmol) was added pyridine (0.062 mL, 0.76 mmol) and 4-
 chlorosulfonyl-2,1,3-benzothiadiazole (0.129 g, 0.55 mmol). The mixture was
 10 stirred at ambient temperature for 12 h then poured into 1 N HCl and extracted
 with DCM (2x). The combined organic extracts were dried ($MgSO_4$) and
 concentrated *in vacuo*. The crude residue was purified by flash
 chromatography (hexanes/EtOAc) to afford the title sulfonamide as an off-white
 solid (0.18 g, 74%). HPLC (reversed-phase): $R_T = 9.68$ min (single peak). MS
 15 (ESI): m/z 481/483 $[M+H]^+$, 503 $[M+Na]^+$; neg. ion m/z 479/481 $[M-H]^-$. 1H NMR
 (400 MHz, $CDCl_3$): (rotameric broadening) 8.95 (s, 1H), 8.25 (dd, $J = 7.0, 1.0$
 Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.80 (d, $J = 1.8$ Hz, 1H), 7.68 (dd, $J =$
 8.8, 7.0 Hz, 1H), 7.14 (dd, $J = 8.2, 1.8$ Hz, 1H), 6.90 (d, $J = 8.2$ Hz, 1H), 3.70–
 2.70 (bm, 4H), 1.80–1.30 (bm, 6H). Elemental analysis: calculated for
 20 $C_{18}H_{17}BrN_4O_3S_2$, C 44.91, H 3.56, N 11.64; found C 44.52, H 3.23, N 11.25.

EXAMPLE 6



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(piperidine-1-carbonyl)-
 25 phenyl]-amide.

A. 4-Iodo-2-nitrobenzoic acid. 4-Iodo-2-nitrotoluene (9.0 g, 34.2 mmol),
 $KMnO_4$ (22.0 g, 139 mmol) and water (340 mL) were heated at reflux for 5 h.
 The resulting brown suspension of MnO_2 was filtered off through a pad of

diatomaceous earth, and the filter cake was washed with water. The basic filtrate was acidified with concentrated HCl causing crystallization of the desired acid. The crystals were collected by suction filtration and dried affording 1.86 g of the acid. The mother liquor was extracted with DCM (3x200 mL), and the combined extracts were dried (Na₂SO₄) and concentrated *in vacuo* to afford an additional 0.16 g of the benzoic acid. Total yield = 2.02 g (20%). ¹H NMR (400 MHz, CD₃OD): 8.13 (d, *J* = 1.6 Hz, 1H), 8.01 (dd, *J* = 8.1, 1.6 Hz, 1H), 7.50 (d, *J* = 8.1 Hz, 1H).

B. 4-Iodo-2-nitrobenzoic acid piperidine amide. A suspension of 4-iodo-2-nitrobenzoic acid (1.0 g, 3.4 mmol) in thionyl chloride (10 mL) was heated to reflux for 45 min. The reaction mixture became homogeneous. The mixture was cooled and concentrated *in vacuo* to give 4-iodo-2-nitrobenzoyl chloride as a yellow oil, which was used immediately in the following reaction. ¹H NMR (500 MHz, CDCl₃): 8.38 (d, *J* = 1.6 Hz, 1H), 8.12 (dd, *J* = 8.1, 1.6 Hz, 1H), 7.48 (d, *J* = 8.1 Hz, 1H). To a solution of 4-iodo-2-nitrobenzoyl chloride (3.4 mmol) in DCM (10 mL) at ambient temperature was added piperidine (1.3 mL, 13.1 mmol). The reaction mixture was stirred for 0.5 h then poured into 1 N HCl and extracted with DCM (2x). The combined organic extracts were dried (Na₂SO₄), and concentrated *in vacuo* affording the title amide as a white solid (1.2 g, 98%). MS (ESI): *m/z* 361 [M+H]⁺, 383 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 8.51 (d, *J* = 1.6 Hz, 1H), 8.01 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.12 (d, *J* = 8.0 Hz, 1H), 3.85-3.65 (bm, 2H), 3.16 (t, *J* = 5.6 Hz, 2H), 1.90-1.35 (bm, 6H).


C. 4-Iodo-2-aminobenzoic acid piperidine amide. A solution of 4-iodo-2-nitrobenzoic acid piperidine amide (0.21 g, .58 mmol) in EtOAc (5 mL) was treated with solid SnCl₂•2H₂O (0.654 g, 2.9 mmol). The mixture was stirred at ambient temperature for 12 h then poured into saturated aqueous NaHCO₃ resulting in formation of a gelatinous emulsion. The emulsion was extracted with DCM (5x). The combined organic extracts were dried (Na₂SO₄) and concentrated *in vacuo* affording the aniline as a yellow foam (0.19 g, 100%). MS (ESI): *m/z* 331 [M+H]⁺, 353 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 7.08 (d, *J* = 1.1 Hz, 1H), 7.03 (d, *J* = 8.0 Hz, 1H), 6.77

(dd, $J = 8.0, 1.1$ Hz, 1H), 4.50–4.20 (bs, 2H), 3.80–3.20 (bm, 4H), 1.75–1.45 (bm, 6H).

D. Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(piperidine-1-carbonyl)-phenyl]-amide.

To a solution of 4-iodo-2-aminobenzoic acid piperidine amide (0.19 g, 0.58 mmol) was added pyridine (0.141 mL, 1.74 mmol) and 4-chlorosulfonyl-2,1,3-benzothiadiazole (0.153 g, 0.64 mmol). The mixture was stirred at ambient temperature for 12 h then poured into 1 N HCl and extracted with DCM (2x). The combined organic extracts were dried (Na_2SO_4) and concentrated *in vacuo*. The crude residue was purified by flash chromatography (hexanes/EtOAc) then recrystallization (methanol/DCM) to afford the title sulfonamide as white crystals (0.23 g, 75%). HPLC (reversed-phase): $R_T = 9.79$ min (single peak). MS (ESI): m/z 529 $[\text{M}+\text{H}]^+$, 551 $[\text{M}+\text{Na}]^+$. ^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 8.90 (s, 1H), 8.27 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.24 (dd, $J = 8.8, 1.0$ Hz, 1H), 8.02 (d, $J = 1.6$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.38 (dd, $J = 8.0, 1.6$ Hz, 1H), 6.76 (d, $J = 8.0$ Hz, 1H), 3.70–2.70 (bm, 4H), 1.75–1.30 (bm, 6H). Elemental analysis: calculated for $\text{C}_{18}\text{H}_{17}\text{IN}_4\text{O}_3\text{S}_2$, C 40.92, H 3.24, N 10.60; found C 41.04, H 3.00, N 10.47.

EXAMPLE 7



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-methylbenzamide.

A. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid methyl ester.

To a solution of methyl 2-amino-4-chlorobenzoate (7.0 g, 37.7 mmol) in DCM (75 mL) at ambient temperature was added 4-chlorosulfonyl-2,1,3-benzothiadiazole (9.45 g, 39.6 mmol), pyridine (9.1 mL, 112 mmol), and DMAP (0.23 g, 1.88 mmol). The mixture was stirred at ambient temperature overnight, poured into 1 N HCl (200 mL), and extracted with DCM (2x100 mL).


The combined organic layers were dried (Na_2SO_4) and concentrated *in vacuo*. The crude residue was purified by flash chromatography (hexanes/EtOAc) to afford the title sulfonamide as a tan solid (11.65 g, 80%). MS (ESI): neg. ion m/z 382 $[\text{M}-\text{H}]^-$. ^1H NMR (400 MHz, CDCl_3): 11.38 (s, 1H), 8.40 (dd, $J = 7.2$, 1.2 Hz, 1H), 8.24 (dd, $J = 8.8$, 1.2 Hz, 1H), 7.80 (d, $J = 8.4$ Hz, 1H), 7.76 (d, $J = 2.0$ Hz, 1H), 7.74 (dd, $J = 8.8$, 7.2 Hz, 1H), 6.94 (dd, $J = 8.4$, 2.0 Hz, 1H), 3.92 (s, 3H). Elemental analysis: calculated for $\text{C}_{14}\text{H}_{10}\text{ClN}_3\text{O}_4\text{S}_2$, C 43.81, H 2.63, N 10.95; found C 44.19, H 3.00, N 11.23.

B. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid. To a stirred suspension of 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid methyl ester (2.0 g, 5.2 mmol) in THF (12 mL) at ambient temperature was added 2 M aqueous LiOH (10 mL). The resulting orange mixture was stirred overnight at ambient temperature then poured into 0.5 M HCl (150 mL) causing precipitation of the desired benzoic acid. After stirring the mixture several minutes to complete precipitation, the product was collected by suction filtration and air-dried to afford the acid as a tan solid (1.87 g, 97%). MS (ESI): neg. ion m/z 368 $[\text{M}-\text{H}]^-$. ^1H NMR (400 MHz, CDCl_3): 11.22 (bs, 1H), 8.43 (dd, $J = 7.2$, 1.0 Hz, 1H), 8.26 (dd, $J = 8.8$, 1.0 Hz, 1H), 7.90 (d, $J = 8.8$ Hz, 1H), 7.80 (d, $J = 2.0$ Hz, 1H), 7.75 (dd, $J = 8.8$, 7.2 Hz, 1H), 6.99 (dd, $J = 8.8$, 2.0 Hz, 1H). Elemental analysis: calculated for $\text{C}_{13}\text{H}_8\text{ClN}_3\text{O}_4\text{S}_2$, C 42.22, H 2.18, N 11.36; found C 41.92, H 2.50, N 11.38.

C. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-methylbenzamide. To a solution of 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid (18 mg, 0.05 mmol) in a mixture of THF (0.08 mL) and DMF (0.40 mL) at ambient temperature was added pyridine (0.012 mL, 0.15 mmol) followed by O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) (0.038 g, 0.1 mmol). The reaction mixture was agitated for 1 h on a shaker. N-Methylbenzylamine (0.013 mL, 0.1 mmol) was added. (If the amine had been a salt, then Hünig's base (0.017 mL, 0.1 mmol) would also have been added.) The reaction mixture was agitated for 1 h. TFA (0.050 mL) was added to quench the reaction. The mixture was diluted with DMF (1 mL), and the product amide was obtained by purification of the entire reaction mixture by preparative HPLC. The title amide was obtained as a solid

(8 mg, 33%). HPLC (reversed-phase): R_T = 9.94 min (single peak). MS (ESI): m/z 471 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.15 (bs, 1H), 8.32 (bd, J = 6.8 Hz, 1H), 8.29–8.18 (bm, 1H), 7.79–7.63 (bm, 2H), 7.48–7.26 (bm, 4H), 7.15–6.83 (bm, 2H), 7.02 (bd, J = 8.2 Hz, 1H), 4.65–4.37 (bs, 1.3H), 4.37–4.00 (bs, 0.7H), 3.15–2.70 (bs, 1.1H), 2.70–2.35 (bs, 1.9H).

EXAMPLE 8



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-bromo-N-methylbenzamide.

A. Methyl 2-amino-4-bromobenzoate. To a stirred solution of 4-bromo-2-nitrobenzoic acid (EXAMPLE 5) (3.81 g, 15 mmol) in DMF (30 mL) at 0 °C was added 1,8-diazabicycloundecane (DBU) (10.3 mL, 75 mmol) followed by methyl iodide (4.67 mL, 75 mmol). The reaction mixture was stirred 15 min at 0 °C then allowed to warm to room temperature and stir overnight. The mixture was poured into water and extracted with EtOAc (2x). The combined organic extracts were washed with water (2x), dried ($MgSO_4$), and concentrated *in vacuo*. The residue was purified by flash chromatography (hexanes/EtOAc) to afford methyl 4-bromo-2-nitrobenzoate as a pale yellow solid (3.52 g, 90%). To a solution of the nitrobenzoate (3.52 g, 13.5 mmol) in 1:1 EtOAc/DCM (30 mL) at ambient temperature was added $SnCl_2 \cdot 2 H_2O$ (15.27 g, 67 mmol). The reaction mixture was allowed to stir overnight. The solvents were evaporated *in vacuo*, and the residue was partitioned between saturated aqueous $NaHCO_3$ and DCM. The layers were separated, and the aqueous layer was further extracted with DCM (2x). The combined organic layers were dried ($MgSO_4$) and concentrated *in vacuo* to provide the pure aminobenzoate as a white solid (2.89 g, 93%). 1H NMR (400 MHz, $CDCl_3$): 7.70 (d, J = 8.6 Hz, 1H), 6.84 (d, J = 1.9 Hz, 1H), 6.75 (dd, J = 8.6, 1.9 Hz, 1H), 5.78 (bs, 2H), 3.86 (s, 3H).

B. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoic acid methyl ester.

This compound was prepared as described in EXAMPLE 7 using the following reagents: methyl 2-amino-4-bromobenzoate (2.89 g, 12.5 mmol), 4-chlorosulfonyl-2,1,3-benzothiadiazole (3.54 g, 15 mmol), pyridine (2.0 mL, 25 mmol), and DCM (40 mL). The title sulfonamide was obtained as a tan solid (3.95 g, 75%). MS (ESI): neg. ion m/z 426 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): 11.34 (bs, 1H), 8.40 (dd, $J = 7.0, 0.9$ Hz, 1H), 8.24 (dd, $J = 8.8, 0.9$ Hz, 1H), 7.92 (d, $J = 1.8$ Hz, 1H), 7.74 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.72 (d, $J = 8.5$ Hz, 1H), 7.10 (dd, $J = 8.5, 1.8$ Hz, 1H), 3.92 (s, 3H).


C. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromobenzoic acid.

This compound was prepared as described in EXAMPLE 7 using the following reagents: 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromobenzoic acid methyl ester (2.95 g, 6.89 mmol), THF (20 mL), and 2 M aqueous LiOH (18 mL). The title acid was obtained as a tan solid (1.87 g, 97%). 1H NMR (500 MHz, $CDCl_3$): 11.14 (bs, 1H), 8.42 (dd, $J = 7.2, 1.1$ Hz, 1H), 8.26 (dd, $J = 8.8, 1.1$ Hz, 1H), 7.98 (d, $J = 1.6$ Hz, 1H), 7.82 (d, $J = 8.5$ Hz, 1H), 7.75 (dd, $J = 8.8, 7.2$ Hz, 1H), 7.16 (dd, $J = 8.5, 1.6$ Hz, 1H).

D. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-bromo-N-methylbenzamide.

This compound was prepared as described in EXAMPLE 7 using the following reagents: 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromobenzoic acid (21 mg, 0.05 mmol), THF (0.08 mL), DMF (0.40 mL), pyridine (0.012 mL, 0.15 mmol), HATU (0.038 g, 0.1 mmol), and N-methylbenzylamine (0.013 mL, 0.1 mmol). The title amide was obtained as a solid (13 mg, 50%). HPLC (reversed-phase): $R_T = 9.91$ min (single peak). MS (ESI): m/z 517/519 $[M+H]^+$, 539/541 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.07 (bs, 1H), 8.32 (bd, $J = 6.9$ Hz, 1H), 8.3–8.2 (bm, 1H), 7.9–7.8 (bm, 1H), 7.8–7.65 (bm, 1H), 7.45–7.25 (bm, 4H), 7.2–7.0 (bm, 2H), 6.95 (bd, $J = 8.5$ Hz, 1H), 4.65–4.4 (bs, 1.3H), 4.4–4.0 (bs, 0.7H), 3.15–2.75 (bs, 1.1H), 2.70–2.35 (bs, 1.9H).

EXAMPLE 9



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-iodo-N-methylbenzamide.


- 5 A. Methyl 2-amino-4-iodobenzoate. This compound was prepared as described in EXAMPLE 8 using the following reagents: 4-iodo-2-nitrobenzoic acid (see EXAMPLE 6) (2.32 g, 7.9 mmol), DMF (30 mL), DBU (2.4 mL, 16 mmol), and methyl iodide (1.5 mL, 24 mmol). Methyl 4-iodo-2-nitrobenzoate was obtained as a pale yellow solid (2.30 g, 95%). The intermediate
- 10 nitrobenzoate was then reduced using the following reagents: nitrobenzoate (2.29 g, 7.4 mmol), 1:1 EtOAc/DCM (10 mL), and $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (8.35 g, 37 mmol). The title aminobenzoate was obtained as a yellow solid (1.87 g, 91%). ^1H NMR (500 MHz, CDCl_3): 7.52 (d, $J = 8.5$ Hz, 1H), 7.07 (d, $J = 1.6$ Hz, 1H), 6.96 (dd, $J = 8.5, 1.6$ Hz, 1H), 5.72 (bs, 2H), 3.86 (s, 3H).
- 15 B. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoic acid methyl ester. This compound was prepared as described in EXAMPLE 7 using the following reagents: methyl 2-amino-4-iodobenzoate (1.60 g, 5.8 mmol), 4-chlorosulfonyl-2,1,3-benzothiadiazole (1.76 g, 7.51 mmol), pyridine (0.93 mL, 11.5 mmol), and DCM (45 mL). The title sulfonamide was obtained as a tan
- 20 solid (1.87 g, 68%). MS (ESI): neg. ion m/z 474 $[\text{M}-\text{H}]^-$. ^1H NMR (400 MHz, CDCl_3): 11.26 (bs, 1H), 8.40 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.24 (dd, $J = 8.8, 1.0$ Hz, 1H), 8.12 (d, $J = 1.5$ Hz, 1H), 7.74 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.53 (d, $J = 8.5$ Hz, 1H), 7.32 (dd, $J = 8.5, 1.5$ Hz, 1H), 3.91 (s, 3H).
- 25 C. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid. This compound was prepared as described in EXAMPLE 7 using the following reagents: 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid methyl ester (1.87 g, 3.93 mmol), THF (20 mL), and 2 M aqueous LiOH (18 mL). The title acid was obtained as a tan solid (1.24 g, 69%). ^1H NMR (500

MHz, CDCl₃): 11.03 (bs, 1H), 8.34 (dd, $J = 7.2, 1.1$ Hz, 1H), 8.19 (dd, $J = 8.8, 1.1$ Hz, 1H), 8.09 (d, $J = 1.6$ Hz, 1H), 7.69 (dd, $J = 8.8, 7.2$ Hz, 1H), 7.56 (d, $J = 8.5$ Hz, 1H), 7.30 (dd, $J = 8.5, 1.6$ Hz, 1H).

D. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-iodo-N-methyl-

- 5 benzamide. This compound was prepared as described in EXAMPLE 7 using the following reagents: 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid (23 mg, 0.05 mmol), THF (0.08 mL), DMF (0.40 mL), pyridine (0.012 mL, 0.15 mmol), HATU (0.038 g, 0.1 mmol), and N-methylbenzylamine (0.013 mL, 0.1 mmol). The title amide was obtained as a solid (14 mg, 50%).
- 10 HPLC (reversed-phase): $R_T = 9.97$ min (single peak). MS (ESI): m/z 565 $[M+H]^+$, 587 $[M+Na]^+$. ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 9.02 (bs, 1H), 8.31 (bd, $J = 6.7$ Hz, 1H), 8.3–8.2 (bm, 1H), 8.05–7.95 (bm, 1H), 7.85–7.65 (bm, 1H), 7.45–7.25 (bm, 5H), 7.15–7.0 (bm, 1H), 6.79 (bd, $J = 8.1$ Hz, 1H), 4.6–4.4 (bs, 1.3H), 4.35–4.0 (bs, 0.7H), 3.05–2.75 (bs, 1.1H), 2.65–
- 15 2.35 (bs, 1.9H).

EXAMPLE 10



- Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methoxy-2-(piperidine-1-carbonyl)-phenyl]-amide.
- 20 A. (4-Methoxy-2-nitro-phenyl)-piperidin-1-yl-methanone. To a stirred solution of (4-iodo-2-nitro-phenyl)-piperidin-1-yl-methanone (100 mg, 0.28 mmol) in methanol (2.0 mL) was added CuI (5.0 g, 0.027 mmol), 1,10-phenanthroline (10 mg, 0.055 mmol), and cesium carbonate (180 mg, 0.55 mmol). The
- 25 reaction mixture was heated in a sealed tube to 110 °C for 24 h, after which it was cooled to room temperature. The mixture was taken up in DCM (5 mL) and washed with water. The organic layers were dried (MgSO₄), filtered, and concentrated *in vacuo*. The resulting oil was purified on silica gel (MPLC, 20%

hexanes/80% EtOAc) to provide the ether product (70 mg, 0.26 mmol, 96%). TLC (silica gel, 3:1 EtOAc/hexanes): $R_f = 0.17$. MS (ESI): m/z 265 $[M+H]^+$, 287 $[M+Na]^+$.


B. (2-Amino-4-methoxy-phenyl)-piperidin-1-yl-methanone. (4-Methoxy-2-nitro-

5 phenyl)-piperidin-1-yl-methanone (70 mg, 0.27 mmol) was dissolved in 1:1 DCM/EtOAc (10 mL), and $SnCl_2 \cdot 2H_2O$ (300 mg, 1.32 mmol) was added. The mixture was stirred overnight at ambient temperature then concentrated *in vacuo*. The resulting oil was suspended in DCM and neutralized by shaking with aqueous $NaHCO_3$. The organic layer was dried ($MgSO_4$), filtered, and
10 concentrated *in vacuo* to provide the title compound (50 mg, 0.21 mmol, 81%). TLC (silica gel, EtOAc): $R_f = 0.39$. MS (ESI): m/z 235 $[M+H]^+$, 257 $[M+Na]^+$.

C. Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methoxy-2-(piperidine-1-carbonyl)-phenyl]-amide. 4-Chlorosulfonyl-2,1,3-benzothiadiazole (60 mg, 0.26

15 mmol) was added to a solution of (2-amino-4-methoxy-phenyl)-piperidin-1-yl-methanone (50 mg, 0.21 mmol) and pyridine (0.026 mL, 0.32 mmol) in DCM (3 mL). The mixture was left standing overnight at ambient temperature. Then the volatiles were stripped *in vacuo*, and the resulting oil was taken up in 8 mL EtOAc and washed with 1 N HCl. The organic layer was dried ($MgSO_4$), filtered, concentrated, and purified on silica gel (MPLC, hexanes/EtOAc) to
20 provide the title compound (40 mg, 0.092 mmol, 43%). TLC (silica gel, EtOAc): $R_f = 0.28$. MS (ESI): m/z 433 $[M+H]^+$, 455 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 9.08$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.34 (s, 1H), 8.23 (dd, $J = 7.0, 1.0$ Hz, 2H), 7.66 (m, 1H), 7.22 (dd, $J = 5.5, 2.5$ Hz, 1H), 6.98 (d, $J = 12$ Hz, 1H), 6.53 (dd, $J = 8.6, 2.5$ Hz, 1H),
25 3.79 (s, 3H), 3.20-3.10 (bs, 4H), 1.63-1.58 (m, 2H), 1.43 (bs, 4H).


EXAMPLE 11



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethoxy-2-(piperidine-1-carbonyl)-phenyl]-amide.

- 5 This compound was prepared as described for the methyl ether analog in EXAMPLE 10 substituting ethanol for methanol in Step A. TLC (silica gel, 3:1 EtOAc/hexanes): $R_f = 0.33$. MS (ESI): m/z 447 $[M+H]^+$, 469 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 9.56$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.34 (s, 1H), 8.23 (dd, $J = 7.0, 1.0$ Hz, 2H), 7.66 (m, 1H), 7.22 (d, $J = 2.5$ Hz, 1H), 6.98 (d, $J = 12$ Hz, 1H), 6.53 (dd, $J = 8.6, 2.5$ Hz, 1H), 4.01 (m, 2H), 3.16 (bs, 4H), 1.63–1.58 (m, 2H), 1.43 (bs, 4H), 1.40 (t, 7Hz, 3H).

EXAMPLE 12




15 Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propoxy-phenyl]-amide.

- This compound was prepared as described for the methyl ether analog in EXAMPLE 10 substituting *n*-propanol for methanol in Step A. TLC (silica gel, 3:1 EtOAc/hexanes): $R_f = 0.34$. MS (ESI): m/z 461 $[M+H]^+$, 483 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 9.96$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.34 (s, 1H), 8.23 (dd, $J = 7.0, 1.0$ Hz, 2H), 7.66 (m, 1H), 7.22 (d, $J = 2.5$ Hz, 1H), 6.95 (d, $J = 12$ Hz, 1H), 6.52 (dd, $J =$

8.6, 2.5 Hz, 1H), 3.89 (t, J = 6.5 Hz, 2H), 3.16 (bs, 4H), 1.80–1.75 (m, 2H), 1.59–1.57 (m, 2H), 1.42 (bs, 4H), 1.02 (t, J = 7.5 Hz, 3H).


EXAMPLE 13



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropoxy-2-(piperidine-1-carbonyl)-phenyl]-amide.

This compound was prepared as described for the methyl ether analog in EXAMPLE 10 substituting substituting *i*-propanol for methanol in Step A. TLC (silica gel, 3:1 EtOAc/hexanes): R_f = 0.40. MS (ESI): m/z 461 $[M+H]^+$, 483 $[M+Na]^+$. HPLC (reversed-phase): R_T = 9.86 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.33 (s, 1H), 8.22 (dd, J = 7.0, 1.0 Hz, 2H), 7.65 (m, 1H), 7.20 (d, J = 2.5 Hz, 1H), 6.97 (d, J = 12 Hz, 1H), 6.49 (dd, J = 8.6, 2.5 Hz, 1H), 4.56–4.50 (m, 1H), 3.16 (bs, 4H), 1.60–1.58 (m, 2H), 1.42–1.38 (bs, 4H), 1.31 (d, J = 6.0 Hz, 6H).

EXAMPLE 14




Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-cyclopentyloxy-2-(piperidine-1-carbonyl)-phenyl]-amide.

This compound was prepared as described for the methyl ether analog in EXAMPLE 10 substituting substituting cyclopentanol for methanol in Step A. TLC (silica gel, 3:1 EtOAc/hexanes): R_f = 0.37. MS (ESI): m/z 487 $[M+H]^+$, 509

[M+Na]⁺. HPLC (reversed-phase): R_T = 10.45 min (single peak). ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 9.35 (s, 1H), 8.22 (dd, J = 7.0, 1.0 Hz, 2H), 7.66 (m, 1H), 7.18 (d, J = 2.5 Hz, 1H), 6.93 (d, J = 12 Hz, 1H), 6.48 (dd, J = 8.6, 2.5 Hz, 1H), 4.73–4.69 (m, 1H), 3.16 (bs, 4H), 2.04 (m, 2H), 1.76 (m, 4H), 1.60 (m, 4H), 1.42 (m, 4H).

EXAMPLE 15



Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-vinylphenyl]-amide.

A. 2-Nitro-4-vinylbenzoic acid piperidine amide. To a stirred solution of tetrakis(triphenylphosphine) palladium(0) (6 mg, 0.0054 mmol), 4-bromo-2-nitrobenzoic acid piperidine amide (EXAMPLE 5; 85 mg, 0.27 mmol), and toluene (10 mL), was added tributylvinylstannane (0.087 mL, 0.30 mmol) under a nitrogen atmosphere. The reaction mixture was heated to 115 °C for 12 h after which it was cooled to room temperature. The mixture was taken up in EtOAc (20 mL) and washed with water and aqueous NaHCO₃. The organic layers were dried (MgSO₄), filtered, and concentrated *in vacuo*. The resulting oil was purified on silica gel (MPLC, hexanes/EtOAc) to afford product (40 mg, 0.15 mmol, 57%). TLC (silica gel, 1:1 EtOAc/hexanes): R_f = 0.25. MS (ESI): *m/z* 261 [M+H]⁺, 283 [M+Na]⁺.


B. 2-Amino-4-vinylbenzoic acid piperidine amide. A solution of 2-nitro-4-vinylbenzoic acid piperidine amide (40 mg, 0.15 mmol) was dissolved in 1:1 EtOAc/DCM (10 mL), and SnCl₂·2H₂O (173 mg, 0.77 mmol) was added. The mixture was stirred overnight at ambient temperature then concentrated *in vacuo*. The resulting oil was suspended in DCM and neutralized by shaking with aqueous NaHCO₃. The organic layer was dried (MgSO₄), filtered, and

concentrated *in vacuo* to afford the title compound (30 mg, 0.13 mmol, 86%).
TLC (silica gel, EtOAc): $R_f = 0.42$. MS (ESI): m/z 231 $[M+H]^+$, 253 $[M+Na]^+$.

C. Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-vinyl-phenyl]-amide. 4-Chlorosulfonyl-2,1,3-benzothiadiazole (37 mg, 0.16 mmol)

- 5 was added to a solution of 2-amino-4-vinylbenzoic acid piperidine amide (30 mg, 0.13 mmol) and pyridine (0.016 ml, 0.20 mmol) in DCM (3 mL). The mixture was left standing overnight at ambient temperature. Then the volatiles were stripped *in vacuo*, and the resulting oil was taken up in 8 mL EtOAc and washed with 1 N HCl. The organic layer was dried ($MgSO_4$), filtered,
10 concentrated, and purified on silica gel (MPLC, hexanes/EtOAc) to provide the title compound (20 mg, 0.047 mmol, 36%). TLC (silica gel, 3:1 EtOAc/hexanes): $R_f = 0.47$. MS (ESI): m/z 429 $[M+H]^+$, 451 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 9.46$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.95 (s, 1H), 8.22 (m, 2H), 7.68 (s, 1H), 7.64 (d, $J = 7$ Hz, 1H), 7.08 (d, $J = 8$ Hz, 1H), 7.06 (d, $J = 14$ Hz, 1H), 6.63 (m, 1H), 5.73 (d, $J = 13$ Hz, 1H), 5.29 (d, $J = 11$ Hz, 1H), 3.41–2.90 (bs, 4H), 1.59 (m, 2H), 1.25 (bs, 4H).

EXAMPLE 16



20


Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-allyl-2-(piperidine-1-carbonyl)-phenyl]-amide.

- This compound was prepared as described in EXAMPLE 15 substituting allyltributylstannane for tributylvinylstannane in Step A. TLC (silica gel, 3:1 EtOAc/hexanes): $R_f = 0.53$. MS (ESI): m/z 443 $[M+H]^+$, 465 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 9.63$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.94 (s, 1H), 8.22 (m, 2H), 7.65 (m, 1H), 7.45 (s, 1H), 6.98 (d, 13 Hz, 1H), 6.85 (d, $J = 8$ Hz, 1H), 5.93–5.79 (m, 1H), 5.06 (m, 2H),

3.32 (d, $J = 7$ Hz, 2H), 3.28–2.96 (bs, 4H), 1.57 (m, 2H), 1.44 (bs, 4H).

Elemental analysis: calculated for $C_{21}H_{22}N_4O_3S_2$, C 56.99, H 5.01, N 12.66; found C 56.60, H 5.40, N 12.28.

5 EXAMPLE 17



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethyl-2-(piperidine-1-carbonyl)-phenyl]-amide.

To a stirred solution of 2-nitro-4-vinylbenzoic acid piperidine amide (100 mg, 0.39 mmol) in methanol (15 mL) was added Pd on carbon (10 wt %, 25 mg).

The reaction mixture was maintained under ~ 1 atm H_2 and stirred for 12 h.


The mixture was filtered through diatomaceous earth and concentrated *in vacuo* to yield (4-ethyl-2-nitro-phenyl)-piperidin-1-yl-methanone, which was subsequently reduced to (2-amino-4-ethyl-phenyl)-piperidin-1-yl-methanone

with $SnCl_2 \cdot 2H_2O$ as described in EXAMPLE 5. The title compound was prepared from the aniline (90 mg, 0.39 mmol) and 4-chlorosulfonyl-2,1,3-benzothiadiazole (181 mg, 0.78 mmol), and purified as described in EXAMPLE

15. TLC (silica gel, 3:1 EtOAc/hexanes): $R_f = 0.32$. MS (ESI): m/z 431 $[M+H]^+$, 453 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 9.52$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.95 (s, 1H), 8.21 (m, 2H), 7.65 (dd, $J = 8.8, 7$ Hz, 1H), 7.47 (d, $J = 1.3$ Hz, 1H), 6.95 (d, $J = 7.8$ Hz, 1H), 6.85 (dd, $J = 7.9, 1.6$ Hz, 1H), 3.14 (bs, 4H), 2.60 (m, 2H), 1.61 (m, 2H), 1.43 (bs, 4H), 1.17 (t, $J = 7.6$ Hz, 3H). Elemental analysis: calculated for $C_{20}H_{22}N_4O_3S_2$, C 55.79, H 5.15, N 13.01; found C 55.44, H 5.50, N 12.62.

25


EXAMPLE 18



Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propyl-phenyl]-amide.

- 5 This compound was prepared via reduction of 2-allyl-2-nitrobenzoic acid piperidine amide as described in the general procedure of EXAMPLE 17. TLC (silica gel, 3:1 EtOAc/hexanes): $R_f = 0.30$. MS (ESI): m/z 445 $[M+H]^+$, 467 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 10.04$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.94 (s, 1H), 8.21 (m, 2H), 7.65 (dd, $J =$
 10 8.8, 7 Hz, 1H), 7.47 (d, $J = 1.3$ Hz, 1H), 6.95 (d, $J = 7.8$ Hz, 1H), 6.82 (dd, $J =$
 7.9, 1.6 Hz, 1H), 3.10 (bs, 4H), 2.52 (t, $J = 7.4$ Hz, 2H), 1.61-1.52 (m, 4H), 1.43
 (bs, 4H), 0.87 (t, $J = 7.3$ Hz, 3H).

EXAMPLE 19



- 15 Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-(piperidine-1-carbonyl)-biphenyl-3-yl]-amide.


- A. 3-Nitrobiphenyl-4-carboxylic acid piperidine amide. 4-Bromo-2-nitrobenzoic acid piperidine amide (EXAMPLE 5; 100 mg, 0.32 mmol) and 2 M Na_2CO_3
 20 (0.32 mL, 0.64 mmol, aqueous) were added to a solution of tetrakis(triphenylphosphine) palladium(0) (15 mg, 0.013 mmol) in ethylene glycol dimethyl ether (8 mL), and the reaction mixture was stirred for 15 min. Phenylboronic acid (39 mg, 0.32 mmol) was added to the mixture, which was

then heated to 80 °C for 12 h. The mixture was cooled to room temperature, taken up in 10 mL of DCM, and washed with water and brine. The organic layers were dried (MgSO₄), filtered, and concentrated *in vacuo*. The resulting oil was purified on silica gel (MPLC, 85% hexanes/15% EtOAc) to yield product
5 (60 mg, 0.19 mmol). TLC (silica gel, 1:1 EtOAc/hexanes): R_f = 0.54. MS (ESI): *m/z* 311 [M+H]⁺, 333 [M+Na]⁺.

B. 3-Aminobiphenyl-4-carboxylic acid piperidine amide. 3-Nitrobiphenyl-4-carboxylic acid piperidine amide (60 mg, 0.19 mmol) was dissolved in 1:1 DCM/EtOAc (8 mL), and SnCl₂·2H₂O (218 mg, 0.97 mmol) was added. The
10 mixture was stirred overnight at ambient temperature then concentrated *in vacuo*. The resulting oil was suspended in DCM and neutralized by shaking with aqueous NaHCO₃. The organic layer was dried (MgSO₄), filtered, and concentrated *in vacuo* to afford the title compound (53 mg, 0.19 mmol, 98%).

C. Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-(piperidine-1-carbonyl)-biphenyl-3-yl]-amide. 4-Chlorosulfonyl-2,1,3-benzothiadiazole (50 mg, 0.21 mmol) was
15 added to a solution of 3-aminobiphenyl-4-carboxylic acid piperidine amide (60 mg, 0.21 mmol) and pyridine (0.025 ml, 0.32 mmol) in DCM (8 mL). The mixture was left standing overnight at ambient temperature. Then the volatiles were stripped *in vacuo*, and the resulting oil was taken up in 10 mL EtOAc and
20 washed with 1 N HCl. The organic layer was dried (MgSO₄), filtered, concentrated, and purified on silica gel (MPLC, hexanes/EtOAc) to provide the title compound (80 mg, 0.17 mmol, 80%). TLC (silica gel, 1:1 EtOAc/hexanes): R_f = 0.38. MS (ESI): *m/z* 479 [M+H]⁺, 501 [M+Na]⁺. HPLC (reversed-phase): R_T = 10.02 min (single peak). ¹H NMR (400 MHz, CDCl₃): (rotameric
25 broadening) 9.00 (s, 1H), 8.22 (m, 2H), 7.89 (d, *J* = 1.6 Hz, 1H), 7.65 (dd, *J* = 8.8, 7.0 Hz, 1H), 7.52 (m, 2H), 7.44 (m, 2H), 7.37 (m, 1H), 7.25 (m, 1H), 7.11 (d, *J* = 8.0 Hz, 1H), 3.22 (bs, 4H), 1.60 (m, 2H), 1.47 (bs, 4H).


EXAMPLE 20



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-2-yl-2-(piperidine-1-carbonyl)-phenyl]-amide.


- 5 This compound was prepared as described in EXAMPLE 19 substituting 2-furylboronic acid for phenylboronic acid in Step A. MS (ESI): m/z 469 $[M+H]^+$, 491 $[M+Na]^+$. HPLC (reversed-phase): R_T = 9.65 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.01 (s, 1H), 8.26 (d, J = 7.0 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 7.96 (s, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.49 (s, 1H),
 10 7.32 (d, J = 8.0, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.71 (d, J = 3.2 Hz, 1H), 6.48 (s, 1H), 3.14 (bs, 4H), 1.59 (m, 2H), 1.45 (bs, 4H).

EXAMPLE 21



- 15 Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-3-yl-2-(piperidine-1-carbonyl)-phenyl]-amide.
- This compound was prepared as described in EXAMPLE 19 substituting 3-furylboronic acid for phenylboronic acid in Step A. MS (ESI): m/z 469 $[M+H]^+$, 491 $[M+Na]^+$. HPLC (reversed-phase): R_T = 9.49 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.01 (s, 1H), 8.22 (m, 2H), 7.78 (d, J = 1.6 Hz, 1H), 7.73 (s, 1H), 7.65 (dd, J = 8.8, 7 Hz, 1H), 7.48 (t, J = 1.8, 1H), 7.14 (dd, J = 8.0, 1.6 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.65 (m, 1H), 3.15 (bs, 4H), 1.59 (m, 2H), 1.44 (bs, 4H).
- 20

EXAMPLE 22




5 Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-2-yl-phenyl]-amide.

This compound was prepared as described in EXAMPLE 19 substituting 2-thienylboronic acid for phenylboronic acid in Step A. TLC (silica gel, 1:1 EtOAc/hexanes): $R_f = 0.37$. MS (ESI): m/z 485 $[M+H]^+$, 507 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 9.88$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.03 (s, 1H), 8.28 (d, $J = 7.0$ Hz, 1H), 8.21 (d, $J = 8.8$ Hz, 1H), 7.90 (s, 1H), 7.68 (t, $J = 8.0$ Hz, 1H), 7.32 (m, 1H), 7.24 (m, 1H), 7.08 (m, 2H), 3.20 (bs, 4H), 1.61 (m, 2H), 1.47 (bs, 4H).

10

EXAMPLE 23




15 Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-3-yl-phenyl]-amide.

This compound was prepared as described in EXAMPLE 19 substituting 3-thienylboronic acid for phenylboronic acid in Step A. TLC (silica gel, 1:1 EtOAc/hexanes): $R_f = 0.33$. MS (ESI): m/z 485 $[M+H]^+$, 507 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 9.82$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.01 (s, 1H), 8.23 (d, $J = 7.0$ Hz, 1H), 8.21 (d, $J = 8.8$ Hz, 1H), 7.90 (s, 1H), 7.65 (t, $J = 8.0$ Hz, 1H), 7.47 (s, 1H), 7.39 (m, 1H), 7.32

20

(m, 1H), 7.25 (m, 1H), 7.07 (d, $J = 8.0$ Hz, 1H), 3.12 (bs, 4H), 1.59 (m, 2H), 1.45 (bs, 4H).

EXAMPLE 24




Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-amino-2-(piperidine-1-carbonyl)-phenyl]-amide.

A solution of benzo[1,2,5]thiadiazole-4-sulfonic acid [5-nitro-2-(piperidine-1-carbonyl)-phenyl]-amide (EXAMPLE 2; 90 mg, 2.0 mmol) was dissolved in 1:1 EtOAc/DCM (10 mL), and $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (2.3 g, 10 mmol) was added. The mixture was stirred overnight at ambient temperature then concentrated *in vacuo*. The resulting oil was suspended in DCM and neutralized by shaking with aqueous NaHCO_3 . The organic layer was dried (MgSO_4), filtered, and concentrated *in vacuo* to afford the title compound (69 mg, 1.7 mmol, 82%).

TLC (silica gel, 3:1 EtOAc/hexanes): $R_f = 0.42$. MS (ESI): m/z 418 $[\text{M}+\text{H}]^+$, 440 $[\text{M}+\text{Na}]^+$. HPLC (reversed-phase): $R_T = 8.15$ min (single peak). ^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 9.80 (s, 1H), 8.40 (dd, $J = 8.8$ Hz, 1.0 Hz, 1H), 8.15 (dd, $J = 7.0$ Hz, 1.0 Hz, 1H), 7.82 (dd, $J = 8.8$ Hz, 1.0 Hz, 1H), 6.77 (d, $J = 8.4$ Hz, 1H), 6.74 (d, $J = 2.2$ Hz, 1H), 6.19 (dd, $J = 8.4$ Hz, 2.3 Hz, 1H), 5.75 (d, $J = 2.3$ Hz, 2H), 2.96 (bs, 4H), 1.45 (bs, 2H), 1.24 (bs, 4H).


EXAMPLE 25



Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-pyrrol-1-yl-phenyl]-amide.

- 5 To a stirred solution of benzo[1,2,5]thiadiazole-4-sulfonic acid [5-amino-2-(piperidine-1-carbonyl)-phenyl]-amide (EXAMPLE 24; 25 mg, 0.06 mmol) in glacial acetic acid (3 mL) was added 2,5-dimethoxytetrahydrofuran (8 μ L, 0.06 mmol). The reaction mixture was heated to 120 °C for 45 min after which it was cooled to room temperature. The mixture was taken up in 4 mL of DCM
- 10 and washed with water. The organic layer was removed, dried, and purified by preparative reversed-phase HPLC to afford the title compound (12 mg, 0.02 mmol, 43%). MS (ESI): m/z 468 $[M+H]^+$, 490 $[M+Na]^+$. HPLC (reversed-phase): R_T = 9.71 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.15 (s, 1H), 8.26 (dd, J = 7.0, 1.0 Hz, 1H), 8.22 (dd, J = 8.8, 1.0
- 15 Hz, 1H), 7.74 (d, J = 2.1 Hz, 1H), 7.67 (dd, J = 8.8, 7 Hz, 1H), 7.10 (d, J = 8.3 Hz, 1H), 7.05 (m, 3H), 6.35 (t, J = 2.2 Hz, 2H), 3.23 (bs, 4H), 1.61 (m, 2H), 1.48 (bs, 4H).


EXAMPLE 26



20 Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-dimethylamino-2-(piperidine-1-carbonyl)-phenyl]-amide.

To a stirred solution of benzo[1,2,5]thiadiazole-4-sulfonic acid [5-amino-2-(piperidine-1-carbonyl)-phenyl]-amide (EXAMPLE 24; 30 mg, 0.072 mmol) in 2:1 acetonitrile/DCM (6 mL), was added formaldehyde (0.1 mL, 3.6 mmol), sodium cyanoborohydride (68 mg, 1.08 mmol) and acetic acid (12 μ L). The reaction mixture was stirred for 3 h at room temperature. 1 M NaOH was added until the solution became basic. The mixture was taken up in DCM (5 mL), and washed with water and brine. The organic layer was removed, dried, and purified by preparative reversed-phase HPLC to afford the title compound (8 mg, 0.02 mmol, 25%). MS (ESI): m/z 446 $[M+H]^+$, 468 $[M+Na]^+$. HPLC (reversed-phase): R_T = 9.14 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.61 (s, 1H), 8.22 (dd, J = 7.0, 1.0 Hz, 1H), 8.18 (dd, J = 8.8, 1.0 Hz, 1H), 7.63 (dd, J = 8.8, 7.0 Hz, 1H), 6.95 (d, J = 7.0, 2.5 Hz, 1H), 6.90 (d, J = 8.7 Hz, 1H), 6.26 (dd, 8.7, 2.5 Hz, 1H), 3.16 (s, 4H), 2.95 (s, 6H), 1.56 (m, 2H), 1.42 (m, 4H).

EXAMPLE 27




Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-(cyclohexylmethyl-amino)-2-(piperidine-1-carbonyl)-phenyl]-amide.

To a stirred solution of benzo[1,2,5]thiadiazole-4-sulfonic acid [5-amino-2-(piperidine-1-carbonyl)-phenyl]-amide (EXAMPLE 24; 50 mg, 0.12 mmol) in dichloroethane (4 mL) was added cyclohexanecarboxaldehyde (43 μ L, 0.36 mmol), followed by sodium triacetoxyborohydride (50 mg, 0.24 mmol). The reaction mixture was stirred for 12 h at room temperature. 1 M NaOH was added until the solution became basic. The mixture was taken up in 5 mL of DCM and washed with water and aqueous $NaHCO_3$. The organic layer was removed, dried, and purified by preparative reversed-phase HPLC to afford the title compound (20 mg, 0.04 mmol, 33%). MS (ESI): m/z 514 $[M+H]^+$, 536

[M+Na]⁺. HPLC (reversed-phase): R_T = 10.93 min (single peak). ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 9.36 (s, 1H), 8.20 (dd, *J* = 8.8, 7.0 Hz, 2H), 7.63 (dd, *J* = 8.8, 7.0 Hz, 1H), 6.85 (d, *J* = 3.8 Hz, 1H), 6.81 (d, *J* = 2.3 Hz, 1H), 6.15 (dd, *J* = 8.5, 2.3 Hz, 1H), 3.21 (m, 4H), 2.90 (d, *J* = 6.7 Hz, 2H), 1.74 (m, 6H), 1.57 (m, 2H), 1.46 (m, 4H), 1.22 (m, 3H), 0.96 (m, 2H).

EXAMPLE 28



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide.

A. 4-Mercapto-2-nitrobenzoic acid piperidine amide. Sodium nitrite (278 mg, 4.0 mmol) in water (2 mL) was added dropwise to a stirred solution of water (15 mL), concentrated HCl (1 mL), and 4-amino-2-nitrobenzoic acid piperidine amide (EXAMPLE 2; 1.0 g, 4.0 mmol) in THF (7 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 20 min, after which O-ethylxanthic acid was added. The mixture was stirred at 0 °C for 15 min, gradually heated to 60 °C, then cooled to room temperature and stirred for 2 h. 1,4-Dioxane (15 mL) and concentrated aqueous NH₄OH (15 mL) were added, and the mixture was stirred at room temperature for 2 h. 1 N HCl was added until the solution was neutral to pH paper. The reaction mixture was taken up in 40 mL DCM and washed with water. The organic layer was dried (MgSO₄), filtered, concentrated, and purified on silica gel (MPLC, hexanes/EtOAc) to provide the title compound (210 mg, 0.89 mmol, 22%). TLC (silica gel, EtOAc): R_f = 0.37. MS (ESI): *m/z* 267 [M+H]⁺, 289 [M+Na]⁺.

B. 4-Methylthio-2-nitrobenzoic acid piperidine amide. To a stirred solution of 4-mercapto-2-nitrobenzoic acid piperidine amide (50 mg, 0.19 mmol) and sodium hydride (5 mg, 0.21 mmol) in DMF (4 mL), was added iodomethane (0.013 mL, 0.21 mmol). The reaction mixture was stirred at room temperature

for 1 h then taken up in 10 mL of EtOAc and washed with water. The organic layer was dried (MgSO₄), filtered, and concentrated *in vacuo* to afford the title compound (35 mg, 0.12 mmol, 67%). TLC (silica gel, EtOAc): R_f = 0.53.


C. 2-Amino-4-methylthiobenzoic acid piperidine amide. 4-Methylthio-2-

5 nitrobenzoic acid piperidine amide (35 mg, 0.13 mmol) was dissolved in 1:1 DCM/EtOAc (6 mL), and SnCl₂·2H₂O (141 mg, 0.62 mmol) was added. The mixture was stirred overnight at ambient temperature then concentrated *in vacuo*. The resulting oil was suspended in DCM and neutralized by shaking with aqueous NaHCO₃. The organic layer was dried (MgSO₄), filtered, and
10 concentrated *in vacuo* to afford the title compound (30 mg, 0.12 mmol, 98%). TLC (silica gel, EtOAc): R_f = 0.48.

D. Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide.

4-Chlorosulfonyl-2,1,3-benzothiadiazole (45 mg, 0.19 mmol) was added to a solution of 2-amino-4-methylthiobenzoic acid piperidine
15 amide (40 mg, 0.16 mmol) and pyridine (0.019 mL, 0.24 mmol) in DCM (5 mL). The mixture was left standing overnight at ambient temperature. Then the volatiles were stripped *in vacuo*, and the resulting oil was taken up in 10 mL EtOAc and washed with 1 N HCl. The organic layer was dried (MgSO₄), filtered, concentrated, and purified on silica gel (MPLC, hexanes/EtOAc) to
20 provide the title compound (30 mg, 0.067 mmol, 42%). TLC (silica gel, EtOAc): R_f = 0.54. MS (ESI): *m/z* 449 [M+H]⁺, 471 [M+Na]⁺. HPLC (reversed-phase): R_T = 9.42 min (single peak). ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 9.13 (s, 1H), 8.22 (m, 2H), 7.66 (dd, *J* = 8.8, 7.0 Hz, 1H), 7.50 (d, *J* = 1.8 Hz, 1H), 6.94 (d, *J* = 8.2 Hz, 1H), 6.85 (dd, *J* = 8.2, 1.8 Hz, 1H), 3.17
25 (bs, 4H), 2.45 (s, 3H), 1.61 (m, 2H), 1.43 (bs, 4H).


EXAMPLE 29



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide.


- 5 This compound was prepared as described in EXAMPLE 28 substituting iodoethane for iodomethane in Step B. TLC (silica gel, 3:1 EtOAc/hexanes): R_f = 0.25. MS (ESI): m/z 463 $[M+H]^+$, 485 $[M+Na]^+$. HPLC (reversed-phase): R_T = 9.66 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.09 (s, 1H), 8.22 (m, 2H), 7.66 (dd, J = 8.8, 7.0 Hz, 1H), 7.54 (d, J = 1.7 Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.88 (dd, J = 8.1, 1.8 Hz, 1H), 3.16 (bs, 4H), 2.97 (m, 2H), 1.59 (m, 2H), 1.43 (bs, 4H), 1.34 (t, J = 7.4 Hz, 3H).

EXAMPLE 30



- 15 Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isobutylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide.
- This compound was prepared as described in EXAMPLE 28 substituting isobutyl iodide for iodomethane in Step B. MS (ESI): m/z 491 $[M+H]^+$, 513 $[M+Na]^+$. HPLC (reversed-phase): R_T = 10.40 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.09 (s, 1H), 8.23 (s, 1H), 8.21 (d, J = 2.8 Hz, 1H), 7.66 (dd, J = 8.8, 7.0 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 6.89 (m, 2H), 3.16 (bs, 4H), 2.78 (d, J = 6.8 Hz, 2H), 1.88 (m, 1H), 1.59 (m, 2H), 1.43 (bs, 4H) 1.04 (d, J = 6.7 Hz, 6H).


EXAMPLE 31



5 Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-benzylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide.

This compound was prepared as described in EXAMPLE 28 substituting benzylbromide for iodomethane in Step B. TLC (silica gel, 3:1 EtOAc/hexanes): R_f = 0.32. MS (ESI): m/z 525 $[M+H]^+$, 547 $[M+Na]^+$. HPLC (reversed-phase): R_T = 10.24 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.05 (s, 1H), 8.19 (dd, J = 8.8, 1.0 Hz, 1H), 8.09 (dd, J = 7.0, 1.0 Hz, 1H), 7.59 (m, 2H), 7.35–7.28 (m, 5H), 6.91–6.86 (m, 2H), 4.21 (s, 2H), 3.15 (bs, 4H), 1.59 (m, 2H), 1.37 (m, 4H).

EXAMPLE 32



15

Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-trifluoromethyl-phenyl]-amide.

A. 2-Nitro-4-trifluoromethylbenzoic acid piperidine amide. To a solution of 2-nitro-4-trifluoromethylbenzoic acid (1.1 g, 4.7 mmol) in acetonitrile (20 mL) was added piperidine (0.42 mL, 4.3 mmol) followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (0.98 g, 5.1 mmol) and DMF (2 mL). The mixture was stirred at ambient temperature overnight, then was diluted with EtOAc and washed repeatedly with 1 N aqueous NaOH then brine. The


organic layer was dried (Na_2SO_4), filtered, and purified on silica gel (MPLC, hexanes/EtOAc) to provide the amide as a white solid (0.19 g, 0.63 mmol, 13%). TLC (silica gel, 1:1 EtOAc/hexanes): $R_f = 0.60$. MS (ESI): m/z 303 $[\text{M}+\text{H}]^+$, 325 $[\text{M}+\text{Na}]^+$.

5 B. 2-Amino-4-trifluoromethylbenzoic acid piperidine amide. 2-Nitro-4-trifluoromethylbenzoic acid piperidine amide (0.19 g, 0.63 mmol) was dissolved in 2:5 DCM/EtOAc (7 mL), and $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (0.71 g, 3.15 mmol) was added. The mixture was stirred overnight at ambient temperature then concentrated *in vacuo*. The resulting oil was suspended in DCM and neutralized by shaking
10 with aqueous NaHCO_3 . The organic layer was dried (MgSO_4), filtered; concentrated and purified on silica gel (MPLC, EtOAc/hexanes 20% to 70%) to provide the title compound as a white solid (130 mg, 0.48 mmol, 76%). TLC (silica gel, 1:1 EtOAc/hexanes): $R_f = 0.65$. MS (ESI): m/z 273 $[\text{M}+\text{H}]^+$, 295 $[\text{M}+\text{Na}]^+$.

15 C. Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-trifluoromethyl-phenyl]-amide. 4-Chlorosulfonyl-2,1,3-benzothiadiazole (0.063 g, 0.27 mmol) was added to a solution of 2-amino-4-trifluoromethylbenzoic acid piperidine amide (0.070 mg, 0.26 mmol) and pyridine (0.030 mL, 0.36 mmol) in DCM (1.5 mL). The mixture was left standing overnight at ambient
20 temperature. Then the volatiles were stripped *in vacuo*, and the resulting oil was taken up in EtOAc (10 mL) and washed with 1 N HCl. The organic layer was removed, dried and purified by preparative reversed-phase HPLC to afford the title compound as a white foam (46 mg, 0.098 mmol, 36%). MS (ESI): m/z 471 $[\text{M}+\text{H}]^+$, 493 $[\text{M}+\text{Na}]^+$. ^1H NMR (400 MHz, CDCl_3): (rotameric broadening)
25 8.86 (bs, 1H), 8.28 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.24 (dd $J = 8.8, 1.0$ Hz, 1H), 7.93 (s, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.30 (m, 1H), 7.18 (d, $J = 8.0$ Hz, 1H), 3.49–3.44 (bs, 2H), 3.02–2.96 (bs, 2H), 1.62 (bs, 2H), 1.53–1.25 (bs, 4H). Elemental analysis: calculated for $\text{C}_{19}\text{H}_{17}\text{F}_3\text{N}_4\text{O}_3\text{S}_2$, C 48.50, H 3.64, N 11.91; found C 48.69, H 3.43, N 11.93.

30

EXAMPLE 33




Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-fluoro-2-(piperidine-1-carbonyl)-phenyl]-amide.

- 5 This compound was prepared as described for the trifluoromethyl analog in EXAMPLE 32 substituting 2-nitro-4-fluoromethylbenzoic acid for 2-nitro-4-trifluoromethylbenzoic acid in Step A. HPLC (reversed-phase): $R_T = 9.30$ min (single peak). MS (ESI): m/z 421 $[M+H]^+$, 443 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.18 (bs, 1H), 8.29 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.23 (dd $J = 8.8, 1.0$ Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.41 (dd, $J = 10.8, 2.5$ Hz, 1H), 7.05 (dd, $J = 8.6, 6.1$ Hz, 1H), 6.71 (ddd, $J = 8.6, 7.0, 2.5$ Hz, 1H), 3.26-3.22 (bs, 4H), 1.62-1.57 (m, 2H), 1.47 (bs, 4H). Elemental analysis: calculated for $C_{18}H_{17}FN_4O_3S_2$, C 51.42, H 4.08, N 13.32; found C 51.12, H 4.01, N 13.17.

15

EXAMPLE 34




Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide.

- 20 To a solution of 2-amino-6-chlorobenzoic acid (1.2 g, 7.0 mmol) in acetonitrile (17 mL) was added piperidine (0.63 mL, 6.3 mmol) followed by EDC (1.46 g, 7.6 mmol) and DMF (21 mL). The mixture was stirred at ambient temperature overnight. An additional 20 mol% piperidine and EDC was added, and the

reaction mixture was stirred 3 h. The mixture was diluted with EtOAc and washed repeatedly with 1 N NaOH then brine. The organic layer was dried (Na_2SO_4), filtered, and purified on silica gel (MPLC, hexanes/EtOAc, 15% to 70%) to provide amino-6-chlorobenzoic acid piperidine amide as a white solid (0.21 g), which was used directly in the next reaction. The title compound was prepared from amino-6-chlorobenzoic acid piperidine amide (60. mg, 0.25 mmol), 4-chlorosulfonyl-2,1,3-benzothiadiazole (61 mg, 0.26 mmol) and pyridine (0.031 mL, 0.38 mmol), and purified as described in EXAMPLE 32. HPLC (reversed-phase): $R_T = 9.15$ min (single peak). MS (ESI): m/z 437/439 $[\text{M}+\text{H}]^+$, 459/461 $[\text{M}+\text{Na}]^+$. ^1H NMR (400 MHz, CDCl_3): 8.24 (dd, $J = 3.3, 1.0$ Hz, 1H), 8.23 (dd, $J = 1.6, 1.0$ Hz, 1H), 7.71 (s, 1H), 7.68 (dd, $J = 8.7, 7.2$ Hz, 1H), 7.31 (dd, $J = 8.1, 1.0$ Hz, 1H), 7.16 (dd, $J = 8.1, 8.1$ Hz, 1H), 7.10 (dd, $J = 8.1, 1.0$ Hz, 1H), 3.67 (m, 1H), 3.54 (m, 1H), 3.16 (m, 1H), 3.02 (m, 1H), 1.65 (m, 5H), 1.48 (m, 1H).

EXAMPLE 35



Benzo[1,2,5]thiadiazole 4-sulfonic acid [4,5-dibromo-2-(piperidine-1-carbonyl)-phenyl]-amide.

A. [5-Nitro-2-(piperidine-1-carbonyl)-phenyl]-carbamic acid tert-butyl ester. To a solution of 2-amino-4-nitrobenzoic acid piperidine amide (EXAMPLE 2; 0.73 g, 2.9 mmol) in dry DMF (5 mL) was added triethylamine (TEA) (0.40 mL, 2.9 mmol) followed by di-*t*-butyldicarbonate (0.70 g, 3.2 mmol). After 24 h, an additional 0.45 g di-*t*-butyldicarbonate was added, and the mixture was heated gently at 50 °C. The reaction was monitored by TLC. Volatiles were removed *in vacuo*, and the resulting oil was purified on silica gel (MPLC, hexanes/EtOAc 10% to 70%) to afford the desired Boc-protected aniline (0.35 g, 1.0 mmol, 34%). MS (ESI): pos. ion m/z 372 $[\text{M}+\text{Na}]^+$, neg. ion m/z 348 $[\text{M}-\text{H}]^-$. ^1H NMR

(400 MHz, CDCl_3): 9.08 (s, 1H), 7.91 (s, 1H), 7.86 (dd, $J = 8.2, 2.3$ Hz, 1H), 3.73 (bm, 2H), 3.33 (bm, 2H), 1.62 (bm, 3H), 1.57 (bm, 3H), 1.53 (s, 9H).

B. [5-Amino-2-(piperidine-1-carbonyl)-phenyl]-carbamic acid tert-butyl ester.

A solution of [5-nitro-2-(piperidine-1-carbonyl)-phenyl]-carbamic acid tert-butyl ester (0.16 g, 0.46 mmol) in ethanol (8 mL), containing 1,4-cyclohexadiene (0.64 mL, 6.8 mmol) and Pd on carbon (10 wt %, 0.022 g) was refluxed overnight. The cooled suspension was filtered through diatomaceous earth, and concentrated *in vacuo*. The crude product was purified on silica gel (MPLC, hexanes/EtOAc 10% to 50%) to provide the aniline as a solid (0.050 g, 0.16 mmol, 34%). MS (ESI): m/z 320 $[\text{M}+\text{H}]^+$, 342 $[\text{M}+\text{Na}]^+$, 661 $[\text{2M}+\text{Na}]^+$. ^1H NMR (400 MHz, CDCl_3): 8.52 (bs, 1H), 7.62 (bs, 1H), 6.99 (d, $J = 8.2$ Hz, 1H), 6.29 (bd, $J = 8.0$ Hz, 1H), 3.55 (m, 4H), 1.68 (m, 3H), 1.61 (m, 3H), 1.49 (s, 9H).

C. [4,5-Dibromo-2-(piperidine-1-carbonyl)-phenyl]-carbamic acid tert-butyl


ester. An oven-dried round-bottom flask was purged with nitrogen and charged with CuBr_2 (0.040 g, 0.18 mmol) and anhydrous acetonitrile (0.5 mL). *t*-Butylnitrite (90%, 0.028 mL, 0.24 mmol) was added via syringe, and the reaction mixture was cooled in ice with stirring. [5-Amino-2-(piperidine-1-carbonyl)-phenyl]-carbamic acid tert-butyl ester (0.040 g, 0.13 mmol) was added in small portions over 5 min. The reaction mixture was allowed to warm slowly to ambient temperature over 6.5 h then was partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc (2x), and the combined organic layers were washed with brine and dried (Na_2SO_4). The crude product was purified on silica gel (MPLC, hexanes/EtOAc 10% to 30%) to provide the dibromo arene as an oil (0.016 g, 0.035 mmol, 30%). MS (ESI): neg. ion m/z 459/461/463 $[\text{M}-\text{H}]^-$. ^1H NMR (400 MHz, CDCl_3): 8.55 (s, 1H), 7.88 (bs, 1H), 7.38 (s, 1H), 3.56 (bs, 4H), 1.70 (m, 3H), 1.60 (m, 3H), 1.49 (s, 9H).

D. Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dibromo-2-(piperidine-1-

carbonyl)-phenyl]-amide. [4,5-Dibromo-2-(piperidine-1-carbonyl)-phenyl]-carbamic acid tert-butyl ester (0.015 g, 0.032 mmol) was dissolved in TFA (2 mL) and allowed to stand at ambient temperature for 1 h. The TFA was removed *in vacuo*, and the resulting oil was taken up in DCM and washed with

5% aqueous NaHCO_3 . The organic layer was dried (MgSO_4), filtered, and concentrated to give the aniline as a crude oil, which was used directly without purification. The aniline was coupled with 4-chlorosulfonyl-2,1,3-benzothiadiazole (0.010 g, 0.039 mmol), and product was purified, as described in EXAMPLE 32 to provide benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dibromo-2-(piperidine-1-carbonyl)-phenyl]-amide (0.0034 g, 0.0061 mmol, 20%, two steps). HPLC (reversed-phase): $R_T = 10.15$ min (single peak). MS (ESI): $m/z \sim 561$ $[\text{M}+\text{H}]^+$, ~ 582 $[\text{M}+\text{Na}]^+$. ^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 8.81 (s, 1H), 8.27 (dd, $J = 4.1, 1.0$ Hz, 1H), 8.25 (dd, $J = 6.0, 1.0$ Hz, 1H), 7.95 (s, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.28 (s, 1H), 3.3–2.8 (bs, 4H), 1.72 (m, 3H), 1.47 (m, 3H).

EXAMPLE 36



15 Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dichloro-2-(piperidine-1-carbonyl)-phenyl]-amide.

A. 1-Bromo-4,5-dichloro-2-nitro-benzene. 4-Bromo-1,2-dichlorobenzene (10.5 g, 46.3 mmol)-was added to 25 mL concentrated sulfuric acid at 0 °C. A 1:1 mixture of 70% nitric acid and concentrated sulfuric acid (20 mL) was added dropwise over 40 min. The reaction mixture was allowed to warm to ambient temperature with stirring over 0.5 h, then was poured onto cracked ice. The resulting mixture was filtered through paper, and the collected solids were washed with water (5x) and then dried at 45 °C under reduced pressure for 30 min to provide 10.7 g of an 88:12 mixture of desired nitroarene to starting material. Recrystalization from absolute ethanol provided 4.76 g of long yellow needles corresponding to a 20:1 mixture of product to starting material. The mother liquor was concentrated and recrystallized twice to provide an additional 1.18 g of product (17:1 mixture with recovered starting material).

TLC (silica gel, 1:1 hexanes/EtOAc): R_f = 0.45. ^1H NMR (400 MHz, CDCl_3): 7.95 (s, 1H), 7.80 (s, 1H).

B. 4,5-Dichloro-2-nitrobenzoic acid methyl ester. Bis-triphenyl-

phosphinepalladium dichloride (0.039 g, 0.055 mmol) was added to an oven-dried two-neck 25 mL flask fitted with a reflux condenser and a rubber septum and flushed with nitrogen. The flask was repeatedly evacuated and filled with CO (1 atm). A solution of 1-bromo-4,5-dichloro-2-nitrobenzene (1.00 g, 3.69 mmol) in TEA (0.64 mL, 4.6 mmol) and methanol (0.5 mL) was added via syringe, and the reaction mixture was stirred at 60 °C under 1 atm CO for 18 h.

The flask was charged with fresh catalyst (0.04 g) and methanol (0.3 mL), and the reaction mixture was allowed to continue stirring an additional 6 h. The mixture was cooled and filtered, and the filtrate was concentrated and purified on silica gel (MPLC, hexanes/EtOAc 3% to 10%) to provide the methyl ester as a yellow oil (0.324 g, 1.30 mmol, 35%). TLC (silica gel, 9:1 hexanes/EtOAc): R_f = 0.31. ^1H NMR (400 MHz, CDCl_3): 8.03 (s, 1H), 7.84 (s, 1H), 3.93 (s, 3H).

C. 4,5-Dichloro-2-nitrobenzoic acid piperidine amide. A solution of 4,5-

dichloro-2-nitrobenzoic acid methyl ester (0.29 g, 1.16 mmol) in 1:1 THF/methanol (4 mL) was stirred as 1 N aqueous LiOH (2 mL) was added.

After 1 h, the mixture was acidified with 1 N HCl and extracted with EtOAc (3x).

The combined organic layers were washed with brine, dried (MgSO_4), filtered, and concentrated to provide crude 4,5-dichloro-2-nitrobenzoic acid as a light yellow solid (0.26 g, 0.90 mmol, 77%). The acid was refluxed in 4 mL thionyl chloride for 2 h, and the crude reaction mixture was concentrated *in vacuo*.

Residual thionyl chloride was removed by the repeated addition and *in vacuo* stripping of DCM. The acid chloride was placed under high vacuum for 10 min, and then taken up in dry DCM (5 mL). The mixture was cooled in an ice bath. Piperidine (0.46 g, 5.4 mmol, 0.53 mL) was added, and the reaction mixture was allowed to stand at 0 °C overnight. The mixture was diluted with DCM, washed with 1 N HCl (2x), 5% aqueous NaHCO_3 and brine, and dried (MgSO_4).


Filtration and concentration provided 0.32 g of the desired amide, which could not be separated from an impurity (10%) that corresponded to the product of displacement of a chlorine by an additional equivalent of piperidine. HPLC

(reversed-phase): $R_T \approx 9.35$ min (90%), 10.58 (10%). MS (ESI): major m/z 303 $[M+H]^+$, minor m/z 352 $[M+H]^+$.

D. Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dichloro-2-(piperidine-1-carbonyl)-phenyl]-amide.

- 4,5-Dichloro-2-nitrobenzoic acid piperidine amide (0.30 g, 0.98 mmol) was reduced with $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (0.88 g, 3.9 mmol), and the product was purified, as described in EXAMPLE 32 to afford 2-amino-4,5-dichlorobenzoic acid piperidine amide (0.19 g, 0.69 mmol, 70%). The aniline was coupled with 4-chlorosulfonyl-2,1,3-benzothiadiazole (0.18 g, 0.77 mmol), and the product was purified, as described in EXAMPLE 32 to provide the title compound as a light yellow solid (0.115 g, 0.244 mmol, 25%, two steps). mp = 178–179 °C. MS (ESI): $m/z \sim 471$ $[M+H]^+$, ~ 493 $[M+Na]^+$. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): (rotameric broadening) 10.12 (bs, 1H), 8.41 (dd, $J = 8.8, 1.0$ Hz, 1H), 8.17 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.83 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.53 (s, 1H), 7.46 (s, 1H), 3.35 (bs, 2H), 2.88 (bs, 2H), 1.49 (m, 3H), 1.38–1.31 (m, 3H).
- Elemental analysis: calculated for $\text{C}_{18}\text{H}_{16}\text{Cl}_2\text{N}_4\text{O}_3\text{S}_2$, C 45.86, H 3.42, N 11.89, S 13.60, Cl 15.04; found C 46.10, H 3.22, N 11.77, S 13.74, Cl 14.94.

EXAMPLE 37



- Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropyl-2-(piperidine-1-carbonyl)-phenyl]-amide.
- A. 4-Isopropyl-2-nitrobenzoic acid. A solution of 2-nitro-*p*-cymene (5.00 g, 27.9 mmol) in dry DMF (30 mL) was heated to 140–150 °C in the presence of DMF-dimethyl acetal (9.98 g, 83.7 mmol) for 16 h. The volatiles were removed *in vacuo*. The crude enamine was taken up in 60 mL THF, and 50 mL water was added followed by NaIO_4 (17.9 g, 83.7 mmol). The deep red solution turned into a yellow slurry within 5 min. After 1 h, the reaction mixture was filtered, and the filtrate was extracted with EtOAc (3x), washed with 5%

NaHCO₃ (3x) and brine, and dried (MgSO₄). Filtration and concentration afforded the crude aldehyde, which was used without further purification. The aldehyde was dissolved in *t*-butanol (60 mL), and a pH 4.0 acetate buffer (30 mL) was added followed by 2-methyl-2-butene (2.9 g, 41.8 mmol, 4.4 mL). A solution of sodium chlorite (3.0 g, 33.5 mmol) in water (30 mL) was added dropwise over 5 min to the vigorously stirred reaction mixture. After 0.5 h, 100 mL 1 N HCl was added to the reaction mixture, which was then extracted with EtOAc (4x). The combined organic layers were extracted with 1 N aqueous NaOH (5x30 mL). The basic extracts were combined, acidified with 225 mL 1 N HCl to pH 1, and extracted with EtOAc (5x). The combined organic extracts were washed with brine, dried (MgSO₄), mixed with decolorizing carbon, and filtered through diatomaceous earth. Concentration provided 4-isopropyl-2-nitrobenzoic acid as an off-white solid (2.13 g, 10.5 mmol, 38%, three steps). ¹H NMR (400 MHz, CDCl₃): 8.44 (bs, 1H), 7.77 (d, *J* = 8.0 Hz, 1H), 7.56 (d, *J* = 1.5 Hz, 1H), 7.45 (dd, *J* = 8.0, 1.5 Hz, 1H), 2.96 (m, 1H), 1.22 (d, *J* = 6.8 Hz, 6H).


B. 4-Isopropyl-2-nitrobenzoic acid piperidine amide. 4-Isopropyl-2-nitrobenzoic acid (3.05 g, 15.1 mmol) was dissolved in 20 mL thionyl chloride and refluxed for 40 min. The thionyl chloride was distilled off. Residual thionyl chloride was stripped from the resulting oil using DCM as described in EXAMPLE 36, step C. The crude acid chloride was taken up in fresh DCM (45 mL), and piperidine (7.7 g, 91 mL) was added. After 24 h, the volatiles were removed *in vacuo*, and the residue was taken up in EtOAc. The resulting solution was washed with 1 N HCl (3x), 5% aqueous NaHCO₃ and brine, and dried (MgSO₄). Filtration and concentration, followed by purification on silica gel (MPLC, hexanes/EtOAc 10% to 50%) provided the amide as a light yellow solid (3.43 g, 12.4 mmol, 82%). MS (ESI): *m/z* 277 [M+H]⁺, 553 [2M+H]⁺, 575 [2M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 8.03 (d, *J* = 1.7 Hz, 1H), 7.55 (ddd, *J* = 7.8, 1.7, 0.4 Hz, 1H), 7.30 (d, *J* = 7.8 Hz, 1H), 3.77 (bm, 2H), 3.18 (t, *J* = 5.6 Hz, 2H), 3.00 (m, 1H), 1.42 (m, 3H), 1.52 (bm, 3H), 1.31 (d, *J* = 6.8 Hz, 6H).

C. Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropyl-2-(piperidine-1-carbonyl)-phenyl]-amide. 4-Isopropyl-2-nitrobenzoic acid piperidine amide (3.43 g, 12.4 mmol) was reduced with SnCl₂•2H₂O (11.2 g, 49.6 mmol), and

the product was purified, as described in EXAMPLE 32. The resulting aniline (0.217 g, 0.882 mmol) was coupled with 4-chlorosulfonyl-2,1,3-benzothiadiazole (0.248 g, 1.06 mmol) and pyridine (0.105 g, 1.32 mmol), and the product was purified, as described in EXAMPLE 32 to provide

- 5 benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropyl-2-(piperidine-1-carbonyl)-phenyl]-amide (45%, two steps). mp = 125–127 °C. MS (ESI): m/z 445 $[M+H]^+$, 467 $[M+Na]^+$, 911 ($2M+Na^+$). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.22 (dd, J = 7.0, 1.0 Hz, 1H), 8.20 (dd, J = 8.0, 1.0 Hz, 1H), 7.65 (dd, J = 8.8, 7.0 Hz, 1H), 7.49 (d, J = 1.5 Hz, 1H), 6.96 (d, J = 7.9 Hz, 1H), 6.87 (dd, J = 7.9, 1.5 Hz, 1H), 3.38 (bs, 4H), 2.84 (m, 1H), 1.57 (m, 3H), 1.44 (m, 3H), 1.18 (d, J = 6.9 Hz, 6H). Elemental analysis: calculated for $C_{21}H_{24}N_4O_3S_2$, C 56.74, H 5.44, N 12.60, S 14.42; found C 56.95, H 5.78, N 12.64, S 14.38.

EXAMPLE 38



15 3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid (4-fluoro-benzyl)-methanamide.


- A. 3-Amino-naphthalene-2-carboxylic acid methyl ester. To a solution of 1H-naphtho[2,3-d][1,3]oxazine-2,4-dione (4.99 g, 23.4 mmol) in dry DMF (25 mL) was added dry methanol (9.5 mL, 234 mmol) and DMAP (0.28 g, 2.34 mmol). After 16 h, the reaction mixture was partitioned between EtOAc and water, and the organic layer was washed with water (3x) and dried ($MgSO_4$). Purification on silica gel (MPLC, hexanes/EtOAc) provided the methyl ester as a yellow solid (2.12 g, 10.6 mmol, 45%). HPLC (reversed-phase): R_T = 8.59 min). 1H NMR (400 MHz, $CDCl_3$): 8.50 (s, 1H), 7.71 (d, J = 8.3 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.40 (m, 1H), 7.19 (m, 1H), 6.98 (m, 1H), 5.7 (bs, 2H), 3.97 (s, 3H).
- 25 B. 3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid methyl ester. Benzo[1,2,5]thiadiazole-4-sulfonyl chloride (2.62 g, 11.1 mmol)

was added to solution of 3-aminonaphthalene-2-carboxylic acid methyl ester (1.5 g, 7.5 mmol) and pyridine (1.21 mL, 15 mmol) in DCM (20 mL). After 16 h, the reaction mixture was washed with 1 N HCl and dried (MgSO₄). Purification on silica gel (MPLC, hexanes/EtOAc) provided the title compound as a yellow solid (1.91 g, 4.86 mmol, 65%). MS (ESI): neg. ion m/z 398 [M-H]⁻. HPLC (reversed-phase): R_T = 9.97 min. ¹H NMR (500 MHz, CDCl₃): 8.43 (s, 1H), 8.40 (dd, J = 7.1, 1.0 Hz, 1H), 8.15 (dd, J = 8.8, 1.0 Hz, 1H), 8.07 (s, 1H), 7.72 (bd, J = 9.2 Hz, 2H), 7.64 (dd, J = 8.8, 7.7 Hz, 1H), 7.52 (m, 1H), 7.38 (m, 1H), 3.97 (s, 3H).

10 C. 3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid.
3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid methyl ester (1.91 g, 4.78 mmol) was dissolved in 3:1 THF/water (10 mL). Lithium hydroxide monohydrate (2 g, 50 mmol) was added, and the reaction mixture was stirred at ambient temperature for 16 h. The mixture was acidified
15 with 1 N HCl, and the resulting precipitate was collected via filtration and washed with water. Drying in air provided the title acid as a tan solid (1.63 g, 4.23 mmol, 89%). MS (ESI): neg. ion m/z 384 [M-H]⁻. ¹H NMR (400 MHz, CDCl₃): 10.97 (s, 1H), 8.61 (s, 1H), 8.43 (dd, J = 7.1, 1.0 Hz, 1H), 8.17 (dd, J = 8.8, 1.0 Hz, 1H), 8.13 (s, 1H), 7.77 (dd, J = 15.8, 8.2 Hz, 2H), 7.67 (dd, J = 8.8, 7.7 Hz, 1H), 7.56 (m, 1H), 7.42 (m, 1H).

20 D. 3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid (4-fluoro-benzyl)-methylamide. 3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid was coupled with (4-fluorobenzyl)methylamine as described in EXAMPLE 7 to provide the title compound. MS (ESI): m/z 507 [M+H]⁺, 529 [M+Na]⁺. HPLC (reversed-phase): R_T = 9.82 min. ¹H NMR (400 MHz, CDCl₃) (rotameric mixture): 8.93 (s, 1H), 8.31 (m, 1H), 8.18 (m, 1H), 7.98 (m, 1H), 7.73 (m, 1H), 7.62 (m, 2H), 7.54 (m, 1H), 7.46 (m, 1H), 7.33 (m, 3H), 7.09 (m, 2H), 4.58 (m, 2H), 2.55 (bs, 3H).

EXAMPLE 39



(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-trifluoromethylbenzamide.

- 5 A. S-(S)-2-Methyl-propane-2-sulfinic acid 2,4-difluoro-benzylideneamide. A suspension of 2,4-difluorobenzaldehyde (0.61 g, 4.3 mmol), (S)-*tert*-butanesulfinamide (0.47 g, 3.9 mmol), and powdered anhydrous CuSO₄ (1.24 g, 7.8 mmol) was stirred in DCM (8 mL) overnight. The reaction mixture was filtered, and the filter cake was washed with DCM. The filtrate was
- 10 concentrated *in vacuo* to give the crude N-sulfinyl imine as a viscous yellow oil. Purification by flash chromatography (EtOAc/hexanes) provided 0.81 g (84%) of the N-sulfinyl imine as a pale yellow viscous oil. ¹H NMR (400 MHz, CDCl₃): 8.83 (s, 1H), 8.02 (m, 1H), 6.98 (m, 1H), 6.90 (m, 1H), 1.27 (s, 9H).
- B. S-(S)-2-Methyl-propane-2-sulfinic acid 1-(R)-[1-(2,4-difluoro-phenyl)-ethyl]-
- 15 amide. To a stirred solution of the above N-sulfinyl imine (0.77 g, 3.1 mmol) in DCM (20 mL) at -50 °C, was added a solution of methyl magnesium bromide (3.0 M in Et₂O) (2.1 mL, 6.3 mmol). The reaction mixture was stirred at -50 °C for 1 h then allowed to warm to room temperature slowly overnight. The
- 20 reaction was quenched by the addition of a saturated aqueous NH₄Cl, and the mixture was poured into water, and extracted with DCM (3x). The combined organic layers were dried (Na₂SO₄) and concentrated *in vacuo*. Purification by flash chromatography (EtOAc/hexanes) provided the title compound as a mixture of diastereomers: ratio of S-(S),1-(R) to S-(S),1-(S) = 95:5 (¹H NMR); 90% de. Combined yield for both diastereomers was 0.80 g (99%) of a
- 25 colorless viscous oil. Major diastereomer: ¹H NMR (400 MHz, CDCl₃): 7.32 (m, 1H), 6.87 (m, 1H), 6.80 (m, 1H), 4.82 (dq, *J* = 6.8, 4.5 Hz, 1H), 3.32 (d, *J* = 4.1 Hz, 1H), 1.56 (d, *J* = 6.8 Hz, 3H), 1.19 (s, 9H).

C. (R)-1-(2,4-Difluoro-phenyl)-ethylamine hydrochloride. To a stirred solution of the above sulfonamide (90% de) (0.80 g, 3.06 mmol) in methanol (7 mL) at ambient temperature, was added 2 mL of a saturated solution of HCl (g) in methanol. After several minutes, precipitated amine hydrochloride was visible.

- 5 The reaction mixture was allowed to stir for 2 h at ambient temperature. The heterogeneous mixture was concentrated *in vacuo* until approximately 2 mL of methanol remained, and then the amine hydrochloride was fully precipitated by the addition of Et₂O (10 mL). The white solid HCl salt was collected by suction filtration, washed with Et₂O, and dried *in vacuo*. Yield = 573 mg (97%), fine
10 white crystals (99% ee). Enantiomeric purity was determined by HPLC on the benzamide derivative of the amine. Chiralcel AS column, 90:10 hexanes/isopropyl alcohol with 0.1% diethylamine, 0.7 mL/min. R enantiomer, R_T = 18.1 min. S enantiomer, R_T = 21.0 min. $[\alpha]_D^{20} = -3.7^\circ$ (H₂O, c = 4.37 g/100 mL). ¹H NMR (400 MHz, methanol-*d*₄): 7.57 (m, 1H), 7.12 (m, 1H), 7.09
15 (m, 1H), 4.72 (q, *J* = 7.0 Hz, 1H), 1.65 (d, *J* = 6.8 Hz, 3H).

- D. 2-Amino-4-trifluoromethylbenzoic acid methyl ester. To a stirred solution of 2-nitro-4-trifluoromethylbenzoic acid (6.0 g, 25 mmol) in dry DMF (30 mL) at 0 °C was added DBU (35 mL, 25 mmol) followed in 15 min by iodomethane (16 mL, 25 mmol). The reaction mixture was allowed to warm to ambient
20 temperature and stir overnight, then was partitioned between water and EtOAc. The organic layer was washed with water and dried (MgSO₄), and the resulting crude product was purified on silica gel (MPLC, hexanes/EtOAc) to provide the methyl ester as a yellow oil (5.7 g, 91%). This material was immediately dissolved in 3:1 EtOAc/DCM (50 mL), and SnCl₂·2H₂O (26 g, 110 mmol) was
25 added with stirring. The mixture was held at ambient temperature for 16 h, then 5% aqueous NaHCO₃ was added cautiously. The aqueous phase was extracted with DCM (3x), and the combined organic layers were dried (MgSO₄). Filtration and concentration provided the aniline as a light yellow solid (4.5 g, 21 mmol, 84% for two steps). HPLC (reversed-phase): R_T = 9.38 min. ¹H
30 NMR (400 MHz, CDCl₃): 7.95 (d, *J* = 8.3 Hz, 1H), 6.91 (s, 1H), 6.85 (dd, *J* = 8.6, 1.3 Hz, 1H), 6.2-5.5 (bs, 2H), 3.90 (s, 3H).

E. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-trifluoromethylbenzoic acid methyl ester. 2-Amino-4-trifluoromethylbenzoic acid methyl ester (1.5 g, 6.8

mmol) was coupled with benzo[1,2,5]thiadiazole-4-sulfonyl chloride (2.4 g, 10 mmol), and the product was purified, as described in EXAMPLE 38 to provide the title compound (0.8 g, 28%). MS (ESI): neg. ion m/z 416 $[M-H]^-$. HPLC (reversed-phase): R_T = 10.03 min. 1H NMR (500 MHz, $CDCl_3$): 11.33 (s, 1H), 8.40 (dd, J = 7.1, 1.0 Hz, 1H), 8.23 (dd, J = 8.8, 1.0 Hz, 1H), 8.04 (s, 1H), 7.98 (d, J = 8.2 Hz, 1H), 7.72 (dd, J = 8.8, 7.1 Hz, 1H), 7.18 (m, 1H), 3.96 (s, 3H).

F. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-trifluoromethylbenzoic acid.


2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-trifluoromethylbenzoic acid methyl ester (0.8 g, 2 mmol) was hydrolyzed with lithium hydroxide

monohydrate (0.8 g, 2 mmol), and the product was purified, as described in EXAMPLE 38 to provide the carboxylic acid as a tan solid (0.75 g, 1.9 mmol, quant.). MS (ESI): neg. ion m/z 402 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): 11.29 (s, 1H), 8.42 (dd, J = 7.1, 1.0 Hz, 1H), 8.24 (dd, J = 8.8, 1.0 Hz, 1H), 8.07 (d, J = 8.2 Hz, 1H), 8.05 (s, 1H), 7.73 (dd, J = 8.8, 7.1 Hz, 1H), 7.22 (m, 1H).

G. (R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-4-trifluoromethylbenzamide.

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-trifluoromethylbenzoic acid was coupled with (R) 1-(2,4-difluorophenyl)-ethylamine, and the product was purified, as described in EXAMPLE 7 to provide the title compound. MS (ESI): m/z 543 $[M+H]^+$, 565 $[M+Na]^+$. HPLC (reversed-phase): R_T = 10.20 min. 1H NMR (400 MHz, $CDCl_3$): 11.40 (s, 1H), 8.36 (dd, J = 7.1, 1.0 Hz, 1H), 8.20 (dd, J = 8.8, 1.0 Hz, 1H), 8.00 (m, 1H), 7.70 (dd, J = 8.8, 7.1 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.33 (ddd, J = 8.5, 8.5, 6.2 Hz, 1H), 7.21 (dd, J = 8.1, 1.0 Hz, 1H), 6.90 (m, 1H), 6.85 (m, 1H), 6.46 (bd, J = 8.1 Hz, 1H), 5.35 (m, 1H), 1.58 (d, J = 6.9 Hz, 3H).

EXAMPLE 40



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)ethyl]-4-fluorobenzamide.

- 5 A. 2-Amino-4-fluorobenzoic acid methyl ester. 2-Amino-4-fluorobenzoic acid (5.0 g, 32 mmol) was dissolved in DCM (50 mL) and cooled to 0 °C. Hünig's base (11 ml, 64 mmol) was added followed by triphosgene (3.8 g, 13 mmol). The reaction mixture was stirred for 5 min then allowed to warm to ambient temperature over 45 min. Water was added to the mixture, which was then
- 10 extracted with DCM (3x), and the combined organic layers were dried (MgSO₄). Filtration and concentration provided 7-fluoro-1H-benzo[d][1,3]oxazine-2,4-dione as a tan solid (3.94 g, 21.8 mmol, 68%), which was taken on directly to the next step. To a solution of 7-fluoro-1H-benzo[d][1,3]oxazine-2,4-dione (3.94 g, 21.8 mmol) in DMF (20 mL) was added dry methanol (8.8 mL, 220
- 15 mmol) and DMAP (0.27 g, 2.2 mmol). The mixture was allowed to stand overnight, and was then partitioned between EtOAc and water. The organic layer was washed with water (3x) and dried (MgSO₄). Filtration and purification on silica gel (MPLC, hexanes/EtOAc) provided the title methyl ester as a white solid (1.89 g, 11.1 mmol, 51%). HPLC (reversed-phase): *R*_T = 8.66 min). ¹H
- 20 NMR (400 MHz, CDCl₃): 7.87 (m, 1H), 6.37 (m, 2H), 3.86 (s, 3H).
- B. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluorobenzoic acid methyl ester. 2-Amino-4-fluorobenzoic acid methyl ester (1.89 g, 11.2 mmol) was coupled with benzo[1,2,5]thiadiazole-4-sulfonyl chloride (4.0 g, 17 mmol), and the product was purified, as described in EXAMPLE 38 to provide the title
- 25 compound (1.34 g, 3.65 mmol, 33%). MS (ESI): neg. ion *m/z* 366 [M-H]⁻. HPLC (reversed-phase): *R*_T = 9.52 min). ¹H NMR (400 MHz, CDCl₃): 11.50 (s, 1H), 8.40 (dd, *J* = 7.1, 1.0 Hz, 1H), 8.23 (dd, *J* = 8.8, 1.0 Hz, 1H), 7.89 (dd, *J* =

8.8, 6.4 Hz, 1H), 7.72 (dd, $J = 8.8, 7.1$ Hz, 1H), 7.47 (dd, $J = 11.0, 2.5$ Hz, 1H), 6.65 (m, 1H), 3.92 (s, 3H).

C. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluorobenzoic acid. 2-


(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluorobenzoic acid methyl ester

5 (1.34 g, 3.65 mmol) was hydrolyzed with lithium hydroxide monohydrate (1.53 g, 36.5 mmol), and the product was purified, as described in EXAMPLE 38 to provide the title carboxylic acid as a tan solid (1.04 g, 2.94 mmol, 81%). MS (ESI): neg. ion m/z 352 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): 11.31 (s, 1H), 8.42 (dd, $J = 7.1, 1.0$ Hz, 1H), 8.25 (dd, $J = 8.8, 1.0$ Hz, 1H), 8.03 (dd, $J = 8.8, 6.4$ Hz, 1H), 7.74 (dd, $J = 8.8, 7.1$ Hz, 1H), 7.52 (dd, $J = 11.0, 2.4$ Hz, 1H); 6.72 (m, 1H).

D. (R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-4-fluorobenzamide. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-

15 fluorobenzoic acid was coupled with (R) 1-(2,4-difluorophenyl)-ethylamine (see EXAMPLE 39), and the product was purified, as described in EXAMPLE 7 to provide the title compound. MS (ESI): m/z 493 $[M+H]^+$, 515 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 9.84$ min). 1H NMR (400 MHz, $CDCl_3$) 11.73 (s, 1H), 8.35 (dd, $J = 7.1, 1.0$ Hz, 1H), 8.19 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.69 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.46 (dd, $J = 11, 2.5$ Hz, 1H), 7.32 (m, 2H), 6.92 (m, 1H), 6.84 (m, 1H), 6.66 (m, 1H); 6.34 (bd, $J = 7.6$ Hz, 1H), 5.36 (m, 1H), 1.57 (d, $J = 6.8$ Hz, 3H).

EXAMPLE-41



25 (R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide

A. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)benzoic acid methyl ester.

Methyl 2-aminobenzoate (2.5 g, 16 mmol) was coupled with


benzo[1,2,5]thiadiazole-4-sulfonyl chloride (2.44 g, 6.99 mmol), and the product was purified, as described in EXAMPLE 38 to provide the title compound (1.34 g, 3.65 mmol, 42%). TLC (silica gel, 2:3 EtOAc/hexanes): R_f = 0.41. ^1H NMR (400 MHz, CDCl_3): 11.27 (s, 1H), 8.37 (dd, J = 7.1, 1.0 Hz, 1H), 8.19 (dd, J = 8.8, 1.0 Hz, 1H), 7.85 (dd, J = 7.9, 1.5 Hz, 1H), 7.71 (m, 1H), 7.68 (dd, J = 8.8, 7.0 Hz, 1H), 7.38 (m, 1H), 6.96 (m, 1H), 3.91 (s, 3H).

B. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)benzoic acid. 2-

(Benzo[1,2,5]thiadiazole-4-sulfonylamino)benzoic acid methyl ester (2.44 g, 6.98 mmol) was hydrolyzed with lithium hydroxide monohydrate (2.93 g, 69.8 mmol), and the product was purified, as described in EXAMPLE 38 to give the title carboxylic acid as a solid (2.13 g, 6.36 mmol, 91%). ^1H NMR (500 MHz, CDCl_3): 11.11 (s, 1H), 8.39 (dd, J = 7.1, 1.0 Hz, 1H), 8.22 (dd, J = 8.8, 1.0 Hz, 1H), 7.99 (dd, J = 7.9, 1.5 Hz, 1H), 7.77 (dd, J = 8.5, 0.6 Hz, 1H), 7.70 (dd, J = 8.8, 7.0 Hz, 1H), 7.46 (m, 1H), 7.05 (m, 1H).

D. (R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]benzamide. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)benzoic acid was coupled with (R) 1-(2,4-difluorophenyl)-ethylamine (see EXAMPLE 39), and the product was purified, as described in EXAMPLE 7 to provide the title compound. MS (ESI): neg. ion m/z 473 $[\text{M}-\text{H}]^-$. HPLC (reversed-phase): R_T = 9.64 min). ^1H NMR (400 MHz, CDCl_3): 11.38 (s, 1H), 8.32 (dd, J = 7.1, 1.0 Hz, 1H), 8.16 (dd, J = 8.8, 1.0 Hz, 1H), 7.68 (m, 1H), 7.65 (dd, J = 8.8, 7.0 Hz, 1H), 7.30 (m, 3H), 6.98 (m, 1H), 6.88 (m, 1H), 6.85 (m, 1H), 6.40 (bd, J = 7.6 Hz, 1H), 5.32 (m, 1H), 1.54 (d, J = 6.8 Hz, 3H).

EXAMPLE 42



(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichlorophenyl)-ethyl]-4-methylbenzamide.

- A. S-(S)-2-Methyl-propane-2-sulfinic acid 2,4-dichloro-benzylideneamide. A suspension of 2,4-dichlorobenzaldehyde (0.75 g, 4.3 mmol), (S)-*tert*-butanesulfinamide (0.47 g, 3.9 mmol), and powdered anhydrous CuSO₄ (1.24 g, 7.8 mmol) in DCM (8 mL) was stirred overnight. The reaction mixture was filtered, and the filter cake was washed with DCM. The filtrate was concentrated *in vacuo* to give the crude N-sulfinyl imine as white solid. Purification by flash chromatography (EtOAc/hexanes) provided 0.97 g (90%) of the N-sulfinyl imine as a white solid. ¹H NMR (400 MHz, CDCl₃): 8.98 (s, 1H), 8.01 (d, *J* = 8.5 Hz, 1H), 7.48 (d, *J* = 2.1 Hz, 1H), 7.34 (m, 1H), 1.27 (s, 9H).
- B. S-(S)-2-Methyl-propane-2-sulfinic acid 1-(R)-[1-(2,4-dichloro-phenyl)-ethyl]-amide. To a stirred solution of the above N-sulfinyl imine (0.97 g, 3.5 mmol) in DCM (20 mL) at -50 °C was added a solution of methyl magnesium bromide (3.0 M in Et₂O) (2.3 mL, 6.9 mmol). The reaction mixture was stirred at -50 °C for 1 h then allowed to warm to room temperature slowly overnight. The reaction was quenched by the addition of saturated aqueous NH₄Cl, and the mixture was poured into water and extracted with DCM (3x). The combined organic layers were dried (Na₂SO₄) and concentrated *in vacuo*. Purification by flash chromatography (EtOAc/hexanes) provided the title compound as a mixture of diastereomers: ratio of S-(S),1-(R) to S-(S),1-(S) = 88:12 (¹H NMR); 76% de. Combined yield for both diastereomers, 1.02 g (99%), colorless solid. Major diastereomer: ¹H NMR (400 MHz, CDCl₃): 7.43-7.35 (m, 2H), 7.24 (m, 1H), 5.01 (dq, *J* = 6.7, 4.0 Hz, 1H), 3.39 (d, *J* = 3.7 Hz, 1H), 1.53 (d, *J* = 6.7 Hz, 3H), 1.21 (s, 9H).
- C. (R)-1-(2,4-Dichloro-phenyl)-ethylamine hydrochloride. To a stirred solution of the above sulfinamide (76% de) (1.02 g, 3.47 mmol) in 7:4 methanol/DCM (11 mL) at ambient temperature was added 2 mL of a saturated solution of HCl (g) in methanol. After several minutes, precipitated amine hydrochloride was visible. The reaction mixture was allowed to stir for 2 h at ambient temperature. The heterogeneous mixture was concentrated *in vacuo* until approximately 2 mL of methanol remained, and then the amine hydrochloride was fully precipitated by the addition of Et₂O (10 mL). The white solid HCl salt was collected by suction filtration, washed with Et₂O, and dried *in vacuo*. Yield


= 722 mg (92%), fine white crystals (76% ee). ¹H NMR (400 MHz, methanol-*d*₄): 7.62 (d, *J* = 2.2 Hz, 1H), 7.57 (d, *J* = 8.4 Hz, 1H), 7.50 (dd, *J* = 8.4, 2.2 Hz, 1H), 1.62 (d, *J* = 6.8 Hz, 3H).

D. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methylbenzoic acid methyl ester. 2-Amino-4-methyl-benzoic acid methyl ester (1.09 g, 6.60 mmol) was coupled with benzo[1,2,5]thiadiazole-4-sulfonyl chloride (2.32 g, 9.90 mmol), and the product was purified, as described in EXAMPLE 38 to provide the title compound (1.22 g, 3.36 mmol, 53%). ¹H NMR (500 MHz, CDCl₃): 11.28 (s, 1H), 8.36 (dd, *J* = 7.1, 1.0 Hz, 1H), 8.19 (dd, *J* = 8.8, 1.0 Hz, 1H), 7.73 (d, *J* = 8.1 Hz, 1H), 7.68 (dd, *J* = 8.8, 7.1 Hz, 1H), 7.51 (bs, 1H), 6.77 (dd, *J* = 8.1, 0.9 Hz, 1H), 3.89 (s, 3H), 2.28 (s, 3H).

E. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methylbenzoic acid. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methylbenzoic acid methyl ester (1.22 g, 3.36 mmol) was hydrolyzed with lithium hydroxide monohydrate (1.41 g, 33.6 mmol), and the product was purified, as described in EXAMPLE 38 to give the title carboxylic acid as a solid (0.89 g, 2.5 mmol, 74%). ¹H NMR (500 MHz, CDCl₃):

F. (R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichlorophenyl)-ethyl]-4-methylbenzamide. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methylbenzoic acid was coupled with (R) 1-(2,4-dichlorophenyl)-ethylamine, and the product was purified, as described in EXAMPLE 7 to provide the title compound. MS (ESI): neg. ion *m/z* 519/521 [M-H]⁻. HPLC (reversed-phase): *R*_T = 10.41 min). ¹H NMR (400 MHz, CDCl₃): 11.46 (s, 1H), 8.30 (d, *J* = 7.1 Hz, 1H), 8.17 (d, *J* = 8.8 Hz, 1H), 7.66 (dd, *J* = 8.8, 7.1 Hz, 1H), 7.51 (s, 1H), 7.42 (s, 1H), 7.24 (m, 3H), 6.79 (d, *J* = 8.0 Hz, 1H), 6.34 (bd, *J* = 7.4 Hz, 1H), 5.38 (m, 1H), 2.28 (s, 3H), 1.53 (d, *J* = 6.8 Hz, 3H).


EXAMPLE 43



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-*N*-[1-(2,4-dichlorophenyl)-ethyl]-benzamide.

- 5 A. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chlorobenzoic acid methyl ester. Methyl 2-amino-5-chlorobenzoate (2.0 g, 11 mmol) was coupled with benzo[1,2,5]thiadiazole-4-sulfonyl chloride (3.0 g, 13 mmol), and the product was purified, as described in EXAMPLE 38 to provide the title compound (1.95 g, 5.08 mmol, 47%). ¹H NMR (500 MHz, CDCl₃): 11.15 (s, 1H), 8.34 (dd, *J* = 7.1, 1.0 Hz, 1H), 8.22 (dd, *J* = 8.8, 1.0 Hz, 1H), 7.82 (d, *J* = 2.5 Hz, 1H), 7.71 (m, 1H), 7.69 (m, 1H), 7.34 (dd, *J* = 9.0, 2.5 Hz, 1H), 3.91 (s, 3H).
- 10 B. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chlorobenzoic acid. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chlorobenzoic acid methyl ester (2.23 g, 5.81 mmol) was hydrolyzed with lithium hydroxide monohydrate (2.44 g, 58.1 mmol), and the product was purified, as described in EXAMPLE 38 to give the title carboxylic acid as a solid (1.7 g, 4.6 mmol, 79%). ¹H NMR (500 MHz, CDCl₃): 11.15 (s, 1H), 8.36 (dd, *J* = 7.1, 1.0 Hz, 1H), 8.23 (dd, *J* = 8.8, 1.0 Hz, 1H), 7.90 (d, *J* = 2.5 Hz, 1H), 7.72 (m, 1H), 7.70 (m, 1H), 7.37 (dd, *J* = 9.0, 2.5 Hz, 1H).
- 15 C. (*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-*N*-[1-(2,4-dichlorophenyl)-ethyl]-benzamide. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chlorobenzoic acid was coupled with (*R*) 1-(2,4-dichlorophenyl)-ethylamine (see EXAMPLE 42), and the product was purified, as described in EXAMPLE 7 to provide the title compound. MS (ESI): neg. ion *m/z* 539/541/543 [M-H]⁻.
- 20 HPLC (reversed-phase): *R*_T = 10.67 min). ¹H NMR (500 MHz, CDCl₃): 11.11 (s, 1H), 8.29 (dd, *J* = 7.1, 1.0 Hz, 1H), 8.17 (d, *J* = 8.8, 1.0 Hz, 1H), 7.68 (m, 1H), 7.66 (m, 1H), 7.43 (dd, *J* = 1.5, 0.5 Hz, 1H), 7.29 (m, 2H), 7.25 (m, 2H), 6.32 (bd, *J* = 7.4 Hz, 1H), 5.36 (m, 1H), 1.54 (d, *J* = 6.8 Hz, 3H).

EXAMPLE 44




5 Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(piperidine-1-carbonyl)-phenyl]-amide.

The title compound was prepared according to the procedure in EXAMPLE 34, substituting 2-amino-4-methylbenzoic acid for 2-amino-6-chlorobenzoic acid.

MS (ESI): m/z 417 $[M+H]^+$, 439 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.95 (bs, 1H), 8.22 (m, 1H), 8.19 (m, 1H), 7.66 (dd, $J =$
10 8.4, 7.0 Hz, 1H), 7.46 (s, 1H), 6.93 (d, $J = 7.8$ Hz, 1H), 6.83 (d, $J = 7.8$ Hz, 1H), 3.12 (bm, 4H), 2.30 (s, 3H), 1.58 (m, 2H), 1.42 (m, 4H). Elemental analysis: calculated for $C_{19}H_{20}N_4O_3S_2$, C 54.79, H 4.84, N 13.45; found C 54.50, H 5.10, N 13.66.

15 EXAMPLE 45




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-benzyl)-benzamide.

This compound was prepared using the general procedure described in
20 EXAMPLE 7. MS (ESI): neg. ion m/z 491/493/495 $[M-H]^-$. HPLC (reversed-phase): $R_T = 10.14$ min. 1H NMR (400 MHz, $CDCl_3$): 11.61 (bs, 1H), 8.37 (m, 1H), 8.20 (m, 1H), 7.70 (m, 2H), 7.45 (m, 1H), 7.37 (m, 1H), 7.32 (m, 2H), 7.27 (m, 1H), 6.92 (bd, $J = 8.4$ Hz, 1H), 6.47 (m, 1H), 4.65 (m, 2H).

(m, 1H), 8.25 (m, 1H), 7.70 (m, 2H), 7.32 (m, 4H), 7.24 (m, 1H), 6.99 (m, 1H), 6.94 (m, 1H), 4.83 (m, 1H), 4.55 (m, 2H), 3.93 (m, 1H), 2.00 (m, 6H), 1.21 (m, 9H).

5 EXAMPLE 47




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methylsulfanylbenzyl)benzamide.

This compound was prepared using the general procedure described in

- 10 EXAMPLE 7. MS (ESI): neg. ion m/z 503/505 $[M-H]^-$. HPLC (reversed-phase): R_T = 10.10 min. 1H NMR (400 MHz, $CDCl_3$): 11.64 (bs, 1H), 8.36 (m, 1H), 8.19 (m, 1H), 7.70 (m, 2H), 7.34 (m, 2H), 7.21 (m, 3H), 6.90 (m, 1H), 6.45 (m, 1H), 4.58 (m, 2H), 2.51 (s, 3H).

15 EXAMPLE 48




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-dimethylamino-1-phenylethyl)-N-methylbenzamide TFA salt.

This compound was prepared using the general procedure described in

- 20 EXAMPLE 7. MS (ESI): neg. ion m/z 528/530 $[M-H]^-$. HPLC (reversed-phase): R_T = 7.75 min.


EXAMPLE 48



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-dimethylamino-1-phenyl-ethyl)-N-methylbenzamide TFA salt.

- 5 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): neg. ion m/z 528/530 $[M-H]^-$. HPLC (reversed-phase): $R_T = 7.75$ min.

EXAMPLE 49




10

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-ethylbenzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): neg. ion m/z 485/487 $[M-H]^-$. HPLC (reversed-phase):

- 15 $R_T = 10.16$ min. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.90 (m, 1H), 8.36 (m, 1H), 8.24 (m, 1H), 7.73 (m, 1H), 7.61 (m, 1H), 7.38 (m, 4H), 7.07 (m, 2H), 6.96 (m, 1H), 4.66 and 4.34 (m, 2H), 3.47 (m, 1H), 2.97 (m, 1H), 1.05 and 0.92 (m, 3H).

EXAMPLE 50




N-Benzhydryl-2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methylbenzamide.

- 5 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): neg. ion m/z 547/549 $[M-H]^-$. HPLC (reversed-phase): R_T = 10.72 min. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.2-9.0 (m, 1H), 8.40 (bd, J = 7.0 Hz, 1H), 8.26 (bd, J = 8.5 Hz, 1H), 7.74 (m, 1H), 7.60 (m, 1H), 7.37 (m, 7H), 7.2-6.9 (m, 5H), 6.14 (bs, 1H), 2.8 and 2.6 (m, 3H).

10

EXAMPLE 51




(S) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenylethyl)-benzamide.

- 15 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): neg. ion m/z 485/487 $[M-H]^-$. HPLC (reversed-phase): R_T = 10.12 min. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.12 (bs, 1H), 8.38 (dd, J = 7.0, 0.8 Hz, 1H), 8.24 (bd, J = 8.8 Hz, 1H), 7.73 (m, 1H), 7.61 (d, J = 2.0 Hz, 1H), 7.41 (m, 4H), 7.33 (m, 1H), 7.05 (m, 1H), 6.96 (d, J = 2.0 Hz, 0.5H), 6.94 (d, J = 2.0 Hz, 0.5H), 6.1 (m, 1H), 2.4 (m, 3H), 1.7 (m, 3H).

20


EXAMPLE 52



(*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-*N*-methyl-*N*-(1-phenyl-ethyl)-benzamide.

- 5 This compound was prepared using the general procedure described in
EXAMPLE 7. MS (ESI): neg. ion m/z 485/487 $[M-H]^-$. HPLC (reversed-phase):
 R_T = 10.12 min. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.12 (bs, 1H), 8.38 (dd, J = 7.0, 0.8 Hz, 1H), 8.24 (bd, J = 8.8 Hz, 1H), 7.73 (m, 1H),
7.61 (d, J = 2.0 Hz, 1H), 7.41 (m, 4H), 7.33 (m, 1H), 7.05 (m, 1H), 6.96 (d, J =
10 2.0 Hz, 0.5H), 6.94 (d, J = 2.0 Hz, 0.5H), 6.1 (m, 1H), 2.4 (m, 3H), 1.7 (m, 3H).


EXAMPLE 53



- 15 (*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-*N*-(1-phenyl-ethyl)-
benzamide.

- This compound was prepared using the general procedure described in
EXAMPLE 7. MS (ESI): neg. ion m/z 471/473 $[M-H]^-$. HPLC (reversed-phase):
 R_T = 10.10 min. 1H NMR (400 MHz, $CDCl_3$): 11.7 (bs, 1H), 8.35 (dd, J = 7.0,
1.0 Hz, 1H), 8.20 (dd J = 8.8, 1.0 Hz, 1H), 7.72 (d, J = 2.0 Hz, 1H), 7.70 (dd, J
20 = 10.8, 2.5 Hz, 1H), 7.34 (m, 5H), 7.23 (d, J = 8.5 Hz, 1H), 6.91 (dd, J = 8.4,
2.0 Hz, 1H), 6.15 (bd, J = 7.6 Hz, 1H), 5.27 (m, 1H), 1.57 (d, J = 6.9 Hz, 3H).


EXAMPLE 54



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1-methyl-10-oxa-4-azatricyclo[5.2.1.0^{2,6}]decane-4-carbonyl)-phenyl]-amide.

- 5 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): neg. ion m/z 503/505 $[M-H]^-$. HPLC (reversed-phase): $R_T = 9.29$ min. ¹H NMR (400 MHz, CDCl₃): 9.51 (bs, 1H), 8.29 (d, $J = 7.0$ Hz, 1H), 8.22 (d $J = 8.8$ Hz, 1H), 7.70 (dd, $J = 10.8, 2.5$ Hz, 1H), 7.67 (d, $J = 2.0$ Hz, 1H), 7.08 (d, $J = 6.6$ Hz, 1H), 7.00 (m, 1H), 4.3–3.7 (m, 3H), 3.4–3.0 (m, 3H), 2.5–2.2 (m, 3H), 1.84 (m, 1H), 1.54 (bs, 3H), 1.26 (1H).


EXAMPLE 55



- 15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-2-fluoro-benzyl)-4-chloro-benzamide.

- This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): neg. ion m/z 553/555/557 $[M-H]^-$. HPLC (reversed-phase): $R_T = 10.37$ min. ¹H NMR (400 MHz, CDCl₃): 11.6 (bs, 1H), 8.36 (d, $J = 7.0$ Hz, 1H), 8.21 (dd $J = 8.8, 0.8$ Hz, 1H), 7.73 (d, $J = 2.0$ Hz, 1H), 7.71 (dd, $J = 7.2, 2.5$ Hz, 1H), 7.33 (m, 2H), 7.29 (m, 1H), 7.22 (d, $J = 8.5$ Hz, 1H), 6.92 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.33 (m, 1H), 4.55 (d, $J = 5.9$ Hz, 2H).


EXAMPLE 56



(*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-bromo-phenyl)-ethyl]-4-chloro-benzamide.


- 5 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): neg. ion m/z 549/551/553 $[M-H]^-$. HPLC (reversed-phase): $R_T = 10.48$ min. 1H NMR (400 MHz, $CDCl_3$): 11.62 (bs, 1H), 8.36 (dd, $J = 7.2, 0.8$ Hz, 1H), 8.21 (dd $J = 8.8, 0.8$ Hz, 1H), 7.73 (d, $J = 2.0$ Hz, 1H), 7.71 (dd, $J = 7.2, 2.5$ Hz, 1H), 7.50 (d, $J = 7.5$ Hz, 2H), 7.22 (m, 3H), 6.92 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.12 (bd, $J = 7.4$ Hz, 1H), 5.22 (m, 1H), 1.55 (d, $J = 5.3$ Hz, 3H).
- 10

EXAMPLE 57



- 15 (*R*) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-p-tolyl-ethyl)-benzamide.
- This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): neg. ion m/z 485/487 $[M-H]^-$. HPLC (reversed-phase): $R_T = 10.36$ min. 1H NMR (400 MHz, $CDCl_3$): 11.68 (bs, 1H), 8.36 (dd, $J = 7.2, 0.8$ Hz, 1H), 8.20 (dd $J = 8.8, 0.8$ Hz, 1H), 7.74 (d, $J = 2.0$ Hz, 1H), 7.70 (dd, $J = 7.2, 2.5$ Hz, 1H), 7.21 (m, 4H), 6.90 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.09 (bd, $J = 6.3$ Hz, 1H), 5.22 (m, 1H), 2.37 (s, 3H), 1.56 (d, $J = 5.3$ Hz, 3H).
- 20


EXAMPLE 58



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-phenylbenzamide.

- 5 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 459 $[M+H]^+$, 481 $[M+Na]^+$. HPLC (reversed-phase): R_T = 9.92 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.83 (s, 1H), 8.37 (dd, J = 7.0, 1.0 Hz, 1H), 8.26 (dd, J = 8.8, 1.0 Hz, 1H), 7.75 (dd, J = 8.8, 7.0, 1H), 7.65 (d, J = 8.8, 7.0 Hz, 1H), 7.07–7.04 (m, 3H), 6.55 (m, 2H), 6.30 (d, J = 7.0 Hz, 2H), 3.37 (s, 3H).


EXAMPLE 59



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-butyl-4-chloro-benzamide.

- 15 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): neg. ion m/z 423/425 $[M-H]^-$. HPLC (reversed-phase): R_T = 9.95 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.61 (s, 1H), 8.35 (dd, J = 7.0, 1.0 Hz, 1H), 8.21 (dd, J = 8.8, 1.0 Hz, 1H), 7.73 (dd, J = 8.8, 7.0, 1H), 7.70 (d, J = 8.8, 7.0 Hz, 1H), 7.20 (d, J = 11.2 Hz, 1H), 6.93 (dd, J = 8.4, 2.0 Hz, 1H), 6.30 (d, J = 7.0 Hz, 2H), 5.89 (s, 20 1H), 3.36 (m, 2H), 1.54 (m, 2H), 1.38 (m, 2H), 0.97 (t, J = 7.3 Hz, 3H).


EXAMPLE 60



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(pyrrolidine-1-carbonyl)-phenyl]-amide.

- 5 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 421 [M-H]⁻. HPLC (reversed-phase): R_T = 9.15 min (single peak). ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 9.81 (s, 1H), 8.31 (dd, J = 7.0, 1.0 Hz, 1H), 8.24 (dd, J = 8.8, 1.0 Hz, 1H), 7.71 (dd, J = 8.8, 7.0, 1H), 7.66 (d, J = 8.8, 7.0 Hz, 1H), 7.14 (d, J = 11.2 Hz, 1H), 6.98 (dd, J = 8.4, 2.0 Hz, 1H), 3.47 (m, 2H), 3.12 (m, 2H), 1.90 (m, 2H), 1.65 (m, 2H).


EXAMPLE 61



- 15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-benzamide.


This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 489 [M-H]⁻. HPLC (reversed-phase): R_T = 9.95 min (single peak). ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 11.63 (s, 1H), 8.37 (dd, J = 7.0, 1.0 Hz, 1H), 8.21 (dd, J = 8.8, 1.0 Hz, 1H), 7.74–7.69 (m, 2H), 7.33–7.21 (m, 3H), 7.09–7.04 (m, 2H), 6.93 (dd, J = 8.4, 2.0 Hz, 1H), 6.09 (d, J = 7.8 Hz, 1H), 5.25 (t, J = 7.0 Hz, 1H), 1.55 (m, 3H). Elemental analysis: calculated for C₂₁H₁₆ClFN₄O₃S₂, C 51.37, H 3.28, N 11.41; found C 51.78, H 3.40, N 11.14.

EXAMPLE 62



- Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-hydroxymethyl)-
 5 piperidine-1-carbonyl]-phenyl]-amide.
 This compound was prepared using the general procedure described in
 EXAMPLE 7. MS (ESI): m/z 465 $[M-H]^+$. HPLC (reversed-phase): R_T = 7.99
 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.00 (s,
 1H), 8.28 (dd, J = 7.0, 1.0 Hz, 1H), 8.24 (dd, J = 8.8, 1.0 Hz, 1H), 7.71 (dd, J =
 10 8.8, 7.0 Hz, 1H), 7.65 (m, 1H), 7.00 (m, 2H), 3.51 (d, J = 5.9 Hz, 2H), 2.55 (t, J
 = 13.6 Hz, 2H), 1.72 (bs, 3H), 1.54 (bs, 2H), 1.11 (bs, 2H). Elemental analysis:
 calculated for $C_{19}H_{19}ClN_4O_4S_2$, C 48.87, H 4.10, N 12.00; found C 48.62, H
 3.90, N 11.81.


15 EXAMPLE 63



- Benzo[1,2,5]thiadiazole-4-sulfonic acid {5-chloro-2-[4-(2-hydroxy-phenyl)-
 piperazine-1-carbonyl]-phenyl}-amide.
 This compound was prepared using the general procedure described in
 20 EXAMPLE 7. MS (ESI): m/z 528 $[M-H]^+$. HPLC (reversed-phase): R_T = 8.36
 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.84 (s,
 1H), 8.34 (dd, J = 7.0, 1.0 Hz, 1H), 8.30 (dd, J = 8.8, 1.0 Hz, 1H), 7.76 (dd, J =
 8.8, 7.0 Hz, 1H), 7.48 (d, J = 1.8 Hz, 1H), 7.23–7.13 (m, 2H), 7.11–7.08 (m,

2H), 7.02 (dd, $J = 8.1, 1.3$ Hz, 1H), 6.97–6.93 (m, 1H), 3.77 (bs, 4H), 3.10 (bs, 4H).

EXAMPLE 64




Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in

EXAMPLE 7. MS (ESI): m/z 451 $[M-H]^-$. HPLC (reversed-phase): $R_T = 8.40$

min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 9.46 (s, 1H), 8.33 (dd, $J = 11.7, 7.0$ Hz, 1H), 8.25 (dd, $J = 8.8, 4.4$ Hz, 1H), 7.14 (d, $J = 8.3$ Hz, 1H), 7.01 (dd, $J = 8.3, 1.8$ Hz, 1H), 4.23 (s, 1H), 4.07 (d, $J = 12.1$ Hz, 1H), 3.70 (m, 1H), 3.39 (m, 1H), 3.19 (m, 1H), 2.15 (m, 1H), 1.87 (m, 1H), 1.78 (m, 1H), 1.56 (m, 1H).

EXAMPLE 65



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N,N-diethyl-benzamide.


This compound was prepared using the general procedure described in

EXAMPLE 7. MS (ESI): m/z 423 $[M-H]^-$. HPLC (reversed-phase): $R_T = 9.43$

min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.87 (s, 1H), 8.32 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.23 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.72 (dd, $J =$

8.8, 7.0 Hz, 1H), 7.48 (d, $J = 1.8$ Hz, 1H), 7.04–6.98 (m, 2H), 3.25 (bs, 4H), 1.05 (bs, 6H).

EXAMPLE 66



5

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-2,5-dihydropyrrole-1-carbonyl)-phenyl]-amide.


This compound was prepared using the general procedure described in

EXAMPLE 7. MS (ESI): m/z 447 $[M-H]^-$. HPLC (reversed-phase): $R_T = 10.00$

10 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.75 (s, 1H), 8.33 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.20 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.78 (d, $J = 2.0$ Hz, 1H), 7.69 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.23 (d, $J = 8.3$ Hz, 1H), 6.97 (dd, $J = 8.2, 2.0$ Hz, 1H), 5.70 (d, $J = 6.4$ Hz, 1H), 5.42 (d, $J = 4.6$ Hz, 1H), 4.97 (m, 1H), 4.60 (m, 1H), 1.40 (d, $J = 6.4$ Hz, 3H), 0.11 (d, $J = 6.4$ Hz, 3H).

15

EXAMPLE 67




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-furan-2-ylmethyl-N-methyl-benzamide.

20 This compound was prepared using the general procedure described in
EXAMPLE 7. MS (ESI): m/z 461 $[M-H]^-$. HPLC (reversed-phase): $R_T = 9.58$
min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 8.97 (s,

1H), 8.30 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.23 (d, $J = 8.8$ Hz, 1H), 7.71 (t, $J = 7.6$ Hz, 1H), 7.67 (s, 1H), 7.43 (s, 1H), 7.04 (s, 2H), 6.37 (s, 2H), 4.57 (s, 1H), 4.06 (s, 1H), 2.86–2.61 (m, 3H).

5 EXAMPLE 68




Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azepane-1-carbonyl)-5-chlorophenyl]-amide.

This compound was prepared using the general procedure described in

10 EXAMPLE 7. MS (ESI): m/z 449 $[M-H]^+$. HPLC (reversed-phase): $R_T = 9.79$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.85 (s, 1H), 8.30 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.24 (d, $J = 8.8$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.64 (s, 1H), 7.01 (s, 2H), 3.47 (s, 2H), 2.99 (s, 2H), 1.75 (s, 2H), 1.57 (s, 2H), 1.49 (s, 4H).

15

EXAMPLE 69




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-naphthalen-1-ylmethyl-benzamide.

20 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 521 $[M-H]^+$. HPLC (reversed-phase): $R_T = 10.45$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.97 (s,

1H), 8.25 (m, 2H); 8.05 (s, 1H), 7.87 (m, 3H), 7.58–7.42 (m, 5H), 7.04 (m, 2H), 5.01 (s, 2H), 2.38 (s, 3H).


EXAMPLE 70



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-methyl-piperidine-1-carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 449 [M-H]⁻. HPLC (reversed-phase): R_T = 9.88 min (single peak). ¹H NMR (500 MHz, CDCl₃): (rotameric broadening) 8.89 (s, 1H), 8.33 (d, J = 7.0 Hz, 1H), 8.24 (d, J = 8.8 Hz, 1H), 7.72 (dd, J = 8.8, 7.0 Hz, 1H), 7.62 (s, 1H), 7.00 (m, 2H), 4.45 (s, 1H), 3.49 (s, 1H), 2.89 (m, 1H), 1.64–1.54 (m, 5H), 1.26 (s, 1H), 1.16 (s, 3H).


EXAMPLE 71



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-isoquinoline-2-carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 489 [M-H]⁻. HPLC (reversed-phase): R_T = 10.67 min (single peak). ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 8.85 (s, 1H), 8.29 (dd, J = 7.0, 1.0 Hz, 1H), 8.25 (dd, J = 8.8, 1.0 Hz, 1H), 7.71 (m, 1H), 7.61 (s, 1H), 7.01 (m, 2H), 3.09 (bs, 4H), 1.85–1.38 (m, 12H).


EXAMPLE 72



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(3-ethyl-2,4-dimethyl-
5 pyrrolidine-1-carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in
EXAMPLE 7. MS (ESI): m/z 477 $[M-H]^-$. HPLC (reversed-phase): R_T = 10.76
min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 10.10
(s, 1H), 8.33 (dd, J = 7.0, 1.0 Hz, 1H), 8.22 (dd, J = 8.8, 1.0 Hz, 1H), 7.72 (dd,
10 J = 9.9, 7.1 Hz, 1H), 7.65 (s, 1H), 7.12 (d, J = 8.3 Hz, 1H), 6.96 (dd, J = 8.3, 2.0
Hz, 1H), 3.83 (m, 1H), 3.14 (m, 1H), 3.00 (m, 1H), 1.83 (bs, 2H), 1.45–1.25 (m,
5H), 1.02–0.92 (m, 6H).


EXAMPLE 73



15 Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-phenyl-piperidine-1-
carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in
EXAMPLE 7. MS (ESI): m/z 511 $[M-H]^-$. HPLC (reversed-phase): R_T = 10.31
20 min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 9.02 (s,
1H), 8.30 (dd, J = 7.0, 1.0 Hz, 1H), 8.24 (dd, J = 8.8, 1.0 Hz, 1H), 7.71 (dd, J =
9.9, 7.1 Hz, 1H), 7.66 (d, J = 1.7 Hz, 1H), 7.33 (t, J = 7.4 Hz, 2H), 7.23 (m, 1H),
7.20 (m, 2H), 7.03 (m, 2H), 2.72–2.67 (m, 2H), 1.86 (bs, 2H), 1.59 (bs, 4H).


EXAMPLE 74



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-cyclohexyl-N-methyl-
5 benzamide.

This compound was prepared using the general procedure described in
EXAMPLE 7. MS (ESI): m/z 463 $[M-H]^+$. HPLC (reversed-phase): R_T = 10.23
min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.00 (s,
1H), 8.33 (d, J = 7.0 Hz, 1H), 8.24 (dd, J = 8.8, 1.0 Hz, 1H), 7.72 (dd, J = 9.9,
10 7.1 Hz, 1H), 7.63 (d, 1H), 7.01 (s, 2H), 1.58–1.04 (m, 11H).


EXAMPLE 75



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-quinoline-1-
15 carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in
EXAMPLE 7. MS (ESI): m/z 489 $[M-H]^+$. HPLC (reversed-phase): R_T = 10.72
min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 9.08 (s,
1H), 8.33 (d, J = 6.7 Hz, 1H), 8.24 (d, J = 8.7 Hz, 1H), 7.71 (m, 1H), 7.60 (s,
1H), 7.05–6.97 (m, 2H), 3.30 (m, 2H), 2.19 (m, 1H), 1.80–1.09 (m, 13H).
20


EXAMPLE 76



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-*N*-(1-cyclohexylethyl)-benzamide.

- 5 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 477 [M-H]⁻. HPLC (reversed-phase): R_T = 10.91 min (single peak). ¹H NMR (500 MHz, CDCl₃): (rotameric broadening) 11.73 (s, 1H), 8.37 (dd, J = 7.0, 1.0 Hz, 1H), 8.22 (dd, J = 8.8, 1.0 Hz, 1H), 7.74 (dd, J = 9.9, 7.1 Hz, 1H), 7.71 (d, J = 1.74 Hz, 1H), 7.21 (d, J = 8.4 Hz, 1H), 6.93 (dd, J = 8.4, 2.0, 1H), 5.75 (d, J = 8.5 Hz, 1H), 4.00 (m, 1H), 1.78–1.67 (m, 5H), 1.54 (s, 2H), 1.42 (m, 1H), 1.22–1.14 (m, 4H), 1.01 (m, 2H).


EXAMPLE 77



- 15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-*N*-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-benzamide.
This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 525 [M-H]⁻. HPLC (reversed-phase): R_T = 9.99 min (single peak). ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 11.04 (s, 1H), 8.33 (dd, J = 7.0, 1.0 Hz, 1H), 8.19 (dd, J = 8.8, 1.0 Hz, 1H), 7.99 (dd, J = 9.9, 7.1 Hz, 1H), 7.81 (d, J = 1.7 Hz, 1H), 7.69 (dd, J = 9.0, 6.8 Hz, 1H), 7.52 (d, J = 2.4 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.04

(dd, $J = 8.4, 2.0$ Hz, 1H), 2.97 (t, $J = 6.4$ Hz, 2H), 2.76 (t, $J = 5.8$ Hz, 2H), 1.94–1.85 (m, 4H).

EXAMPLE 78




5

Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azetidine-1-carbonyl)-5-chlorophenyl]-amide.

This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 407 $[M-H]^-$. HPLC (reversed-phase): $R_T = 9.12$

10 min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 10.97 (s, 1H), 8.34 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.24 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.72 (dd, $J = 9.9, 7.1$ Hz, 2H), 7.10 (d, $J = 1.7$ Hz, 1H), 6.93 (dd, $J = 9.0, 6.8$ Hz, 1H), 4.04 (m, 4H), 2.27 (m, 2H).

15 EXAMPLE 79




Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(thiazolidine-3-carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in

20 EXAMPLE 7. MS (ESI): m/z 441 $[M+H]^+$, 463 $[M+Na]^+$. HPLC (reversed-phase): $R_T = 9.24$ min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.52 (s, 1H), 8.31 (d, $J = 7.0$, 1H), 8.26 (d, $J = 8.8$ Hz, 1H), 7.72

(m, 2H), 7.13 (d, $J = 8.3$ Hz, 1H), 7.01 (dd, $J = 8.3, 1.8$ Hz, 1H), 4.56 (bs, 1H), 4.21 (bs, 1H), 3.68 (bs, 2H), 2.84 (bs, 2H).

EXAMPLE 80




Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,2,3,4-tetrahydronaphthalene-2-carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in

EXAMPLE 7. MS (ESI): m/z 485 $[M+H]^+$. HPLC (reversed-phase): $R_T = 9.93$

min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.24 (s, 1H), 8.28 (d, $J = 7.0$ Hz, 1H), 8.15 (s, 1H), 7.74 (s, 1H), 7.66 (s, 1H), 7.25–6.99 (m, 6H), 4.49 (m, 2H), 3.56 (m, 2H), 2.70 (m, 2H).

EXAMPLE 81




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluorobenzyl)benzamide.

This compound was prepared using the general procedure described in

EXAMPLE 7. MS (ESI): m/z 495 $[M+H]^+$. HPLC (reversed-phase): $R_T = 10.02$

min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.60 (s, 1H), 8.36 (d, $J = 7.0$ Hz, 1H), 8.21 (d, $J = 8.8$ Hz, 1H), 7.71 (m, 2H), 7.44 (m, 1H), 7.21 (m, 1H), 6.93–6.82 (m, 3H), 6.31 (bs, 1H), 4.56 (d, $J = 5.8$ Hz, 2H).


EXAMPLE 82



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-fluoro-benzyl)-
5 benzamide.

This compound was prepared using the general procedure described in
EXAMPLE 7. MS (ESI): m/z 477 $[M+H]^+$. HPLC (reversed-phase): R_T = 9.95
min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.63
(s, 1H), 8.36 (dd, J = 7.0, 1.0 Hz, 1H), 8.20 (dd, J = 8.8, 1.0 Hz, 1H), 7.75–7.68
10 (m, 2H), 7.48 (m, 1H), 7.43 (m, 1H), 7.18 (m, 2H), 7.09 (m, 1H), 6.91 (dd, J =
8.4, 2.0 Hz, 1H), 6.33 (s, 1H), 4.61 (d, J = 5.8 Hz, 2H).


EXAMPLE 83



15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichloro-benzyl)-
benzamide.

This compound was prepared using the general procedure described in
EXAMPLE 7. MS (ESI): m/z 525/527/529 $[M-H]^-$. HPLC (reversed-phase): R_T
= 10.57 min (single peak). 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening)
20 11.56 (s, 1H), 8.36 (dd, J = 7.0, 1.0 Hz, 1H), 8.21 (dd, J = 8.8, 1.0 Hz, 1H),
7.75–7.69 (m, 2H), 7.46–7.43 (m, 2H), 7.30 (m, 2H), 6.93 (dd, J = 8.4, 2.0 Hz,
1H), 6.42 (m, 1H), 4.61 (d, J = 5.8 Hz, 2H).


EXAMPLE 84



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(3,4-dichloro-benzyl)-benzamide.

- 5 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 525/527/529 $[M-H]^-$. HPLC (reversed-phase): R_T = 10.51 min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.58 (s, 1H), 8.36 (dd, J = 7.0, 1.0 Hz, 1H), 8.21 (dd, J = 8.8, 1.0 Hz, 1H), 7.75–7.70 (m, 2H), 7.44–7.40 (m, 2H), 7.24 (m, 1H), 7.17 (dd, J = 8.4, 2.0 Hz, 1H), 6.94 (dd, J = 8.4, 2.0 Hz, 1H), 6.29 (s, 1H), 4.52 (d, J = 5.8 Hz, 2H).


EXAMPLE 85



- 15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-benzyl)-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 491/493 $[M-H]^-$. HPLC (reversed-phase): R_T = 10.23 min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.60 (s, 1H), 8.37 (dd, J = 7.0, 1.0 Hz, 1H), 8.23 (dd, J = 8.8, 1.0 Hz, 1H), 7.75–7.70 (m, 2H), 7.35–7.33 (m, 2H), 7.24 (m, 3H), 6.92 (dd, J = 8.4, 2.0 Hz, 1H), 6.23 (s, 1H), 4.52 (d, J = 5.8 Hz, 2H).


EXAMPLE 86



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluorobenzyl)-benzamide.

- 5 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 477 $[M+H]^+$. HPLC (reversed-phase): R_T = 9.94 min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.62 (s, 1H), 8.37 (dd, J = 7.0, 1.0 Hz, 1H), 8.23 (dd, J = 8.8, 1.0 Hz, 1H), 7.74–7.71 (m, 2H), 7.30–7.27 (m, 2H), 7.22 (m, 1H), 7.06 (t, J = 8.6 Hz, 2H), 6.92 (dd, J = 8.4, 2.0 Hz, 1H), 6.23 (s, 1H), 4.52 (d, J = 5.8 Hz, 2H).


EXAMPLE 87



- 15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 497 $[M-H]^-$. HPLC (reversed-phase): R_T = 10.54 min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.79 (s, 1H), 8.40 (dd, J = 7.0, 1.0 Hz, 1H), 8.24 (dd, J = 8.8, 1.0 Hz, 1H), 7.76–7.71 (m, 2H), 7.21–7.13 (m, 5H), 6.90 (dd, J = 8.5, 2.0 Hz, 1H), 6.17 (d, J = 8.1 Hz, 1H), 5.30 (m, 1H), 2.86–2.80 (m, 2H), 2.13–2.09 (m, 1H), 1.90–1.80 (m, 3H).


EXAMPLE 88



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3,4-dichlorophenyl)-ethyl]-benzamide.

- 5 This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 539/541/543 $[M-H]^+$. HPLC (reversed-phase): R_T = 10.59 min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.51 (s, 1H), 8.35 (dd, J = 7.0, 1.0 Hz, 1H), 8.20 (dd, J = 8.8, 1.0 Hz, 1H), 7.75 (d, J = 2.0 Hz, 1H), 7.70 (dd, J = 8.8, 7.0 Hz, 1H), 7.44 (m, 1H), 7.29–7.23 (m, 3H), 6.95 (dd, J = 8.5, 2.0 Hz, 1H), 6.39 (d, J = 8.1 Hz, 1H), 5.50 (t, J = 7.2 Hz, 1H), 1.58 (m, 4H).
- 10


EXAMPLE 89



- 15 Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine-3-carbonyl)-phenyl]-amide. This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 540/542 $[M-H]^+$. HPLC (reversed-phase): R_T = 7.73 min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 8.37 (bs, 1H), 8.26 (m, 2H), 7.72 (dd, J = 8.8, 1.0 Hz, 1H), 7.47 (d, J = 1.8 Hz, 1H), 7.35 (m, 1H), 7.22 (m, 1H), 6.86 (bs, 1H), 6.59 (d, J = 9.0 Hz, 1H), 6.06 (bs, 1H), 4.20 (d, J = 15.5 Hz, 1H), 3.85 (d, J = 13.5 Hz, 1H), 3.06 (bs, 1H),
- 20

2.94 (d, $J = 12.7$ Hz, 2H), 2.55 (bs, 1H), 2.07 (d, $J = 13.4$ Hz, 1H), 2.00 (d, $J = 13.3$ Hz, 1H).

EXAMPLE 90




5

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 451 $[M+H]^+$. HPLC (reversed-phase): $R_T = 9.84$ min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 9.07 (s, 1H), 8.34 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.24 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.72 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.61 (d, $J = 2.0$ Hz, 1H), 7.16 (d, $J = 8.2$ Hz, 1H), 7.00 (dd, $J = 8.5, 2.0$ Hz, 1H), 4.00 (bs, 2H), 1.85 (bs, 4H), 1.12 (bs, 6H).

EXAMPLE 91




Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(morpholine-4-carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in EXAMPLE 7. MS (ESI): m/z 439 $[M+H]^+$. HPLC (reversed-phase): $R_T = 8.49$ min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 9.04 (s,

1H), 8.32 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.26 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.73 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.63 (s, 1H), 7.01 (m, 1H), 3.49 (m, 8H).

EXAMPLE 92




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-2-fluorobenzyl)-benzamide.

This compound was prepared using the general procedure described in

EXAMPLE 7. MS (ESI): m/z 509/511 $[M-H]^+$. HPLC (reversed-phase): $R_T =$

10.31 min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.56 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.74–7.69 (m, 2H), 7.39 (t, $J = 8.2$ Hz, 1H), 7.21–7.12 (m, 3H), 6.93 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.31 (s, 1H), 4.57 (d, $J = 6.0$ Hz, 2H).

EXAMPLE 93



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluorobenzyl)-benzamide.


This compound was prepared using the general procedure described in

EXAMPLE 7. MS (ESI): m/z 509/511 $[M-H]^+$. HPLC (reversed-phase): $R_T =$

10.24 min (single peak). 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.57 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$ Hz, 1H),

7.73–7.69 (m, 2H), 7.51 (m, 1H), 7.18 (m, 1H), 7.16 (m, 1H), 7.03 (m, 1H), 6.93 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.41 (s, 1H), 4.61 (d, $J = 6.0$ Hz, 2H).


EXAMPLE 94



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-trifluoromethylbenzyl)-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.27$ min (single peak). MS (ESI): neg. ion m/z 525 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.62 (s, 1H), 8.37 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.22 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.75–7.66 (m, 4H), 7.61 (app t, $J = 7.3$ Hz, 1H), 7.49 (app t, $J = 7.6$ Hz, 1H), 7.19 (d, $J = 8.5$ Hz, 1H), 6.92 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.29 (bm, 1H), 4.75 (d, $J = 6.0$ Hz, 1H).

EXAMPLE 95




(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydroxy-1-phenylethyl)-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. HPLC (reversed-phase): $R_T = 9.13$ min (single peak). MS (ESI): neg. ion m/z 487 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.59 (s, 1H), 8.35 (d, $J = 7.0$ Hz, 1H), 8.20 (d, $J = 8.8$ Hz, 1H), 7.76 (d, $J = 1.6$

Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.43–7.34 (m, 4H), 7.31 (d, $J = 6.9$ Hz, 2H), 6.96 (dd, $J = 8.3, 1.8$ Hz, 1H), 6.76 (bd, $J = 7.2$ Hz, 1H), 5.24 (bm, 1H), 3.99 (bm, 2H), 2.01 (bs, 1H).


5 EXAMPLE 96



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-benzyl)-4-chloro-benzamide.

This compound was prepared using the general procedure described in
 10 EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.29$ min (single peak). MS (ESI): neg. ion m/z 535/537/539 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.58 (s, 1H), 8.37 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.22 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.75 (d, $J = 2.0$ Hz, 1H), 7.72 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.50 (d, $J = 8.4$ Hz, 2H), 7.23 (d, $J = 8.4$ Hz, 2H), 7.19 (d, $J = 8.4$ Hz, 1H), 6.92 (dd, $J = 8.4, 2.0$
 15 Hz, 1H), 6.23 (bm, 1H), 4.52 (d, $J = 5.8, 2H$).

EXAMPLE 97




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-propyl)-
 20 benzamide.

This compound was prepared using the general procedure described in
 EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.33$ min (single peak). MS (ESI): neg. ion m/z 485 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric

broadening) 11.66 (bs, 1H), 8.35 (bd, $J = 7.0$ Hz, 1H), 8.18 (bd, $J = 8.8$ Hz, 1H), 7.74 (d, $J = 2.0$ Hz, 1H), 7.69 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.42–7.22 (m, 6H), 6.92 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.12 (bm, 1H), 5.02 (bm, 1H), 1.98–1.78 (m, 2H), 0.92 (t, $J = 7.3$, 3H).

5


EXAMPLE 98



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methyl-benzyl)-benzamide.

- 10 This compound was prepared using the general procedure described in EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.14$ min (single peak). MS (ESI): neg. ion m/z 471 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.70 (bs, 1H), 8.37 (bd, $J = 7.0$ Hz, 1H), 8.23 (bd, $J = 8.8$ Hz, 1H), 7.75 (d, $J = 2.0$ Hz, 1H), 7.72 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.30–7.15 (m, 5H), 6.91 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.03 (bm, 1H), 4.57 (d, $J = 5.2$ Hz, 2H), 2.35 (s, 3H).
- 15

EXAMPLE 99




- 20 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-bromo-benzyl)-4-chloro-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.18$ min (single peak). MS

(ESI): neg. ion m/z 535/537/539 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.61 (bs, 1H), 8.36 (bd, $J = 7.0$ Hz, 1H), 8.20 (bd, $J = 8.8$ Hz, 1H), 7.74 (d, $J = 2.0$ Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.60 (m, 1H), 7.50 (m, 1H), 7.36 (m, 1H), 7.26–7.18 (m, 2H), 6.93 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.48 (bm, 1H), 4.64 (d, $J = 5.9$ Hz, 2H).


EXAMPLE 100



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-methyl-N-(1-phenyl-ethyl)-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 9. HPLC (reversed-phase): $R_T = 10.19$ min (single peak). MS (ESI): m/z 579 $[M+H]^+$, 601 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.97 (bs, 1H), 8.36 (bd, $J = 7.0$ Hz, 1H), 8.24 (bd, $J = 8.8$ Hz, 1H), 7.94 (d, $J = 1.4$ Hz, 1H), 7.74 (bm, 1H), 7.5–7.35 (bm, 3H), 7.38–7.30 (bm, 2H), 7.32 (dd, $J = 8.0, 1.4$ Hz, 1H), 6.83 (bd, $J = 8.2$ Hz, 1H), 6.08 (bm, 1H), 2.8–2.2 (bs, 3H), 1.7–1.35 (bs, 3H).

EXAMPLE 101



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methyl-N-(1-phenyl-ethyl)-benzamide.

This compound was prepared using the general procedure described in


EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.14$ min (single peak). MS

(ESI): $m/z \sim 532$ $[M+H]^+$, ~ 554 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric

broadening) 9.08 (bs, 1H), 8.37 (dd, $J = 7.0, 0.9$ Hz, 1H), 8.24 (bd, $J = 8.8$ Hz,

5 1H), 7.77 (d, $J = 1.8$ Hz, 1H), 7.73 (bm, 1H), 7.5–7.35 (bm, 3H), 7.38–7.30
(bm, 2H), 7.11 (dd, $J = 8.2, 1.8$ Hz, 1H), 6.98 (bm, 1H), 6.05 (bm, 1H), 2.85–
2.2 (bs, 3H), 1.8–1.3 (bs, 3H).

EXAMPLE 102



10 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-
benzamide.


This compound was prepared using the general procedure described in

EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.58$ min (single peak). MS

15 (ESI): $m/z \sim 572$ $[M+H]^+$, ~ 594 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric
broadening) 11.51 (s, 1H), 8.37 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$
Hz, 1H), 7.90 (d, $J = 1.8$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.45 (d, $J = 7.8$
Hz, 1H), 7.44 (d, $J = 1.8$ Hz, 1H), 7.30 (dd, $J = 8.2, 2.1$ Hz, 1H), 7.16 (d, $J = 8.4$
Hz, 1H), 7.09 (dd, $J = 8.4, 1.8$ Hz, 1H), 6.42 (bm, 1H), 4.60 (d, $J = 6.0$ Hz, 2H).

20


EXAMPLE 103



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-N-methyl-benzamide.


- 5 This compound was prepared using the general procedure described in EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.70$ min (single peak). MS (ESI): $m/z \sim 633$ $[M+H]^+$, ~ 655 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.00 (bs, 1H), 8.33 (bd, $J = 6.8$ Hz, 1H), 8.26 (bd, $J = 8.8$ Hz, 1H), 7.77 (d, $J = 1.8$ Hz, 1H), 7.74 (bm, 1H), 7.45 (bm, 1H), 7.2–7.1 (bm, 2H), 7.05
10 (ddd, $J = 8.4, 8.1, 2.6$ Hz, 1H), 6.91 (bm, 1H), 4.7–4.35 (bs, 1.3H), 4.35–4.0 (bs, 0.7H), 3.25–3.1 (bs, 1.1H), 2.7–2.4 (bs, 1.9H).

EXAMPLE 104



- 15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-N-methyl-benzamide.
- This compound was prepared using the general procedure described in EXAMPLE 9. HPLC (reversed-phase): $R_T = 10.08$ min (single peak). MS (ESI): m/z 601 $[M+H]^+$, 623 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.92 (bs, 1H), 8.31 (bd, $J = 7.0$ Hz, 1H), 8.25 (bd, $J = 8.8$ Hz, 1H),
20 7.96 (d, $J = 1.5$ Hz, 1H), 7.73 (bm, 1H), 7.35 (bd, $J = 7.6$ Hz, 1H), 6.93 (bm, 1H), 6.85 (bm, 1H), 6.78 (bd, $J = 8.0$ Hz, 1H), 4.6–4.35 (bs, 1.3H), 4.35–4.1 (bs, 0.7H), 3.05–2.7 (bs, 1.1H), 2.7–2.45 (bs, 1.9H).


EXAMPLE 105



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4-
5 iodo-N-methyl-benzamide.

This compound was prepared using the general procedure described in
EXAMPLE 9. HPLC (reversed-phase): $R_T = 10.17$ min (single peak). MS
(ESI): m/z 597 $[M+H]^+$, 619 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric
broadening) 8.94 (bs, 1H), 8.37 (bd, $J = 7.0$ Hz, 1H), 8.25 (bd, $J = 8.8$ Hz, 1H),
10 7.90 (bs, 1H), 7.75 (bm, 1H), 7.5–7.25 (bm, 4H), 7.34 (dd, $J = 8.1, 1.6$, 1H),
7.10 (bm, 1H), 6.82 (bd, $J = 8.0$ Hz, 1H), 6.05 (bm, 1H), 2.8–2.3 (bs, 3H), 1.8–
1.4 (bs, 3H).

EXAMPLE 106




15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-
iodo-N-methyl-benzamide.

This compound was prepared using the general procedure described in
EXAMPLE 9. HPLC (reversed-phase): $R_T = 10.33$ min (single peak). MS
20 (ESI): m/z 617 $[M+H]^+$, 639 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric
broadening) 8.96 (bs, 1H), 8.32 (bd, $J = 7.0$ Hz, 1H), 8.26 (bd, $J = 9.0$ Hz, 1H),
7.97 (d, $J = 1.5$ Hz, 1H), 7.74 (bm, 1H), 7.5–7.3 (bm, 2H), 7.15 (bm, 1H), 7.04

(ddd, $J = 8.4, 8.1, 2.5$ Hz, 1H), 6.80 (bm, 1H), 4.7–4.4 (bs, 1.3H), 4.4–4.0 (bs, 0.7H), 3.1–2.7 (bs, 1.1H), 2.7–2.5 (bs, 1.9H).

EXAMPLE 107




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide.

This compound was prepared using the general procedure described in

EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.61$ min (single peak). MS

(ESI): m/z 541 $[M+H]^+$, 563 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.07 (bs, 1H), 8.33 (dd, $J = 7.0, 0.9$ Hz, 1H), 8.26 (bd, $J = 8.9$ Hz, 1H), 7.74 (bm, 1H), 7.63 (d, $J = 1.8$, 1H), 7.43 (bm, 1H), 7.31 (dd, $J = 8.2, 2.0$, 1H), 7.08–6.8 (bm, 2H), 4.8–4.4 (bs, 1.3H), 4.4–4.0 (bs, 0.7H), 3.1–2.7 (bs, 1.1H), 2.7–2.5 (bs, 1.9H).

EXAMPLE 108




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.25$ min (single peak). MS (ESI): m/z 525 $[M+H]^+$, 547 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.03 (bs, 1H), 8.33 (bd, $J = 6.8$ Hz, 1H), 8.26 (bd, $J = 8.9$ Hz, 1H),

7.96 (d, $J = 1.5$ Hz, 1H), 7.73 (bm, 1H), 7.61 (d, $J = 1.8$ Hz, 1H), 7.44 (bm, 1H), 7.16 (bm, 1H), 7.1–6.9 (bm, 2H), 7.05 (ddd, $J = 8.3, 8.1, 2.6$ Hz, 1H), 4.8–4.4 (bs, 1.3H), 4.4–4.0 (bs, 0.7H), 3.1–2.7 (bs, 1.1H), 2.7–2.5 (bs, 1.9H).


5 EXAMPLE 109



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide.

This compound was prepared using the general procedure described in
 10 EXAMPLE 7. HPLC (reversed-phase): $R_T = 9.92$ min (single peak). MS (ESI): m/z 509 $[M+H]^+$, 531 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.00 (bs, 1H), 8.32 (bd, $J = 6.9$ Hz, 1H), 8.25 (bd, $J = 8.8$ Hz, 1H), 7.73 (bm, 1H), 7.60 (bs, 1H), 7.50 (bm, 1H), 7.01 (bm, 1H), 6.93 (bm, 1H), 6.85 (bm, 1H), 4.7–4.4 (bs, 1.3H), 4.4–4.1 (bs, 0.7H), 3.1–2.7 (bs, 1.1H), 2.7–2.5
 15 (bs, 1.9H).

EXAMPLE 110




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide.
 20

This compound was prepared using the general procedure described in
 EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.28$ min (single peak). MS
 (ESI): m/z 569/571 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening)

9.00 (bs, 1H), 8.33 (bd, $J = 6.8$ Hz, 1H), 8.26 (bd, $J = 8.8$ Hz, 1H), 7.77 (d, $J = 1.8$ Hz, 1H), 7.74 (bm, 1H), 7.44 (bm, 1H), 7.15 (bm, 2H), 7.05 (ddd, $J = 8.4$, 8.1, 2.6 Hz, 1H), 6.96 (bm, 1H), 4.7–4.5 (bs, 1.3H), 4.4–4.0 (bs, 0.7H), 3.1–2.7 (bs, 1.1H), 2.7–2.4 (bs, 1.9H).

5


EXAMPLE 111



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-N-methyl-benzamide.

- 10 This compound was prepared using the general procedure described in EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.02$ min (single peak). MS (ESI): $m/z \sim 555$ $[M+H]^+$, ~ 576 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.95 (bs, 1H), 8.32 (bd, $J = 6.9$ Hz, 1H), 8.25 (bd, $J = 8.6$ Hz, 1H), 7.77 (d, $J = 1.8$ Hz, 1H), 7.72 (bm, 1H), 7.50 (bm, 1H), 7.15 (bd, $J = 6.8$ Hz, 1H), 7.0–6.8 (bm, 3H), 4.7–4.5 (bs, 1.3H), 4.5–4.1 (bs, 0.7H), 3.1–2.7 (bs, 1.1H), 2.7–2.5 (bs, 1.9H).
- 15

EXAMPLE 112




- 20 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.12$ min (single peak). MS

(ESI): m/z ~ 550 $[M+H]^+$, ~ 573 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.98 (bs, 1H), 8.38 (dd, $J = 7.0, 0.9$ Hz, 1H), 8.25 (bd, $J = 8.7$ Hz, 1H), 7.75 (bm, 1H), 7.72 (d, $J = 1.8$ Hz, 1H), 7.5–7.3 (bm, 2H), 7.17–7.05 (bm, 3H), 6.98 (bd, $J = 8.1$ Hz, 1H), 6.05 (bm, 1H), 2.47 (bs, 3H), 1.55 (bs, 3H).

5


EXAMPLE 113



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-N-methyl-benzamide.

- 10 This compound was prepared using the general procedure described in EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.65$ min (single peak). MS (ESI): m/z ~ 587 $[M+H]^+$, ~ 609 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.02 (bs, 1H), 8.33 (dd, $J = 7.0, 0.8$ Hz, 1H), 8.26 (bd, $J = 8.8$ Hz, 1H), 7.79 (d, $J = 1.8$ Hz, 1H), 7.74 (bm, 1H), 7.45–7.30 (bm, 2H), 7.31 (dd, $J =$
- 15 8.2, 1.9 Hz, 1H), 7.15 (bm, 1H), 6.97 (bm, 1H), 4.8–4.4 (bs, 1.3H), 4.4–4.0 (bs, 0.7H), 3.1–2.7 (bs, 1.1H), 2.7–2.5 (bs, 1.9H).

EXAMPLE 114




- 20 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 9. HPLC (reversed-phase): $R_T = 10.53$ min (single peak). MS

(ESI): m/z 619 $[M+H]^+$, 641 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.43 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$ Hz, 1H), 8.08 (d, $J = 1.6$ Hz, 1H), 7.72 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.49–7.40 (m, 2H), 7.33–7.22 (m, 1H), 6.99 (d, $J = 8.2$ Hz, 1H), 6.43 (bm, 1H), 4.59 (d, $J = 6.0$ Hz, 2H).


EXAMPLE 115



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(1-phenyl-ethyl)-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 9. HPLC (reversed-phase): $R_T = 10.07$ min (single peak). MS (ESI): m/z 565 $[M+H]^+$, 587 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.55 (s, 1H), 8.36 (dd, $J = 7.0, 1.1$ Hz, 1H), 8.20 (dd, $J = 8.8, 1.1$ Hz, 1H), 8.10 (d, $J = 1.6$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.41–7.36 (m, 2H), 7.36–7.26 (m, 4H), 6.98 (d, $J = 8.3$ Hz, 1H), 6.12 (d, $J = 8.0$ Hz, 1H), 5.25 (quint. $J = 7.3$ Hz, 1H), 1.56 (d, $J = 6.9$ Hz, 3H).


EXAMPLE 116



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-phenyl-ethyl)-benzamide.

This compound was prepared using the general procedure described in
 EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.00$ min (single peak). MS
 (ESI): m/z 517/519 $[M+H]^+$, 539/541 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$):
 (rotameric broadening) 11.63 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.20 (dd, J
 5 = 8.8, 1.0 Hz, 1H), 7.91 (d, $J = 1.8$ Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H),
 7.43–7.30 (m, 5H), 7.15 (d, $J = 8.4$ Hz, 1H), 7.07 (dd, $J = 8.4, 1.8$ Hz, 1H), 6.12
 (d, $J = 7.4$ Hz, 1H), 5.29 (quint, $J = 7.4$ Hz, 1H), 1.57 (d, $J = 6.8$ Hz, 2H).

EXAMPLE 117




10

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methoxy-N-methyl-
 benzamide.

This compound was prepared using the general procedure described in
 EXAMPLE 8. HPLC (reversed-phase): $R_T = 9.09$ min (single peak). MS (ESI):
 15 m/z 457 $[M+H]^+$, 479 $[M+Na]^+$. 1H NMR (500 MHz, $CDCl_3$): (rotameric
 broadening) 9.37 (bs, 1H), 8.27 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.22 (dd, $J = 8.8, 1.0$
 Hz, 1H), 7.88 (d, $J = 1.8$ Hz, 1H), 7.68 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.25 (d, $J = 8.4$
 Hz, 1H), 7.16 (dd, $J = 8.4, 1.9$ Hz, 1H), 3.16 (s, 3H), 3.10 (s, 3H).


20 EXAMPLE 118



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-methyl-N-(1-phenyl-
 ethyl)-benzamide.

This compound was prepared as described using the general procedure of EXAMPLE 43. HPLC (reversed-phase): $R_T = 9.83$ min (single peak). MS (ESI): m/z 487 $[M+H]^+$, 509 $[M+Na]^+$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 8.71 (bs, 1H), 8.32 (bd, $J = 6.7$ Hz, 1H), 8.23 (bd, $J = 7.8$ Hz, 1H), 7.69 (bm, 1H), 7.49 (bd, $J = 8.8$ Hz, 1H), 7.49–7.30 (m, 5H), 7.21 (bd, $J = 8.9$ Hz, 1H), 7.08 (bm, 1H), 6.05 (bm, 1H), 2.42 (bs, 3H), 1.58 (bs, 3H).


EXAMPLE 119



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-benzamide.

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 9.94$ min (single peak). MS (ESI): $m/z \sim 494$ $[M+H]^+$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.36 (s, 1H), 8.32 (bd, $J = 6.9$ Hz, 1H), 8.18 (bd, $J = 8.7$ Hz, 1H), 7.75–7.60 (bm, 2H), 7.46–7.40 (bm, 2H), 7.35–7.26 (bm, 3H), 6.97 (bm, 1H), 6.44 (bm, 1H), 4.59 (d, $J = 6.0$ Hz, 2H).

EXAMPLE 120




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-methylbenzamide.

This compound was prepared as described in EXAMPLE 44. HPLC (reversed-phase): $R_T = 10.43$ min (single peak). MS (ESI): m/z 507 $[M+H]^+$, 529 $[M+Na]^+$.

^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 11.50 (s, 1H), 8.32 (bd, $J = 7.0$ Hz, 1H), 8.18 (bd, $J = 8.8$ Hz, 1H), 7.66 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.50 (bs, 1H), 7.45–7.40 (m, 2H), 7.30–7.26 (m, 1H), 7.18 (d, $J = 8.0$ Hz, 1H), 6.76 (bd, $J = 8.1$ Hz, 1H), 4.58 (d, $J = 6.1$ Hz, 2H), 2.27 (s, 3H).

5

EXAMPLE 121




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-benzamide.

10 This compound was prepared as described using the general procedure of EXAMPLE 43. HPLC (reversed-phase): $R_T = 10.41$ min (single peak). MS (ESI): m/z 527/529 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 11.15 (s, 1H), 8.31 (dd, $J = 7.0, 0.9$ Hz, 1H), 8.20 (dd, $J = 8.8, 0.9$ Hz, 1H), 7.68 (d, $J = 8.9$ Hz, 1H), 7.66 (d, $J = 8.8$ Hz, 1H), 7.44 (s, 1H), 7.43 (d, $J = 8.2$ Hz, 1H), 7.31–7.24 (m, 3H), 6.36 (bm, 1H), 4.57 (d, $J = 6.0$ Hz, 2H).

15

EXAMPLE 122




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-N-methylbenzamide.

20

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 10.08$ min (single peak). MS (ESI): m/z 507 $[\text{M}+\text{H}]^+$, 529 $[\text{M}+\text{Na}]^+$. ^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 8.86 (bs, 1H), 8.28 (bd, $J =$

7.0 Hz, 1H), 8.24 (bd, $J = 8.7$ Hz, 1H), 7.69 (bm, 1H), 7.57 (d, $J = 8.2$ Hz, 1H), 7.44–7.35 (bm, 2H), 7.35–7.26 (bm, 2H), 7.13–6.95 (bm, 2H), 4.7–4.5 (bs, 1.3H), 4.3–3.9 (bs, 0.7H), 3.0–2.7 (bs, 1.1H), 2.7–2.45 (bs, 1.9 H).

5 EXAMPLE 123




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4,N-dimethyl-benzamide.

This compound was prepared as described in EXAMPLE 44. HPLC (reversed-phase): $R_T = 10.39$ min (single peak). MS (ESI): m/z 521 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.92 (bs, 1H), 8.27 (bd, $J = 7.0$ Hz, 1H), 8.24 (bd, $J = 9.0$ Hz, 1H), 7.70 (bm, 1H), 7.43–7.35 (bm, 3H), 7.30 (bm, 1H), 7.02–6.70 (bm, 2H), 4.7–4.4 (bs, 1.3H), 4.25–3.9 (bs, 0.7H), 3.0–2.7 (bs, 1.1H), 2.7–2.5 (bs, 1.9 H), 2.28 (s, 3H).

15

EXAMPLE 124




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide.

This compound was prepared as described using the general procedure of EXAMPLE 43. HPLC (reversed-phase): $R_T = 10.48$ min (single peak). MS (ESI): m/z ~542 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.72 (bs, 1H), 8.28–8.23 (bm, 2H), 7.70 (bm, 1H), 7.53 (bd, $J = 8.8$ Hz, 1H),

7.45–7.31 (bm, 2H), 7.31 (dd, $J = 8.2, 1.9$ Hz, 1H), 7.05 (bm, 1H), 4.65–4.4 (bs, 1.3H), 4.4–4.1 (bs, 0.7H), 3.0–2.7 (bs, 1.1H), 2.7–2.45 (bs, 1.9H).


EXAMPLE 125



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide.

This compound was prepared as described using the general procedure of EXAMPLE 43. HPLC (reversed-phase): $R_T = 9.82$ min (single peak). MS (ESI): m/z 509 $[M+H]^+$, 531 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.70 (bs, 1H), 8.32–8.17 (bm, 2H), 7.69 (bm, 1H), 7.54 (d, $J = 8.8$ Hz, 1H), 7.53–7.40 (bm, 1H), 7.24 (d, $J = 2.4$ Hz, 1H), 7.02 (bm, 1H), 6.96–6.80 (bm, 2H), 4.57–4.4 (bs, 1.3H), 4.4–4.1 (bs, 0.7H), 3.0–2.7 (bs, 1.1H), 2.7–2.45 (bs, 1.9H).

EXAMPLE 126




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide.

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 9.65$ min (single peak). MS (ESI): m/z 491 $[M+H]^+$, 513 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.81 (bs, 1H), 8.28 (bd, $J = 7.0$ Hz, 1H), 8.24 (bd, $J = 8.7$ Hz, 1H), 7.69 (bm, 1H), 7.53 (bd, $J = 7.9$ Hz, 1H),

7.46 (bm, 1H), 7.31 (bd, $J = 8.8$ Hz, 1H), 7.20–6.97 (bm, 3H), 7.05 (ddd, $J = 8.2, 8.2, 2.6$ Hz, 1H), 4.65–4.4 (bs, 1.3H), 4.4–4.0 (bs, 0.7H), 3.0–2.7 (bs, 1.1H), 2.7–2.4 (bs, 1.9H).


5 EXAMPLE 127



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluorobenzyl)-4,N-dimethylbenzamide.

This compound was prepared as described in EXAMPLE 44. HPLC (reversed-phase): $R_T = 10.00$ min (single peak). MS (ESI): m/z 505 $[M+H]^+$, 527 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.99 (bs, 1H), 8.27 (bd, $J = 7.0$ Hz, 1H), 8.23 (bd, $J = 8.8$ Hz, 1H), 7.69 (bm, 1H), 7.41 (bm, 1H), 7.40 (bs, 1H), 7.15 (bm, 1H), 7.04 (ddd, $J = 8.3, 8.2, 2.5$ Hz, 1H), 6.96 (bm, 1H), 7.62 (bm, 1H), 4.65–4.3 (bs, 1.3H), 4.3–3.9 (bs, 0.7H), 2.9–2.65 (bs, 1.1H), 2.65–2.4 (bs, 1.9 H), 2.28 (s, 3H).

EXAMPLE 128




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluorobenzyl)-N-methylbenzamide.

This compound was prepared as described using the general procedure of EXAMPLE 43. HPLC (reversed-phase): $R_T = 10.10$ min (single peak). MS (ESI): $m/z \sim 526$ $[M+H]^+$, 547 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric

broadening) 8.69 (bs, 1H), 8.32–8.23 (bm, 2H), 7.70 (bm, 1H), 7.52 (d, $J = 8.8$ Hz, 1H), 7.43 (bm, 1H), 7.17 (bm, 1H), 7.09–7.01 (bm, 2H), 4.65–4.4 (bs, 1.3H), 4.4–4.05 (bs, 0.7H), 3.0–2.7 (bs, 1.1H), 2.7–2.45 (bs, 1.9H).

5 EXAMPLE 129




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluorophenyl)-ethyl]-N-methyl-benzamide.

This compound was prepared using the general procedure described in

10 EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.00$ min (single peak). MS (ESI): m/z 505 $[M+H]^+$, 527 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.00 (bs, 1H), 8.38 (bd, $J = 7.0$ Hz, 1H), 8.25 (bd, $J = 8.8$ Hz, 1H), 7.74 (bm, 1H), 7.56 (d, $J = 1.8$ Hz, 1H), 7.5–7.22 (bm, 2H), 7.13–7.02 (bm, 3H), 6.97 (bm, 1H), 6.05 (bm, 1H), 2.7–2.3 (bs, 3H), 2.25–1.8 (bs, 3H).

15

EXAMPLE 130




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(4-fluorophenyl)-ethyl]-N-methyl-benzamide.

20 This compound was prepared as described using the general procedure of EXAMPLE 43. HPLC (reversed-phase): $R_T = 9.93$ min (single peak). MS (ESI): m/z 505 $[M+H]^+$, 527 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.68 (bs, 1H), 8.32 (bd, $J = 7.0$ Hz, 1H), 8.24 (bd, $J = 8.8$ Hz, 1H),

7.71 (bm, 1H), 7.5–7.3 (bm, 2H), 7.46 (bd, $J = 8.8$ Hz, 1H), 7.21 (dd, $J = 8.8$, 2.3 Hz, 1H), 7.14–7.07 (bm, 3H), 6.05 (bm, 1H), 2.6–2.3 (bs, 3H), 2.1–1.7 (bs, 3H).

5 EXAMPLE 131




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-benzamide.

This compound was prepared using the general procedure described in

- 10 EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.02$ min (single peak). MS (ESI): m/z 539/541 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.54 (s, 1H), 8.36 (dd, $J = 7.0$, 1.0 Hz, 1H), 8.21 (d, $J = 8.8$ Hz, 1H), 7.90 (d, $J = 1.8$ Hz, 1H), 7.71 (dd, $J = 8.8$, 7.0 Hz, 1H), 7.43 (m, 1H), 7.15 (d, $J = 8.4$ Hz, 1H), 7.08 (dd, $J = 8.4$, 1.8 Hz, 1H), 6.92 (m, 1H), 6.85 (m, 1H), 6.31 (bm, 1H),
15 4.56 (d, $J = 5.7$ Hz, 2H).

EXAMPLE 132



- 20 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-benzamide.


This compound was prepared using the general procedure described in

EXAMPLE 9. HPLC (reversed-phase): $R_T = 10.07$ min (single peak). MS (ESI): m/z 587 $[M+H]^+$, 609 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric

broadening) 11.54 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (d, $J = 8.8$ Hz, 1H), 8.09 (d, $J = 1.6$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.43 (m, 1H), 7.30 (dd, $J = 8.3, 1.6$ Hz, 1H), 6.98 (d, $J = 8.3$ Hz, 1H), 6.92 (m, 1H), 6.84 (m, 1H), 6.30 (bm, 1H), 4.55 (d, $J = 5.8$ Hz, 2H).

5


EXAMPLE 133



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-methylbenzamide.

- 10 This compound was prepared as described in EXAMPLE 44. HPLC (reversed-phase): $R_T = 9.70$ min (single peak). MS (ESI): m/z 475 $[M+H]^+$, 497 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.53 (bs, 1H), 8.32 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.18 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.66 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.51 (bs, 1H), 7.43 (m, 1H), 7.17 (d, $J = 8.0$ Hz, 1H), 6.91 (m, 1H), 6.84 (m, 1H), 6.76 (bd, $J = 8.4$ Hz, 1H), 6.28 (bm, 1H), 4.54 (d, $J = 5.9$ Hz, 2H), 2.26 (s, 3H).

EXAMPLE 134




- 20 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-benzamide.

This compound was prepared as described in EXAMPLE 43. HPLC (reversed-phase): $R_T = 9.95$ min (single peak). MS (ESI): m/z 495 $[M+H]^+$, 517 $[M+Na]^+$.

^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 11.17 (s, 1H), 8.31 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.20 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.68 (d, $J = 8.9$ Hz, 1H), 7.67 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.45 (m, 1H), 7.31–7.23 (m, 2H), 6.92 (m, 1H), 6.87 (m, 1H), 6.26 (bm, 1H), 4.53 (d, $J = 5.8$ Hz, 2H).

5

EXAMPLE 135




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-benzamide.

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 9.28$ min (single peak). MS (ESI): m/z 439 $[\text{M}+\text{H}]^+$, 461 $[\text{M}+\text{Na}]^+$. ^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 8.82 (bs, 1H), 8.37–8.17 (bm, 1H), 7.66 (bm, 1H), 7.55 (bm, 1H), 7.45–7.25 (bm, 5H), 7.2–6.9 (bm, 3H), 4.63–4.4 (bs, 1.3H), 4.4–4.1 (bs, 0.7H), 3.1–2.65 (bs, 1.1H), 2.65–2.4 (bs, 1.9H).

15

EXAMPLE 136




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4,N-dimethyl-benzamide.

This compound was prepared as described in EXAMPLE 44. HPLC (reversed-phase): $R_T = 9.62$ min (single peak). MS (ESI): m/z 453 $[\text{M}+\text{H}]^+$, 475 $[\text{M}+\text{Na}]^+$. ^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 8.96 (bs, 1H), 8.29–8.19 (bm, 2H), 7.67 (bm, 1H), 7.42–7.26 (bm, 5H), 7.15–6.95 (bm, 2H), 6.80 (bm,

20

1H), 4.55–4.3 (bs, 1.3H), 4.3–4.1 (bs, 0.7H), 3.0–2.7 (bs, 1.1H), 2.7–2.35 (bs, 1.9H), 2.27 (s, 3H).


EXAMPLE 137



Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(morpholine-4-carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in EXAMPLE 8. HPLC (reversed-phase): R_T = 8.43 min (single peak). MS (ESI): m/z ~484 $[M+H]^+$, ~506 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.97 (s, 1H), 8.32 (dd, J = 7.0, 1.0 Hz, 1H), 8.27 (dd, J = 8.8, 1.0 Hz, 1H), 7.78 (d, J = 1.8 Hz, 1H), 7.74 (dd, J = 8.8, 7.0 Hz, 1H), 7.18 (dd, J = 8.2, 1.8 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 3.7–3.18 (bm, 8H).

EXAMPLE 138




Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide.

This compound was prepared using the general procedure described in EXAMPLE 9. HPLC (reversed-phase): R_T = 8.50 min (single peak). MS (ESI): m/z 531 $[M+H]^+$, 553 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.91 (s, 1H), 8.31 (dd, J = 7.0, 0.9 Hz, 1H), 8.27 (dd, J = 8.8, 0.9

Hz, 1H), 7.97 (d, $J = 1.5$ Hz, 1H), 7.74 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.41 (dd, $J = 8.1, 1.6$ Hz, 1H), 6.78 (d, $J = 8.1$ Hz, 1H), 3.75–3.0 (bm, 8H).

EXAMPLE 139




5

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(morpholine-4-carbonyl)-phenyl]-amide.

This compound was prepared as described in EXAMPLE 44. HPLC (reversed-phase): $R_T = 8.02$ min (single peak). MS (ESI): m/z 419 $[M+H]^+$, 441 $[M+Na]^+$.

10 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.95 (s, 1H), 8.26 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.24 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.69 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.40 (bs, 1H), 6.95 (d, $J = 7.8$ Hz, 1H), 6.85 (bd, $J = 7.8$ Hz, 1H), 3.75–3.1 (bm, 8H), 2.29 (s, 3H).

15 EXAMPLE 140



7-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide.


20 A. 4-Chlorosulfonyl-7-methyl-2,1,3-benzothiadiazole. A solution of 4-methyl-2,1,3-benzothiadiazole (1.0 g, 6.7 mmol) and chlorosulfonic acid (2 mL) was heated to 140 °C for 2 h, and then was allowed to cool to 23 °C. The mixture was carefully poured over crushed ice, and the resulting precipitate was collected by filtration and dried under vacuum to provide the title compound as

a tan solid (1.08 g, 65%). This material was sufficiently pure to be used directly. ^1H NMR (500 MHz, CDCl_3): 8.31 (d, $J = 7.4$ Hz, 1H), 7.57 (dd, $J = 7.4$ Hz, 1.1, 1H), 2.91 (d, $J = 1.1$ Hz, 3H).

B. 7-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-

5 carbonyl)-phenyl]-amide. This compound was prepared as described in EXAMPLE 5 substituting 4-chlorosulfonyl-7-methyl-2,1,3-benzothiadiazole for 4-chlorosulfonyl-2,1,3-benzothiadiazole in step D. HPLC (reversed-phase): $R_T = 10.01$ min (single peak). MS (ESI): $m/z \sim 496$ $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, CDCl_3): (rotameric broadening) 8.92 (s, 1H), 8.18 (d, $J = 7.2$ Hz, 1H), 7.82 (d, $J = 1.8$ Hz, 1H), 7.42 (dd, $J = 7.2, 1.0$ Hz, 1H), 7.14 (dd, $J = 8.2, 1.8$ Hz, 1H), 6.92 (d, $J = 8.2$ Hz, 1H), 3.7–2.8 (bm, 4H), 2.80 (d, $J = 1.0$ Hz, 3H), 1.8–1.2 (bm, 6H).

EXAMPLE 141




15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-difluoro-benzyl)-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. HPLC (reversed-phase): $R_T = 9.85$ min (single peak). MS (ESI): 20 neg. ion m/z 493/495 $[\text{M}-\text{H}]^-$. ^1H NMR (400 MHz, CDCl_3): (rotameric broadening) 11.52 (s, 1H), 8.35 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.20 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.76 (d, $J = 2.0$ Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.32 (m, 1H), 7.20 (d, $J = 8.4$ Hz, 1H), 7.0–6.89 (m, 3H), 6.22 (bm, 1H), 4.68 (d, $J = 5.6$ Hz, 2H).

25


EXAMPLE 142



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-dichloro-benzyl)-benzamide.

- 5 This compound was prepared using the general procedure described in EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.31$ min (single peak). MS (ESI): neg. ion m/z 525/527/529 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.52 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.20 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.76 (d, $J = 2.0$ Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.37 (d, $J = 8.0$ Hz, 1H), 7.25 (m, 1H), 7.18 (d, $J = 8.4$ Hz, 1H), 6.91 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.16 (bm, 1H), 4.88 (d, $J = 5.4$ Hz, 2H).


EXAMPLE 143



- 15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trifluoro-benzyl)-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. HPLC (reversed-phase): $R_T = 9.95$ min (single peak). MS (ESI): neg. ion m/z 511/513 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.48 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.75 (d, $J = 2.0$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.19 (d, $J = 8.4$ Hz, 1H), 6.92 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.76–6.69 (m, 2H), 6.18 (bm, 1H), 4.62 (d, $J = 5.6$ Hz, 2H).


EXAMPLE 144



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trichloro-benzyl)-
5 benzamide.

This compound was prepared using the general procedure described in
EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.74$ min (single peak). MS
(ESI): neg. ion m/z 559/561/563 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric
broadening) 11.47 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.22 (dd, $J = 8.8, 1.0$
10 Hz, 1H), 7.76 (d, $J = 2.0$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.40 (s, 2H),
7.18 (d, $J = 8.4$ Hz, 1H), 6.92 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.13 (bm, 1H), 4.83 (d,
 $J = 5.4$ Hz, 2H).

EXAMPLE 145




15

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-methyl-1-phenyl-
ethyl)-benzamide.

This compound was prepared using the general procedure described in
EXAMPLE 7. HPLC (reversed-phase): $R_T = 10.21$ min (single peak). MS
20 (ESI): neg. ion m/z 485/487 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric
broadening) 11.59 (s, 1H), 8.35 (dd, $J = 7.1, 1.0$ Hz, 1H), 8.22 (dd, $J = 8.8, 1.0$
Hz, 1H), 7.75 (d, $J = 2.0$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.1$ Hz, 1H), 7.41–7.32 (m,

4H), 7.32–7.26 (m, 2H), 6.94 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.21 (s, 1H), 1.78 (s, 6H).

EXAMPLE 146




5

(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-*N*-[1-(2,4-dichlorophenyl)-ethyl]-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. See EXAMPLE 42 for preparation of (*R*)-1-(2,4-dichlorophenyl)-ethylamine. HPLC (reversed-phase): $R_T = 10.63$ min (single peak). MS (ESI): neg. ion m/z 539/541/543 [$M-H$]⁻. ¹H NMR (400 MHz, CDCl₃): (rotameric broadening) 11.53 (s, 1H), 8.35 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.74 (d, $J = 2.0$ Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.42 (d, $J = 1.0$ Hz, 1H), 7.3–7.25 (m, 2H), 7.28 (d, $J = 8.4$ Hz, 1H), 6.95 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.37 (d, $J = 7.2$ Hz, 1H), 5.42 (quint, $J = 7.2$ Hz, 1H), 1.57 (d, $J = 7.0$ Hz, 3H).

15

EXAMPLE 147




20

(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-*N*-[1-(2,4-difluorophenyl)-ethyl]-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 7. See EXAMPLE 39 for preparation of (*R*)-1-(2,4-difluorophenyl)-

ethylamine. HPLC (reversed-phase): $R_T = 10.10$ min (single peak). MS (ESI): neg. ion m/z 507/509 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.58 (s, 1H), 8.35 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.20 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.73 (d, $J = 2.0$ Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.32 (dt, $J = 8.5, 6.3$ Hz, 1H), 7.25 (d, $J = 8.4$ Hz, 1H), 6.94 (dd, $J = 8.4, 2.0$ Hz, 1H), 6.93–6.80 (m, 2H), 6.39 (d, $J = 7.7$ Hz, 1H), 5.34 (quint, $J = 7.4$ Hz, 1H), 1.56 (d, $J = 7.0$ Hz, 3H).


EXAMPLE 148



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-difluoro-benzyl)-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 8. HPLC (reversed-phase): $R_T = 9.93$ min (single peak). MS (ESI): neg. ion m/z 537/539 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.46 (s, 1H), 8.35 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.20 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.92 (d, $J = 1.8$ Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.32 (m, 1H), 7.12 (d, $J = 8.4$ Hz, 1H), 7.08 (dd, $J = 8.4, 1.8$ Hz, 1H), 7.00–6.92 (m, 2H), 6.21 (bm, 1H), 4.67 (d, $J = 5.6$ Hz, 2H).


EXAMPLE 149



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-dichloro-benzyl)-benzamide.


- 5 This compound was prepared using the general procedure described in EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.34$ min (single peak). MS (ESI): neg. ion m/z 569/571/573 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.45 (s, 1H), 8.36 (dd, $J = 7.0, 0.9$ Hz, 1H), 8.21 (dd, $J = 8.8, 0.9$ Hz, 1H), 7.92 (d, $J = 1.8$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.37 (d, $J = 8.0$ Hz, 2H), 7.25 (m, 1H), 7.11 (d, $J = 8.4$ Hz, 1H), 7.07 (dd, $J = 8.4, 1.8$ Hz, 1H), 6.15 (bm, 1H), 4.87 (d, $J = 5.4$ Hz, 2H).

EXAMPLE 150



- 15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trifluoro-benzyl)-benzamide.
- This compound was prepared using the general procedure described in EXAMPLE 8. HPLC (reversed-phase): $R_T = 9.97$ min (single peak). MS (ESI): neg. ion m/z 555/557 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.44 (s, 1H), 8.35 (dd, $J = 7.1, 0.8$ Hz, 1H), 8.22 (dd, $J = 8.8, 0.8$ Hz, 1H), 7.91 (d, $J = 1.7$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.1$ Hz, 1H), 7.12 (d, $J = 8.4$ Hz, 1H), 7.08 (dd, $J = 8.4, 1.7$ Hz, 1H), 6.78–6.67 (m, 2H), 6.19 (bm, 1H), 4.61 (d, $J = 5.6$ Hz, 2H).


EXAMPLE 151



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trichloro-benzyl)-
5 benzamide.

This compound was prepared using the general procedure described in
EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.78$ min (single peak). MS
(ESI): neg. ion m/z 603/605/607 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric
broadening) 11.42 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.22 (dd, $J = 8.8, 1.0$
10 Hz, 1H), 7.92 (d, $J = 1.6$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.40 (s, 2H),
7.10 (d, $J = 8.4$ Hz, 1H), 7.07 (dd, $J = 8.4, 1.6$ Hz, 1H), 6.13 (bm, 1H), 4.82 (d,
 $J = 5.5$ Hz, 2H).

EXAMPLE 152




15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-
benzyl)-benzamide.

This compound was prepared using the general procedure described in
EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.20$ min (single peak). MS
20 (ESI): neg. ion m/z 553/555/557 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric
broadening) 11.51 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$
Hz, 1H), 7.90 (d, $J = 1.8$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.49 (m, 1H),

7.17 (dd, $J = 8.4, 2.6$ Hz, 1H), 7.15 (d, $J = 8.4$ Hz, 1H), 7.10 (dd, $J = 8.4, 1.9$ Hz, 1H), 7.03 (m, 1H), 6.41 (bm, 1H), 4.60 (d, $J = 6.0$ Hz, 2H).


EXAMPLE 153



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-methyl-1-phenylethyl)-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 8. HPLC (reversed-phase): $R_T = 10.26$ min (single peak). MS (ESI): neg. ion m/z 529/531 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.54 (s, 1H), 8.35 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.22 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.91 (d, $J = 1.9$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.41–7.33 (m, 4H), 7.31–7.27 (m, 1H), 7.22 (d, $J = 8.4$ Hz, 1H), 7.10 (dd, $J = 8.4, 1.9$ Hz, 1H), 6.21 (bs, 1H), 1.78 (s, 6H).

EXAMPLE 154




(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-dichlorophenyl)ethyl]-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 8. See EXAMPLE 42 for preparation of (*R*)-1-(2,4-dichlorophenyl)ethylamine. HPLC (reversed-phase): $R_T = 10.70$ min (single peak). MS (ESI): neg. ion m/z 583/585/587 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric

broadening) 11.47 (s, 1H), 8.35 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.91 (d, $J = 1.8$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.43 (t, $J = 1.2$ Hz, 1H), 7.20 (d, $J = 8.4$ Hz, 1H), 7.11 (dd, $J = 8.4, 1.8$ Hz, 1H), 6.36 (d, $J = 7.3$ Hz, 1H), 5.41 (quint, $J = 7.2$ Hz, 1H), 1.56 (d, $J = 7.2$ Hz, 3H).

5


EXAMPLE 155



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-difluorophenyl)ethyl]-benzamide.

- 10 This compound was prepared using the general procedure described in EXAMPLE 8. See EXAMPLE 39 for preparation of (*R*)-1-(2,4-difluorophenyl)-ethylamine. HPLC (reversed-phase): $R_T = 10.17$ min (single peak). MS (ESI): neg. ion m/z 551/553 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.52 (s, 1H), 8.35 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.20 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.90 (d, $J = 1.8$ Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.31 (dt, $J = 8.4, 6.2$ Hz, 1H), 7.16 (d, $J = 8.4$ Hz, 1H), 7.10 (dd, $J = 8.4, 1.8$ Hz, 1H), 6.89 (m, 1H), 6.85 (m, 1H), 6.37 (d, $J = 7.6$ Hz, 1H), 5.33 (quint, $J = 7.5$ Hz, 1H), 1.56 (d, $J = 7.0$ Hz, 3H).
- 15


20 EXAMPLE 156



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trifluorobenzyl)-benzamide.

This compound was prepared using the general procedure described in
 EXAMPLE 6. HPLC (reversed-phase): $R_T = 9.96$ min (single peak). MS (ESI):
 neg. ion m/z 603 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening)
 11.34 (s, 1H), 8.35 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$ Hz, 1H),
 5 8.10 (d, $J = 1.6$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.30 (dd, $J = 8.3, 1.6$
 Hz, 1H), 6.95 (d, $J = 8.3$ Hz, 1H), 6.78–6.69 (m, 2H), 6.18 (bm, 1H), 4.60 (d, J
 = 5.6 Hz, 2H).

EXAMPLE 157




10 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trichloro-benzyl)-
 benzamide.

This compound was prepared using the general procedure described in
 EXAMPLE 9. HPLC (reversed-phase): $R_T = 10.83$ min (single peak). MS

15 (ESI): neg. ion m/z 651/653/655 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric
 broadening) 11.34 (s, 1H), 8.35 (dd, $J = 7.0, 0.9$ Hz, 1H), 8.22 (dd, $J = 8.8, 0.9$
 Hz, 1H), 8.10 (d, $J = 1.5$ Hz, 1H), 7.72 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.39 (s, 2H),
 7.29 (dd, $J = 8.2, 1.5$ Hz, 1H), 6.93 (d, $J = 8.2$ Hz, 1H), 6.13 (bm, 1H), 4.81 (d,
 20 $J = 5.5$ Hz, 2H).


EXAMPLE 158



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-iodo-benzamide.

- 5 This compound was prepared using the general procedure described in EXAMPLE 9. HPLC (reversed-phase): $R_T = 10.26$ min (single peak). MS (ESI): neg. ion m/z 601/603 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.45 (s, 1H), 8.36 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.8, 1.0$ Hz, 1H), 8.08 (d, $J = 1.6$ Hz, 1H), 7.72 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.49 (m, 1H),
 10 7.30 (dd, $J = 8.2, 1.6$ Hz, 1H), 7.17 (dd, $J = 8.3, 1.6$ Hz, 1H), 7.03 (m, 1H), 6.98 (d, $J = 8.3$ Hz, 1H), 6.41 (bm, 1H), 4.60 (d, $J = 6.0$ Hz, 2H).

EXAMPLE 159




- 15 (*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-iodo-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 9. See EXAMPLE 42 for preparation of (*R*)-1-(2,4-dichloro-phenyl)-ethylamine. HPLC (reversed-phase): $R_T = 10.75$ min (single peak). MS (ESI):
 20 neg. ion m/z 631/633 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.38 (s, 1H), 8.34 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.22 (dd, $J = 8.8, 1.0$ Hz, 1H), 8.09 (d, $J = 1.6$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.42 (t, $J = 1.2$ Hz, 1H), 7.31 (dd, $J = 8.2, 1.6$ Hz, 1H), 7.25 (t, $J = 0.8$ Hz, 1H), 7.03 (d, $J = 8.3$

Hz, 1H), 6.36 (d, $J = 7.2$ Hz, 1H), 5.40 (quint, $J = 7.2$ Hz, 1H), 1.56 (d, $J = 6.9$ Hz, 3H).


EXAMPLE 160



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-iodo-benzamide.

This compound was prepared using the general procedure described in EXAMPLE 9. See EXAMPLE 39 for preparation of (*R*)-1-(2,4-difluoro-phenyl)-ethylamine. HPLC (reversed-phase): $R_T = 10.20$ min (single peak). MS (ESI): neg. ion m/z 599 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.43 (s, 1H), 8.34 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.20 (dd, $J = 8.8, 1.0$ Hz, 1H), 8.08 (d, $J = 1.6$ Hz, 1H), 7.71 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.35–7.27 (m, 2H), 6.99 (d, $J = 8.3$ Hz, 1H), 6.89 (m, 1H), 6.84 (m, 1H), 6.37 (d, $J = 7.9$ Hz, 1H), 5.32 (quint, $J = 7.4$ Hz, 1H), 1.56 (d, $J = 7.1$ Hz, 3H).

EXAMPLE 161




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-benzamide.

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 9.78$ min (single peak). MS (ESI): neg. ion m/z 491/493 $[M-H]^-$. 1H NMR (500 MHz, $CDCl_3$): (rotameric broadening) 11.32 (s, 1H), 8.31 (dd, $J =$

7.0, 0.8 Hz, 1H), 8.18 (d, $J = 8.8$ Hz, 1H), 7.72 (d, $J = 8.1$ Hz, 1H), 7.66 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.37 (d, $J = 8.0$ Hz, 2H), 7.32 (m, 1H), 7.24 (m, 1H), 6.95 (m, 1H), 6.16 (bm, 1H), 4.86 (d, $J = 5.4$ Hz, 2H).

5 EXAMPLE 162




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4,6-trifluorobenzyl)-benzamide.

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 9.46$ min (single peak). MS (ESI): neg. ion m/z 477 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.28 (s, 1H), 8.32 (d, $J = 7.0$ Hz, 1H), 8.18 (d, $J = 8.8$ Hz, 1H), 7.70 (d, $J = 8.4$ Hz, 1H), 7.66 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.33 (m, 1H), 7.25 (m, 1H), 6.96 (m, 1H), 6.73 (m, 1H), 6.21 (bm, 1H), 4.60 (d, $J = 5.6$ Hz, 2H).

15

EXAMPLE 163




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluorobenzyl)-benzamide.

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 9.68$ min (single peak). MS (ESI): neg. ion m/z 475/477 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.39 (s, 1H), 8.33 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.18 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.69 (m, 1H), 7.66 (dd, $J = 8.8,$

7.0 Hz, 1H), 7.50 (m, 1H), 7.37–7.26 (m, 2H), 7.17 (dd, $J = 8.3, 2.6$ Hz, 1H), 7.03 (m, 1H), 7.00 (m, 1H), 6.43 (bm, 1H), 4.60 (d, $J = 6.0$ Hz, 2H).

EXAMPLE 164




5

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trifluorobenzyl)-benzamide.

This compound was prepared as described in EXAMPLE 44. HPLC (reversed-phase): $R_T = 9.69$ min (single peak). MS (ESI): neg. ion m/z 491 $[M-H]^-$. 1H

10 NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.42 (s, 1H), 8.31 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.18 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.66 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.51 (bs, 1H), 7.14 (d, $J = 8.0$ Hz, 1H), 6.77–6.67 (m, 3H), 6.16 (bm, 1H), 4.58 (d, $J = 5.7$ Hz, 2H), 2.27 (s, 3H).

15 EXAMPLE 165




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trichlorobenzyl)-benzamide.

This compound was prepared as described in EXAMPLE 44. HPLC (reversed-phase): $R_T = 10.47$ min (single peak). MS (ESI): neg. ion m/z 539/541/543 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.40 (s, 1H), 8.31 (d, $J = 7.0$ Hz, 1H), 8.18 (d, $J = 8.8$ Hz, 1H), 7.67 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.52 (s,

20

1H), 7.39 (s, 2H), 7.11 (d, $J = 8.0$ Hz, 1H), 6.75 (d, $J = 8.5$ Hz, 1H), 6.10 (bm, 1H), 4.79 (d, $J = 5.5$ Hz, 2H), 2.27 (s, 3H).

EXAMPLE 166




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluorobenzyl)-4-methylbenzamide.

This compound was prepared as described in EXAMPLE 44. HPLC (reversed-phase): $R_T = 9.89$ min (single peak). MS (ESI): neg. ion m/z 489/491 $[M-H]^-$.

1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.52 (s, 1H), 8.32 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.18 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.66 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.50 (s, 1H), 7.49 (dd, $J = 8.5, 6.0$ Hz, 1H), 7.18 (d, $J = 8.0$ Hz, 1H), 7.16 (dd, $J = 8.3, 2.6$ Hz, 1H), 7.02 (m, 1H), 6.76 (dd, $J = 8.0, 0.8$ Hz, 1H), 6.39 (bm, 1H), 4.58 (d, $J = 6.0$ Hz, 2H), 2.27 (s, 3H).

EXAMPLE 167




(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)ethyl]-4-methylbenzamide.

This compound was prepared as described in EXAMPLE 44. See EXAMPLE 39 for preparation of (*R*)-1-(2,4-difluorophenyl)ethylamine. HPLC (reversed-phase): $R_T = 9.76$ min (single peak). MS (ESI): neg. ion m/z 487 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.52 (s, 1H), 8.31 (dd, $J =$

7.1, 1.0 Hz, 1H), 8.16 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.66 (dd, $J = 8.8, 7.1$ Hz, 1H), 7.50 (s, 1H), 7.31 (dt, $J = 8.8, 6.4$ Hz, 1H), 7.19 (d, $J = 8.0$ Hz, 1H), 6.91-6.80 (m, 2H), 6.78 (d, $J = 7.3$ Hz, 1H), 6.35 (d, $J = 7.0$ Hz, 1H), 5.51 (quint, $J = 7.4$ Hz, 1H), 2.28 (s, 3H), 1.54 (d, $J = 7.0$ Hz, 3H).

5


EXAMPLE 168



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluorobenzyl)-benzamide.

10 This compound was prepared as described using the general procedure of EXAMPLE 43. HPLC (reversed-phase): $R_T = 10.15$ min (single peak). MS (ESI): neg. ion m/z 509/511 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.17 (s, 1H), 8.31 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.20 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.67 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.67 (d, $J = 8.9$ Hz, 1H), 7.48 (m, 1H),
15 7.29 (m, 1H), 7.25 (m, 1H), 7.18 (dd, $J = 8.3, 2.6$ Hz, 1H), 7.04 (m, 1H), 6.37 (bm, 1H), 4.58 (d, $J = 6.0$ Hz, 2H).

EXAMPLE 169




20 (R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-difluorophenyl)ethyl]-benzamide.

This compound was prepared as described using the general procedure of EXAMPLE 43. See EXAMPLE 39 for preparation of (R)-1-(2,4-difluoro-

phenyl)-ethylamine. HPLC (reversed-phase): $R_T = 10.12$ min (single peak).
 MS (ESI): neg. ion m/z 507/509 $[M-H]^-$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.17 (s, 1H), 8.30 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.18 (dd, $J = 8.8, 1.0$ Hz, 1H), 7.67 (d, $J = 8.8$ Hz, 1H), 7.66 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.34–7.25 (m, 3H), 6.92–6.82 (m, 2H), 6.32 (d, $J = 7.8$ Hz, 1H), 5.29 (quint, $J = 7.4$ Hz, 1H),
 5 1.56 (d, $J = 7.2$ Hz, 3H).


EXAMPLE 170



10 (R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,N-dimethyl-N-(1-phenyl-ethyl)-benzamide.

This compound was prepared as described in EXAMPLE 44. HPLC (reversed-phase): $R_T = 9.81$ min (single peak). MS (ESI): m/z 467 $[M+H]^+$, 489 $[M+Na]^+$.
 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.08 (bs, 1H), 8.34 (dd, $J = 7.0, 0.7$ Hz, 1H), 8.20 (bd, $J = 8.8$ Hz, 1H), 7.69 (bm, 1H), 7.45–7.37 (bm, 4H),
 15 7.37–7.26 (bm, 2H), 7.01 (bd, $J = 7.6$ Hz, 1H), 6.78 (bd, $J = 7.8$ Hz, 1H), 6.05 (bm, 1H), 2.7–2.25 (bs, 3H), 2.25 (s, 3H), 1.7–1.4 (bs, 3H).

EXAMPLE 171




20

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-N-methyl-benzamide.

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 9.41$ min (single peak). MS (ESI): m/z 475 $[M+H]^+$, 497 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.83 (bs, 1H), 8.27 (bd, $J = 6.7$ Hz, 1H), 8.22 (bd, $J = 8.7$ Hz, 1H), 7.67 (bm, 1H), 7.55–7.45 (bm, 1H), 7.54 (d, $J = 8.3$ Hz, 1H), 7.30 (bm, 1H), 7.10–7.00 (bm, 2H), 6.93 (bm, 1H), 6.84 (bm, 1H), 4.65–4.4 (bs, 1.3H), 4.4–4.1 (bs, 0.7H), 3.0–2.65 (bs, 1.1H), 2.65–2.4 (bs, 1.9H).


EXAMPLE 172



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4,N-dimethyl-benzamide.

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 9.80$ min (single peak). MS (ESI): m/z 489 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.00 (bs, 1H), 8.27 (bd, $J = 6.9$ Hz, 1H), 8.22 (bd, $J = 8.8$ Hz, 1H), 7.68 (bm, 1H), 7.6–7.4 (bm, 1H), 7.42 (bs, 1H), 6.96–6.85 (bm, 2H), 6.85–6.75 (bm, 2H), 4.65–4.3 (bs, 1.4H), 4.3–4.0 (bs, 0.6H), 2.9–2.65 (bs, 1H), 2.65–2.45 (bs, 2H), 2.28 (s, 3H).


20 EXAMPLE 173



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide.

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 9.48$ min (single peak). MS (ESI): m/z 471 $[M+H]^+$, 493 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.83 (bs, 1H), 8.35 (bd, $J = 6.9$ Hz, 1H), 8.22 (bd, $J = 8.7$ Hz, 1H), 7.70 (bm, 1H), 7.48 (bd, $J = 8.3$ Hz, 1H), 7.48–7.35 (bm, 2H), 7.23 (bm, 1H), 7.19–7.05 (bm, 3H), 7.01 (bm, 1H), 6.05 (bm, 1H), 2.9–2.3 (bs, 3H), 2.2–1.8 (bs, 3H).


EXAMPLE 174



10 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4,N-dimethyl-benzamide.

This compound was prepared as described in EXAMPLE 43. HPLC (reversed-phase): $R_T = 9.72$ min (single peak). MS (ESI): m/z 485 $[M+H]^+$, 507 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 9.03 (bs, 1H), 8.35 (dd, $J = 7.0, 0.8$ Hz, 1H), 8.22 (bd, $J = 8.8$ Hz, 1H), 7.70 (dd, $J = 8.8, 7.0$ Hz, 1H), 7.5–7.25 (bm, 1H), 7.35 (bs, 1H), 7.11–7.05 (bm, 2H), 7.01 (bd, $J = 7.6$ Hz, 1H), 6.79 (dd, $J = 7.8, 0.6$ Hz, 1H), 6.05 (bm, 1H), 2.8–2.2 (bm, 2H), 2.25 (s, 3H), 1.65–1.45 (bm, 6H).


20 EXAMPLE 175



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-benzamide.

This compound was prepared as described in EXAMPLE 41. HPLC (reversed-phase): $R_T = 9.47$ min (single peak). MS (ESI): m/z 461 $[M+H]^+$, 483 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 11.39 (s, 1H), 8.32 (d, $J = 7.0$ Hz, 1H), 8.17 (d, $J = 8.8$ Hz, 1H), 7.69 (d, $J = 8.3$ Hz, 1H), 7.66 (dd, $J = 8.8$, 7.0 Hz, 1H), 7.43 (m, 1H), 7.35–7.25 (m, 2H), 6.97 (d, $J = 7.6$ Hz, 1H), 6.91 (m, 1H), 6.84 (m, 1H), 6.35 (bm, 1H), 4.55 (d, $J = 5.8$ Hz, 2H).

EXAMPLE 176




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-5-chloro-N-methylbenzamide.

This compound was prepared as described using the general procedure of EXAMPLE 43. HPLC (reversed-phase): $R_T = 9.75$ min (single peak). MS (ESI): m/z 473 $[M+H]^+$, 495 $[M+Na]^+$. 1H NMR (400 MHz, $CDCl_3$): (rotameric broadening) 8.82 (bs, 1H), 8.30–8.18 (bm, 2H), 7.75–7.50 (bm, 2H), 7.42–7.29 (bm, 5H), 7.24 (bm, 1H), 7.1–7.0 (bm, 1H), 4.6–4.3 (bs, 1.3H), 4.3–4.1 (bs, 0.7H), 3.0–2.7 (bs, 1.1H), 2.7–2.35 (bs, 1.9H).

The compounds of EXAMPLES 177 and 178 were prepared using the general procedure of EXAMPLE 5.


EXAMPLE 177



5-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide.

5 MS (ESI): m/z 495 $[M+H]^+$.

EXAMPLE 178




10 7-Bromo-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide.

MS (ESI): m/z 559/561/563 $[M+H]^+$, 581/583/585 $[M+Na]^+$.

The compounds of EXAMPLES 180 through 182 were prepared using the general procedure of EXAMPLE 7.

15


EXAMPLE 180



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluoro-benzyl)-N-methyl-benzamide.

MS (ESI): neg. ion m/z 489/491 $[M-H]^-$.


EXAMPLE 181



- 5 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-benzyl)-N-methyl-benzamide.

MS (ESI): neg. ion m/z 505/507 $[M-H]^-$.

EXAMPLE 182




10

Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide.

MS (ESI): m/z 499/501. $[M+H]^+$, 521/523 $[M+Na]^+$.

- 15 The compounds of EXAMPLES 183 through 185 were prepared using the general procedure of EXAMPLE 8.


EXAMPLE 183



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-benzamide.

5 MS (ESI): neg. ion m/z 533/535 $[M-H]^-$.

EXAMPLE 184




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-fluoro-benzyl)-N-methyl-benzamide.

10

MS (ESI): neg. ion m/z 533/535 $[M-H]^-$.

EXAMPLE 185




15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-chloro-benzyl)-N-methyl-benzamide.

MS (ESI): neg. ion m/z 549/551/553 $[M-H]^-$.

The compounds of EXAMPLES 186 through 189 were prepared using the general procedure of EXAMPLE 9.

EXAMPLE 186




5

2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-4-iodo-benzamide.

MS (ESI): neg. ion m/z 617/619 $[M-H]^-$.

10 EXAMPLE 187




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-chloro-phenyl)-ethyl]-4-iodo-benzamide.

MS (ESI): neg. ion m/z 597/599 $[M-H]^-$.

15


EXAMPLE 188



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-4-iodo-N-methyl-benzamide.

MS (ESI): neg. ion m/z 581 $[M-H]^-$.

EXAMPLE 189




5 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-4-iodo-N-methyl-benzamide.

MS (ESI): neg. ion m/z 597/599 $[M-H]^-$.

The compounds of EXAMPLES 190 through 195 were prepared using the
10 general procedure of EXAMPLE 39.


EXAMPLE 190



15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-trifluoromethyl-benzamide.

MS (ESI): m/z 575/577 $[M+H]^+$, 597/599 $[M+Na]^+$.


EXAMPLE 191



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-4-trifluoromethyl-benzamide.

5 MS (ESI): m/z 507 $[M+H]^+$, 529 $[M+Na]^+$.

EXAMPLE 192




2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-N-methyl-4-trifluoromethyl-benzamide.

10

MS (ESI): m/z 525 $[M+H]^+$, 547 $[M+Na]^+$.


EXAMPLE 193



15 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-N-methyl-4-trifluoromethyl-benzamide.

MS (ESI): m/z 541 $[M+H]^+$, 563 $[M+Na]^+$.


EXAMPLE 194



2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-4-trifluoromethyl-benzamide.

5 MS (ESI): m/z 539 $[M+H]^+$, 561 $[M+Na]^+$.

EXAMPLE 195




10 (*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-methyl-N-(1-phenyl-ethyl)-4-trifluoromethyl-benzamide.

MS (ESI): m/z 521 $[M+H]^+$, 543 $[M+Na]^+$.

The compounds of EXAMPLES 196 through 198 were prepared using the general procedure of EXAMPLE 40.

15


EXAMPLE 196



(*R*)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-fluoro-benzamide.

MS (ESI): m/z 525/527 $[M+H]^+$, 547/549 $[M+Na]^+$.


EXAMPLE 197



- 5 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-fluoro-N-methylbenzamide.

MS (ESI): m/z 457 $[M+H]^+$, 479 $[M+Na]^+$.

EXAMPLE 198



10

- 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluoro-N-[1-(4-fluorophenyl)ethyl]-N-methylbenzamide.

MS (ESI): m/z 489 $[M+H]^+$, 511 $[M+Na]^+$.

15

Assay Methods

Binding Assay

Assay development

- 20 Zinc Finger Proteins (ZFP) specific for the CCK2R gene were identified by Sangamo Biosciences. The ZFP domain was fused with the herpes simplex virus VP16 activation domain, and the fusion protein was subsequently cloned into the pcDNA3 mammalian expression vector (Invitrogen, San Diego, CA). Tet-inducible cell lines expressing the coding region from the ZFP vector were

created using the T-REx-293TM cell line (Invitrogen). After 2 weeks of selection in culture medium containing 400 mg/mL Zeocin (Invitrogen), sixty drug-resistant stable clones were isolated and analyzed for ZFP expression as well as CCK2R induction upon addition of doxycycline to the culture medium. The cell line with the most appropriate CCK2R ZFP construct was used in all further assays and was termed the HEKZFP cell line.

Cell culture

HEKZFP cells were grown in DMEM supplemented with L-glutamine (2 mM), penicillin (50 units/mL) and streptomycin (50 µg/mL) and 10% FBS (v/v). HEKZFP cells were treated with 2mM doxycycline (Sigma-Aldrich, MO; USA) for 2 days to de-repress the tet-regulated expression of the CCK2 receptor selective zinc finger proteins and were harvested using a rubber cell scraper.

Membrane Preparation

Membranes were prepared from the HEKZFP cells after induction. Frozen cell pellets (−40 °C) were thawed in 14 mL of buffer A (10 mM HEPES, 130 mM NaCl, 4.7 mM KCl, 5 mM MgCl, 1 mM EGTA and 15.4 mg/100mL bacitracin at pH 7.2), adapted from E. A. Harper et al. (Br. J. Pharmacol. (1996) 118(7):1717–1726). The thawed pellets were homogenized using a Polytron PT-10 (7 X 1 s). The homogenates were centrifuged for 5 min at 1500 rpm (600 X g), and the resulting pellets were discarded. The supernatants were re-centrifuged in order to collect the receptor-membrane pellets (25 min 15,000 rpm; 39,800 X g), which were re-suspended in buffer A.

25

Incubation Conditions

All assays were conducted in 96-well plates (GF/B millipore filter plates) using buffer A. For the optimal cell number determination experiments, cells in concentrations ranging from 2.5×10^5 to 12.5×10^5 cells/well were incubated with 20 pM [¹²⁵I]-BH-CCK-8S (50 µL 60 pM solution) in a total volume of 150 µL. Total binding of [¹²⁵I]-BH-CCK-8S was determined in the presence of 15 µL of buffer A. Non-specific binding of [¹²⁵I]-BH-CCK-8S was determined in the presence of 15 µL of 10 µM YF476, a CCK-2 receptor selective antagonist that

is structurally unrelated to the radioligand [¹²⁵I]-BH-CCK-8S. The assay preparation was incubated for 1 h at 21±3 °C, and then the assay was terminated by rapid filtration of the preparation under reduced pressure. The loaded filters were washed three times using undiluted PBS (100 µL), and then 100 µL of scintillation fluid was added to the filter plate. Bound radioactivity was determined using a Topcount (Packard BioScience, Meriden, CT) with a count time of 1 min. From these experiments a cell concentration of 1 pellet in 15 mL of buffer was chosen for use in other assays. To validate the radioligand concentration and incubation time for the assay, saturation and kinetic binding studies were also conducted (see M.F. Morton, The Pharmacological Characterization of Cholecystokinin Receptors in the Human Gastrointestinal Tract. PhD Thesis, University of London, 2000). The affinity of novel compounds was estimated by incubating membrane preparations with 15 µL of competing ligand (0.1 pM–1 mM) for 60 min at 21±3 °C. The assay was then terminated according to the procedure outlined above.

Data Analysis

The pK_i values were determined using the equation of Y.-C. Cheng and W. H. Prusoff (Biochem. Pharmacol., 1973, 22(23):3099–3108):

$$K_i = \frac{IC_{50}}{1 + \frac{[L]}{K_D}}$$

To circumvent problems associated with computer-assisted data analysis of compounds with low affinity, the data obtained in the current study were weighted according to a method described by Morton. In brief, 100% and 0% specific binding were defined independently using total binding and binding obtained in the presence of a high concentration of the reference antagonist, 2-NAP.

Table 1

EXAMPLE	pK _i	EXAMPLE	pK _i
2	6.8	63	6.2
4	7.0	70	7.5

5	7.6	79	7.1
6	8.4	89	6.2
10	6.2	138	7.5
22	6.7	140	7.0
36	7.8		

Table 2


EXAMPLE	pK _i	EXAMPLE	pK _i
48	6.4	117	6.4
58	6.9	118	6.9
59	6.2	155	7.6
105	8.0	167	7.6
111	7.8	195	8.1
112	8.3		

Guinea-pig Gastric Corpeal Muscle Assay

5. CCK2 receptor-mediated muscle contraction was measured in an isolated muscle-strip assay of guinea-pig gastric corpeal muscle according to the methods described by Roberts et al. (S.P. Roberts, E.A. Harper, G.F. Watt, V.P. Gerskowitch, R.A. Hull, N.P. Shankley, and J.W. Black, Br. J. Pharmacol., 1996, 118(7):1779–1789). In brief, strips of muscle were dissected and
- 10 suspended in isolated tissue organ baths for isotonic muscle contraction recording. The baths, containing Krebs-Henseleit solution, were maintained at 24 °C and gassed continuously with 95% O₂ and 5% CO₂. CCK1 receptors known to be present in this assay were blocked using a selective concentration of a suitable CCK1 receptor antagonist (e.g. 2-NAP). The effectiveness of the
- 15 test compounds was assessed by measuring their effect on contractile concentration-response curves obtained using a well-characterized surrogate for the hormone gastrin (pentagastrin). The title compound of Example 5 behaved as a competitive antagonist in this assay with a pK_B value of 8.8.

What is claimed is:

1. A compound of formula (I):



5

R^1 and R^2 are each independently selected from the group consisting of

- a) H, C_{1-7} alkyl, C_{2-7} alkenyl, C_{2-7} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl, benzo-fused C_{4-7} cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C_{3-7} cycloalkyl C_{1-7} alkyl,
- 10 b) naphthyl- (CR^s_2) -, benzoyl C_{0-3} alkyl- (CR^s_2) -, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f , phenyl- (CR^s_2) -, said phenyl optionally fused at two adjacent carbon atoms to R^f , R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,
- 15 c) Ar^6 -(CR^s_2)-, where Ar^6 is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused or pyrido fused,
- d) Ar^5 -(CR^s_2)-, where Ar^5 is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC $_{1-4}$ alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzo fused or pyrido fused,
- 20 e) Ar^{6-6} -(CR^s_2)-, where Ar^{6-6} is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are -N=,
- 25

- f) $\text{Ar}^{6-5}-(\text{CR}^s)_2-$, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl and having 0 or 1 additional heteroatom member which is -N=,
- 5 g) C₁₋₄alkylO- and HSC₁₋₄alkyl,
 where R¹ and R² are not simultaneously H and, except in positions where R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q,
 R^q is independently selected from the group consisting of C₁₋₄alkyl,
 hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl,
 10 C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO-C₁₋₄alkyl,
 C₁₋₄alkylO-C₁₋₄alkyl, HS-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy and
 C₁₋₄alkylS-,
 R^s is independently selected from the group consisting of hydrogen,
 C₁₋₄alkyl, trifluoromethyl, aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl,
 15 diC₁₋₄alkylaminoC₁₋₄alkyl, HO-C₁₋₄alkyl, HS-C₁₋₄alkyl, C₁₋₄alkylS-
 C₁₋₄alkyl and phenyl;
 or, alternatively,
 R¹ and R² may be taken together with the nitrogen to which they are attached
 and are selected from the group consisting of
- 20 i) 10-Oxa-4-aza-tricyclo[5.2.1.0^{2,6}]dec-4-yl, optionally mono- or
 di-substituted with R^p,
 R^p is independently selected from the group consisting of hydroxy,
 C₁₋₄alkyl, hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted
 phenyl and hydroxyphenyl,
- 25 ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1
 additional heteroatom members separated from the nitrogen of
 attachment by at least one carbon member and selected from O, S,
 -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1
 or 2 carbon members which is a carbonyl, optionally having one
 30 carbon member which forms a bridge and having 0, 1 or 2
 substituents R^p,
- iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring
 having 0 or 1 additional heteroatom members separated from the

nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^P, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R^P,

iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^P, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^P, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^P;

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^P;

R^a is, independently, selected from the group consisting of -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC₁₋₆alkyl, -SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO₂, -N(R^y)R^z (wherein R^y and R^z are independently selected from H, C₁₋₄alkyl or C₁₋₆cycloalkyl/C₁₋₄alkyl), -(C=O)C₁₋₄alkyl, -SCF₃, halo, -CF₃, -OCF₃, and -COOC₁₋₄alkyl, or, alternatively, two adjacent R^a, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R^b is, independently, selected from the group consisting of -C₁₋₄alkyl and halogen;


and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

with the proviso that the compound of formula I cannot include compounds in which:

A) one of R^1 and R^2 is phenyl substituted with 1, 2, or 3 of halo, or

B) a compound of the formula:

5



2. The compound of claim 1 wherein R^1 and R^2 are, independently, selected from the group consisting of

10 a) H, C_{1-7} alkyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl, cyclobutyl C_{1-4} alkyl, cyclopentyl C_{1-4} alkyl, cyclohexyl C_{1-4} alkyl, cycloheptyl C_{1-4} alkyl,

15 b) phenyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-yl, optionally 5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3 or 4-yl, optionally 5,6,7 or 8-oxo-substituted, benzyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-ylmethyl, optionally 5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3 or 4-ylmethyl, optionally 5,6,7 or 8 oxo substituted, 1-phenyleth-1-yl, benzhydryl, naphthylmethyl, benzoylmethyl, 20 1-benzoylth-1-yl,

c) pyridylmethyl, pyrazinylmethyl, pyrimidinylmethyl, pyridazinylmethyl, quinolin-2,3 or 4-ylmethyl, isoquinolin-1,3 or 4-ylmethyl, quinazolin-2 or 4-ylmethyl, quinoxalin-2 or 3-ylmethyl,

25 d) furanylmethyl, thiophenylmethyl, 1-(H or C_{1-4} alkyl)pyrrolylmethyl, oxazolylmethyl, thiazolylmethyl, pyrazolylmethyl, imidazolylmethyl, isoxazolylmethyl, isothiazolylmethyl, benzofuran-2 or 3-ylmethyl,

benzothiophen-2 or 3-ylmethyl, 1-(H or C₁₋₄alkyl)-1H-indol-2 or 3-ylmethyl, 1-(H or C₁₋₄alkyl)-1H-benzimidazol-2-ylmethyl, benzooxazol-2-ylmethyl, benzothiazol-2-ylmethyl,

- e) quinolin-5,6,7 or 8-ylmethyl, isoquinolin-5,6,7 or 8-ylmethyl,
 5 quinazolin-5,6,7 or 8-ylmethyl, quinoxalin-5,6,7 or 8-ylmethyl,
 f) benzofuran-4,5,6 or 7-ylmethyl, benzothiophen-4,5,6 or 7-ylmethyl, 1-(H or C₁₋₄alkyl)-1H-indol-4,5,6 or 7-ylmethyl, 1-(H or C₁₋₄alkyl)-1H-benzimidazol-4,5,6 or 7-ylmethyl, benzooxazol-4,5,6 or 7-ylmethyl, benzothiazol-4,5,6 or 7-ylmethyl,
 10 g) C₁₋₄alkylo- and HSC₁₋₄alkyl,
 where each of a) to g) is substituted with 0, 1, 2, or 3 of R^q.

3. The compound of claim 1 wherein R¹ and R² are, independently, selected from the group consisting of hydrogen, methyl, ethyl, butyl, hexyl,
 15 phenyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl, optionally 5,6,7,8 or 9 oxo substituted, benzyl, 1-phenyleth-1-yl, furanylmethyl, benzoylethyl, 1-benzoyleth-1-yl, methylO-, cyclohexyl, cyclohexylmethyl, pyridylmethyl, naphthylmethyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, benzhydryl, where each member is substituted with 0, 1, 2, or 3 of R^q.

20


4. The compound of claim 1 wherein R¹ and R² are, independently, selected from the group consisting of hydrogen, methyl, ethyl, butyl, phenyl, benzyl, 2-bromobenzyl, 2-chlorobenzyl, 4-chlorobenzyl, 2,4-dichlorobenzyl,
 3,4-dichlorobenzyl, 2,6-dichlorobenzyl, 2,4,6-trichlorobenzyl, 2-fluorobenzyl,
 25 4-fluorobenzyl, 2,4-difluorobenzyl, 2,6-difluorobenzyl, 2,4,6-trifluorobenzyl, 2-chloro-4-fluorobenzyl, 2-fluoro-4-bromobenzyl, 2-fluoro-4-chlorobenzyl, 2-methylbenzyl, 2-methylsulfanylbenzyl, 2-trifluoromethylbenzyl, 1-phenyleth-1-yl, 1-phenylprop-1-yl, 1-(4-bromophenyl)eth-1-yl, 1-(4-fluorophenyl)eth-1-yl, 1-(2,4-dibromophenyl)eth-1-yl,
 30 1-(2,4-dichlorophenyl)eth-1-yl, 1-(3,4-dichlorophenyl)eth-1-yl, 1-(2,4-difluorophenyl)eth-1-yl, 1-(4-methylphenyl)eth-1-yl, 1-methyl-1-phenyleth-1-yl, 1-phenyl-2-dimethylaminoeth-1-yl, 1-benzoyleth-1-yl, cyclohexyl, 1-cyclohexyleth-1-yl, furan-2-ylmethyl, naphth-1-ylmethyl, methoxy,

methylthioethyl, 6-methyl-6-hydroxyhept-2-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 1-phenyl-2-hydroxyeth-1-yl, benzhydryl, 4-hydroxymethylpiperidin-1-yl, and 9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl.

5 5. The compound of claim 1 wherein one of R^1 and R^2 is H or C_{1-4} alkyl where the other is not H or C_{1-4} alkyl.

6. The compound of claim 1 wherein one of R^1 and R^2 is H, methyl or ethyl.

10 7. The compound of claim 1 wherein, at least one of R^1 and R^2 are, independently, selected from the groups consisting of



15 where R^s is not hydrogen, said phenyl is optionally fused at two adjacent carbon atoms to R^f and, except in positions where R^s is indicated, each member is substituted with 0, 1, 2, or 3 of R^q .

20 8. The compound of claim 1 wherein R^f is selected from the group consisting of $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2CH_2-$ and $-(C=O)CH_2CH_2CH_2-$.

25 9. The compound of claim 1 wherein R^s is selected from the group consisting of hydrogen, methyl, ethyl, propyl, trifluoromethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, methoxymethyl, thiomethyl, methylthiomethyl and phenyl.

10. The compound of claim 1 wherein R^s is selected from the group consisting of H, methyl, ethyl, hydroxymethyl and dimethylaminomethyl.

30 11. The compound of claim 1 wherein R^q is selected from the group consisting of methyl, ethyl, propyl, t-butyl, hydroxy, fluoro, chloro, bromo, iodo,

trifluoromethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, methoxymethyl, thiomethyl, methylthiomethyl, methoxy, ethoxy, methylmercapto and ethylmercapto.

5 12. The compound of claim 1 wherein R^q is selected from the group consisting of methyl, hydroxy, fluoro, chloro, bromo, iodo and trifluoromethyl.

13. The compound of claim 1 wherein, R^1 and R^2 taken together with the nitrogen to which they are attached are selected from the group consisting of

10 i) 10-Oxa-4-aza-tricyclo[5.2.1.0^{2,6}]dec-4-yl,

ii) 2-pyrrolin-1-yl, 3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl, 3-(H or R^p)imidazolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 3-(H or R^p)piperazin-1-yl, azepan-1-yl, thiazolidin-3-yl, oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl, azetidin-1-yl, where each member of ii) in each ring has 0 or 1

15 unsaturated bond and has 0, 1 or 2 carbon members which is a carbonyl,

iii) 3,4-dihydro-2H-quinolin-1-yl, 3,4-dihydro-2H-quinolin-2-yl, 2,3-dihydro-indol-1-yl, 1,3-dihydro-isoindol-2-yl, 1-oxo-1,3-dihydro-isoindol-2-yl, tetrahydro-benzo[b, c or d]azepin-1-yl, where each member of iii) in each ring has 0 or 1 unsaturated bond and has 0, 1 or 2 carbon members which are a

20 carbonyl,

iv) decahydro-quinolin-1-yl, octahydro-isoquinolin-2-yl, octahydro-[1 or 2]pyrindin-1 or 2-yl, octahydro-indol-1-yl, octahydro-isoindol-2-yl, hexahydro-cyclopenta[b]pyrrol-1-yl, hexahydro-cyclopenta[c]pyrrol-2-yl, (5,6,7 or 8-H or R^p)-decahydro-[1,5 or 1,6 or 1,7 or 1,8]naphthyridin-1-yl, (5,6,7 or 8-H or R^p)-decahydro-[2,5 or 2,6 or 2,7 or 2,8]naphthyridin-2-yl, 1-H or R^p -octahydro-pyrrolo[2,3-c]pyridin-6-yl, 2-H or R^p -octahydro-pyrrolo[3,4-c]pyridin-5-yl, 1-H or R^p -octahydro-pyrrolo[3,2-c]pyridin-5-yl, 1-H or R^p -octahydro-pyrrolo[2,3-b]pyridin-7-yl, 6-H or R^p -octahydro-pyrrolo[3,4-b]pyridin-1-yl, 1-H or R^p -octahydro-pyrrolo[3,2-b]pyridin-4-yl, 5-H or R^p -octahydro-pyrrolo[3,4-c]pyridin-2-yl, 6-H or R^p -octahydro-pyrrolo[2,3-c]pyridin-1-yl, 1-H or R^p -octahydro-pyrrolo[3,4-b]pyridin-6-yl, 7-H or R^p -octahydro-pyrrolo[2,3-b]pyridin-1-yl, octahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, where each member of

30 iv) in each ring has 0, 1 or 2 carbon members which is a carbonyl, each ring of

attachment has 0 or 1 unsaturated bonds and each secondary ring has 0, 1 or 2 unsaturated bonds,

v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,

- 5 where each member of i), ii), iii), iv) or v) is further substituted with 0, 1 or 2 of R^P .

14. The compound of claim 1 wherein, R^1 and R^2 taken together with the nitrogen to which they are attached are selected from the group consisting of
 10 10-oxa-4-aza-tricyclo[5.2.1.0^{2,6}]dec-4-yl, 2-pyrrolin-1-yl, 3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl, imidazolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl, azepan-1-yl, thiazolidin-3-yl, oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl, 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, azetidin-1-yl, octahydro-quinolin-1-yl, 3,4-dihydro-2H-
 15 quinolin-1-yl, 3,4-dihydro-2H-quinolin-2-yl, where each member is further substituted with 0, 1 or 2 of R^P .

15. The compound of claim 1 wherein R^1 and R^2 taken together with the nitrogen to which they are attached are selected from the group consisting of
 20 1-methyl-10-oxa-4-aza-tricyclo[5.2.1.0^{2,6}]dec-4-yl, azetidin-1-yl, pyrrolidin-1-yl, 2-hydroxymethylpyrrolidin-1-yl, 2,4-dimethyl-3-ethylpyrrolidin-1-yl, piperidin-1-yl, 2-methylpiperidin-1-yl, 4-hydroxymethylpiperidin-1-yl, 4-phenylpiperidin-1-yl, azepan-1-yl, 4-(2-hydroxyphenyl)piperazin-1-yl, morpholin-4-yl, octahydro-isoquinolin-2-yl, decahydro-quinolin-1-yl, thiazolidin-3-yl, 2,5-dimethyl-2,5-
 25 dihydro-pyrrol-1-yl, 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl and 3,4-dihydro-2H-quinolin-2-yl.

16. The compound of claim 1 wherein R^P is selected from the group consisting of hydroxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl,
 30 phenyl, p-halophenyl, m-halophenyl, o-halophenyl, and p-hydroxyphenyl.

17. The compound of claim 1 wherein R^p is selected from the group consisting of hydroxy, methyl, ethyl, hydroxymethyl, hydroxyethyl, phenyl, mono-fluorosubstituted phenyl and mono-chlorosubstituted phenyl.
- 5 18. The compound of claim 1 wherein R^a is selected from the group consisting of methyl, ethyl, propyl, ethenyl, propenyl, cyclopropyl, cyclobutyl, phenyl, furanyl, thienyl, pyrrol-1-yl, benzyl, hydroxy, methoxy, ethoxy, propoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, phenoxy, benzoxy, -SH, -Smethyl, -Sethyl, -S-t-butyl, -Scyclopropyl, -Sphenyl, -Sbenzyl, -NO₂, -CN, amino, 10 dimethylamino, (cyclohexylmethyl)amino, acetyl, -SCF₃, I, F, Cl, Br, -CF₃, -OCF₃ and carboxymethyl.
19. The compound of claim 1 wherein there is one R^a .
- 15 20. The compound of claim 1 wherein there is one R^a positioned on the ring para to the amide substituent.
21. The compound of claim 1 wherein two adjacent R^a are taken together with the carbons of attachment to form a fused ring.
- 20 22. The compound of claim 21 wherein the fused ring is benzo.
23. The compound of claim 1 wherein R^a is selected from the group consisting of nitro, F, Cl, Br, fused benzo, I, CF₃, methoxy, ethoxy, propoxy, i- 25 propoxy, ethenyl, cyclopentoxy, 2-propenyl, phenyl, furanyl, thienyl, amino, pyrrol-1-yl, dimethylamino, (cyclohexylmethyl)amino, -Smethyl, -Sethyl, -S-t-butyl, -Sbenzyl, -SCF₃, i-propyl and methyl.
24. The compound of claim 1 wherein R^b is absent or selected from the 30 group consisting of methyl, ethyl, I, F, Cl and Br.
25. The compound of claim 1 wherein R^b is absent.

26. The compound of claim 1 wherein said pharmaceutically acceptable salts are selected from the group consisting of hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, trifluoroacetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate and laurylsulfonate salts.

27. A compound selected from the group consisting of:

EX	Compound
1	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide;
2	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-nitro-2-(piperidine-1-carbonyl)-phenyl]-amide;
3	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
4	Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-(piperidine-1-carbonyl)-naphthalen-2-yl]-amide;
5	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
6	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(piperidine-1-carbonyl)-phenyl]-amide;
10	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methoxy-2-(piperidine-1-carbonyl)-phenyl]-amide;
11	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethoxy-2-(piperidine-1-carbonyl)-phenyl]-amide;
12	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propoxy-phenyl]-amide;
13	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropoxy-2-(piperidine-1-carbonyl)-phenyl]-amide;
14	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-cyclopentyloxy-2-(piperidine-1-carbonyl)-phenyl]-amide;

15	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-vinyl-phenyl]-amide;
16	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-allyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
17	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
18	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-propyl-phenyl]-amide;
19	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-(piperidine-1-carbonyl)-biphenyl-3-yl]-amide;
20	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-2-yl-2-(piperidine-1-carbonyl)-phenyl]-amide;
21	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-furan-3-yl-2-(piperidine-1-carbonyl)-phenyl]-amide;
22	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-2-yl-phenyl]-amide;
23	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-thiophen-3-yl-phenyl]-amide;
24	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-amino-2-(piperidine-1-carbonyl)-phenyl]-amide;
25	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-pyrrol-1-yl-phenyl]-amide;
26	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-dimethylamino-2-(piperidine-1-carbonyl)-phenyl]-amide;
27	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-(cyclohexylmethyl-amino)-2-(piperidine-1-carbonyl)-phenyl]-amide;
28	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
29	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-ethylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
30	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isobutylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;

31	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-benzylsulfanyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
32	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(piperidine-1-carbonyl)-5-trifluoromethyl-phenyl]-amide;
33	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-fluoro-2-(piperidine-1-carbonyl)-phenyl]-amide;
34	Benzo[1,2,5]thiadiazole-4-sulfonic acid [3-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide;
35	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dibromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
36	Benzo[1,2,5]thiadiazole-4-sulfonic acid [4,5-dichloro-2-(piperidine-1-carbonyl)-phenyl]-amide;
37	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-isopropyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
44	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(piperidine-1-carbonyl)-phenyl]-amide;
54	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1-methyl-10-oxa-4-aza-tricyclo[5.2.1.0 ^{2,6}]decane-4-carbonyl)-phenyl]-amide;
60	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(pyrrolidine-1-carbonyl)-phenyl]-amide;
62	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-hydroxymethyl-piperidine-1-carbonyl)-phenyl]-amide;
63	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-[4-(2-hydroxy-phenyl)-piperazine-1-carbonyl]-phenyl]-amide;
64	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-phenyl]-amide;
66	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-2,5-dihydro-pyrrole-1-carbonyl)-phenyl]-amide;
68	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azepane-1-carbonyl)-5-chloro-phenyl]-amide;
70	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2-methyl-piperidine-1-carbonyl)-phenyl]-amide;

71	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-isoquinoline-2-carbonyl)-phenyl]-amide;
72	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(3-ethyl-2,4-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide;
73	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(4-phenyl-piperidine-1-carbonyl)-phenyl]-amide;
75	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(octahydro-quinoline-1-carbonyl)-phenyl]-amide;
78	Benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(azetidine-1-carbonyl)-5-chloro-phenyl]-amide;
79	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(thiazolidine-3-carbonyl)-phenyl]-amide; -
80	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,2,3,4-tetrahydronaphthalene-2-carbonyl)-phenyl]-amide;
89	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine-3-carbonyl)-phenyl]-amide;
90	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(2,5-dimethyl-pyrrolidine-1-carbonyl)-phenyl]-amide;
91	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(morpholine-4-carbonyl)-phenyl]-amide;
137	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(morpholine-4-carbonyl)-phenyl]-amide;
138	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide;
139	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-methyl-2-(morpholine-4-carbonyl)-phenyl]-amide;
140	7-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;
177	5-Methyl-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide;

178	7-Bromo-benzo[1,2,5]thiadiazole-4-sulfonic acid [5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide; and
182	Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-chloro-2-(1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide.

28. A compound selected from the group consisting of:

EX	Compound
7	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-methyl-benzamide;
8	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-bromo-N-methyl-benzamide;
9	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-iodo-N-methyl-benzamide;
38	3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-naphthalene-2-carboxylic acid (4-fluoro-benzyl)-methylanide;
39	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-4-trifluoromethylbenzamide;
40	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-4-fluorobenzamide;
41	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluorophenyl)-ethyl]-benzamide;
42	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichlorophenyl)-ethyl]-4-methylbenzamide;
43	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-dichlorophenyl)-ethyl]-benzamide;
45	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chlorobenzyl)-benzamide;
46	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-(5-hydroxy-1,5-dimethylhexyl)benzamide;
47	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methylsulfanyl-benzyl)benzamide;

48	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-dimethylamino-1-phenyl-ethyl)-N-methylbenzamide TFA salt;
49	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-chloro-N-ethylbenzamide;
50	N-Benzhydryl-2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methylbenzamide;
51	(S) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide;
52	(R) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide;
53	(R) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-ethyl)-benzamide;
55	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-2-fluorobenzyl)-4-chloro-benzamide;
56	(R) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-bromophenyl)ethyl]-4-chloro-benzamide;
57	(R) 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-p-tolylethyl)-benzamide;
58	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-phenylbenzamide;
59	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-butyl-4-chlorobenzamide;
61	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluorophenyl)ethyl]-benzamide;
65	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N,N-diethylbenzamide;
67	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-furan-2-ylmethyl-N-methylbenzamide;
69	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-naphthalen-1-ylmethylbenzamide;
74	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-cyclohexyl-N-methylbenzamide;

76	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-cyclohexyl-ethyl)-benzamide;
77	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-benzamide;
81	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluorobenzyl)-benzamide;
82	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-fluorobenzyl)-benzamide;
83	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichlorobenzyl)-benzamide;
84	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(3,4-dichlorobenzyl)-benzamide;
85	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chlorobenzyl)-benzamide;
86	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluorobenzyl)-benzamide;
87	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1,2,3,4-tetrahydro-naphthalen-1-yl)-benzamide;
88	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3,4-dichlorophenyl)-ethyl]-benzamide;
92	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-2-fluorobenzyl)-benzamide;
93	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluorobenzyl)-benzamide;
94	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-trifluoromethyl-benzyl)-benzamide;
95	(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydroxy-1-phenyl-ethyl)-benzamide;
96	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-bromo-benzyl)-4-chloro-benzamide;
97	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-phenyl-propyl)-benzamide;

98	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-methyl-benzyl)-benzamide;
99	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-bromo-benzyl)-4-chloro-benzamide;
100	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-methyl-N-(1-phenyl-ethyl)-benzamide;
101	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methyl-N-(1-phenyl-ethyl)-benzamide;
102	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-benzamide;
103	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-N-methyl-benzamide;
104	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-N-methyl-benzamide;
105	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4-iodo-N-methyl-benzamide;
106	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-iodo-N-methyl-benzamide;
107	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;
108	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
109	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
110	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
111	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
112	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide;
113	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;

114	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-iodo-benzamide;
115	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(1-phenyl-ethyl)-benzamide;
116	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-phenyl-ethyl)-benzamide;
117	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methoxy-N-methyl-benzamide;
118	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-methyl-N-(1-phenyl-ethyl)-benzamide;
119	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-benzamide;
120	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4-methyl-benzamide;
121	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-benzamide;
122	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;
123	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-dichloro-benzyl)-4,N-dimethyl-benzamide;
124	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-dichloro-benzyl)-N-methyl-benzamide;
125	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
126	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
127	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4,N-dimethyl-benzamide;
128	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluoro-benzyl)-N-methyl-benzamide;
129	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(4-fluorophenyl)-ethyl]-N-methyl-benzamide;


130	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide;
131	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4-difluoro-benzyl)-benzamide;
132	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-iodo-benzamide;
133	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4-methyl-benzamide;
134	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2,4-difluoro-benzyl)-benzamide;
135	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-benzamide;
136	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4,N-dimethyl-benzamide;
141	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-difluoro-benzyl)-benzamide;
142	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,6-dichloro-benzyl)-benzamide;
143	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trifluoro-benzyl)-benzamide;
144	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2,4,6-trichloro-benzyl)-benzamide;
145	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(1-methyl-1-phenyl-ethyl)-benzamide;
146	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide;
147	(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide;
148	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-difluoro-benzyl)-benzamide;
149	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,6-dichloro-benzyl)-benzamide;

150	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trifluoro-benzyl)-benzamide;
151	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2,4,6-trichloro-benzyl)-benzamide;
152	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-chloro-4-fluoro-benzyl)-benzamide;
153	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(1-methyl-1-phenyl-ethyl)-benzamide;
154	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-dichloro-phenyl)-ethyl]-benzamide;
155	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide;
156	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trifluoro-benzyl)-benzamide;
157	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-N-(2,4,6-trichloro-benzyl)-benzamide;
158	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-iodo-benzamide;
159	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-iodo-benzamide;
160	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-iodo-benzamide;
161	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-benzamide;
162	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4,6-trifluoro-benzyl)-benzamide;
163	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-benzamide;
164	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trifluoro-benzyl)-benzamide;
165	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-N-(2,4,6-trichloro-benzyl)-benzamide;

166	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2-chloro-4-fluoro-benzyl)-4-methyl-benzamide;
167	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-difluoro-phenyl)-ethyl]-4-methyl-benzamide;
168	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(2-chloro-4-fluoro-benzyl)-benzamide;
169	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide;
170	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,N-dimethyl-N-(1-phenyl-ethyl)-benzamide;
171	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-N-methyl-benzamide;
172	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-4,N-dimethyl-benzamide;
173	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide;
174	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-4,N-dimethyl-benzamide;
175	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,4-difluoro-benzyl)-benzamide;
176	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-5-chloro-N-methyl-benzamide;
180	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-fluoro-benzyl)-N-methyl-benzamide;
181	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(4-chloro-benzyl)-N-methyl-benzamide;
183	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(4-fluoro-phenyl)-ethyl]-benzamide;
184	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-fluoro-benzyl)-N-methyl-benzamide;
185	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(4-chloro-benzyl)-N-methyl-benzamide;

186	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(2,6-dichloro-benzyl)-4-iodo-benzamide;
187	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-chloro-phenyl)-ethyl]-4-iodo-benzamide;
188	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-4-iodo-N-methyl-benzamide;
189	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-4-iodo-N-methyl-benzamide;
190	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-trifluoromethyl-benzamide;
191	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-N-methyl-4-trifluoromethyl-benzamide;
192	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-fluoro-benzyl)-N-methyl-4-trifluoromethyl-benzamide;
193	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-(4-chloro-benzyl)-N-methyl-4-trifluoromethyl-benzamide;
194	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-4-trifluoromethyl-benzamide;
195	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-methyl-N-(1-phenyl-ethyl)-4-trifluoromethyl-benzamide;
196	(<i>R</i>)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-(2,4-dichloro-phenyl)-ethyl]-4-fluoro-benzamide;
197	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-benzyl-4-fluoro-N-methyl-benzamide; and
198	2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluoro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide.

29. A pharmaceutical composition comprising a suitable amount of inert pharmaceutically acceptable diluent and a pharmaceutically efficacious amount of a compound of formula (I):



wherein

R^1 and R^2 are each independently selected from the group consisting of

a) H, C_{1-7} alkyl, C_{2-7} alkenyl, C_{2-7} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl, benzo-fused C_{4-7} cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C_{3-7} cycloalkyl C_{1-7} alkyl,

b) naphthyl- (CR^s_2) -, benzoyl C_{0-3} alkyl- (CR^s_2) -, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f , phenyl- (CR^s_2) -, said phenyl optionally fused at two adjacent carbon atoms to R^f ,

R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

c) Ar^6 -(CR^s_2)-, where Ar^6 is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused or pyrido fused,

d) Ar^5 -(CR^s_2)-, where Ar^5 is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC $_{1-4}$ alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzo fused or pyrido fused,

e) Ar^{6-6} -(CR^s_2)-, where Ar^{6-6} is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are -N=,

f) Ar^{6-5} -(CR^s_2)-, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC $_{1-4}$ alkyl and having 0 or 1 additional heteroatom member which is -N=,

g) C₁₋₄alkylO- and HSC₁₋₄alkyl,

where R¹ and R² are not simultaneously H and, except in positions where

R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q,

R^q is independently selected from the group consisting of C₁₋₄alkyl,

5 hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO-C₁₋₄alkyl, C₁₋₄alkylO-C₁₋₄alkyl, HS-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy and C₁₋₄alkylS-,

R^s is independently selected from the group consisting of hydrogen,

10 C₁₋₄alkyl, trifluoromethyl, aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO-C₁₋₄alkyl, HS-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl and phenyl;

or, alternatively,

R¹ and R² may be taken together with the nitrogen to which they are attached
15 and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.0^{2,6}]dec-4-yl, optionally mono- or di-substituted with R^p,

R^p is independently selected from the group consisting of hydroxy, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,
20

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of

attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1
25 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents R^p,

iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected
30 from O, S, -N=, >NH or >NR^p, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having

0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R^P ,

iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^P, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^P, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^P ;


v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^P ;

R^a is, independently, selected from the group consisting of -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC₁₋₆alkyl, -SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO₂, -N(R^Y)R^Z (wherein R^Y and R^Z are independently selected from H, C₁₋₄alkyl or C₁₋₆cycloalkylC₁₋₄alkyl), -(C=O)C₁₋₄alkyl, -SCF₃, halo, -CF₃, -OCF₃, and -COOC₁₋₄alkyl, or, alternatively, two adjacent R^a , may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R^b is, independently, selected from the group consisting of -C₁₋₄alkyl and halogen;

and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

30. A method for treating or preventing CCK2 mediated disease states comprising administering to a mammal in need of such treatment or prevention an effective dose of a compound of formula (I):



wherein

R¹ and R² are each independently selected from the group consisting of

a) H, C₁₋₇alkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, benzo-fusedC₄₋₇cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C₃₋₇cycloalkylC₁₋₇alkyl,

b) naphthyl-(CR^s₂)-, benzoylC₀₋₃alkyl-(CR^s₂)-, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f, phenyl-(CR^s₂)-, said phenyl optionally fused at two adjacent carbon atoms to R^f,

R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

c) Ar⁶-(CR^s₂)-, where Ar⁶ is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused or pyrido fused,

d) Ar⁵-(CR^s₂)-, where Ar⁵ is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl, having 0 or 1 additional heteroatom member which is -N= and optionally benzo fused or pyrido fused,

e) Ar⁶⁻⁶-(CR^s₂)-, where Ar⁶⁻⁶ is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are -N=,

f) $\text{Ar}^{6-5}-(\text{CR}^s_2)-$, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl and having 0 or 1 additional heteroatom member which is -N=,

5 g) C₁₋₄alkylO- and HSC₁₋₄alkyl,
 where R¹ and R² are not simultaneously H and, except in positions where R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q,
 R^q is independently selected from the group consisting of C₁₋₄alkyl,
 hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl,
 10 C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO-C₁₋₄alkyl,
 C₁₋₄alkylO-C₁₋₄alkyl, HS-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy and
 C₁₋₄alkylS-,

R^s is independently selected from the group consisting of hydrogen,
 C₁₋₄alkyl, trifluoromethyl, aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl,
 15 diC₁₋₄alkylaminoC₁₋₄alkyl, HO-C₁₋₄alkyl, HS-C₁₋₄alkyl, C₁₋₄alkylS-
 C₁₋₄alkyl and phenyl;

or, alternatively,

R¹ and R² may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

20 i) 10-Oxa-4-aza-tricyclo[5.2.1.0^{2,6}]dec-4-yl, optionally mono- or di-substituted with R^p,

R^p is independently selected from the group consisting of hydroxy, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

25 ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one
 30 carbon member which forms a bridge and having 0, 1 or 2 substituents R^p,

iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the

nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^P, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R^P,

iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^P, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^P, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^P;


v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^P;

R^a is, independently, selected from the group consisting of -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC₁₋₆alkyl, -SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO₂, -N(R^y)R^z (wherein R^y and R^z are independently selected from H, C₁₋₄alkyl or C₁₋₆cycloalkylC₁₋₄alkyl), -(C=O)C₁₋₄alkyl, -SCF₃, halo, -CF₃, -OCF₃, and -COOC₁₋₄alkyl, or, alternatively, two adjacent R^a, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R^b is, independently, selected from the group consisting of -C₁₋₄alkyl and halogen;

and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

31. A method for treating or preventing pancreatic adenocarcinoma, pain, eating disorders, gastro-esophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors, gastric tumors, Barrett's esophagus, antral G cell hyperplasia, pernicious anaemia and Zollinger-Ellison syndrome comprising administering to a mammal in need of such treatment or prevention an effective dose of a compound of formula (I):



wherein

R^1 and R^2 are each independently selected from the group consisting of

a) H, C_{1-7} alkyl, C_{2-7} alkenyl, C_{2-7} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl, benzo-fused C_{4-7} cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C_{3-7} cycloalkyl C_{1-7} alkyl,

b) naphthyl- (CR^s_2) -, benzoyl C_{0-3} alkyl- (CR^s_2) -, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f , phenyl- (CR^s_2) -, said phenyl optionally fused at two adjacent carbon atoms to R^f ,

R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl,

c) Ar^6 -(CR^s_2)-, where Ar^6 is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are -N= and optionally benzo fused or pyrido fused,

d) Ar^5 -(CR^s_2)-, where Ar^5 is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC $_{1-4}$ alkyl, having 0 or 1 additional

heteroatom member which is -N= and optionally benzo fused or pyrido fused,

e) $\text{Ar}^{6-6}-(\text{CR}^s)_2-$, where Ar^{6-6} is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are -N=,

f) $\text{Ar}^{6-5}-(\text{CR}^s)_2-$, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl and having 0 or 1 additional heteroatom member which is -N=,

g) C₁₋₄alkylO- and HSC₁₋₄alkyl,

where R¹ and R² are not simultaneously H and, except in positions where

R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q,

R^q is independently selected from the group consisting of C₁₋₄alkyl,

hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl,

C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO-C₁₋₄alkyl,

C₁₋₄alkylO-C₁₋₄alkyl, HS-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy and

C₁₋₄alkylS-,

R^s is independently selected from the group consisting of hydrogen,

C₁₋₄alkyl, trifluoromethyl, aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl,

diC₁₋₄alkylaminoC₁₋₄alkyl, HO-C₁₋₄alkyl, HS-C₁₋₄alkyl, C₁₋₄alkylS-

C₁₋₄alkyl and phenyl;

or, alternatively,

R¹ and R² may be taken together with the nitrogen to which they are attached and are selected from the group consisting of

i) 10-Oxa-4-aza-tricyclo[5.2.1.0^{2,6}]dec-4-yl, optionally mono- or di-substituted with R^p,

R^p is independently selected from the group consisting of hydroxy,

C₁₋₄alkyl, hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1

or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents R^p ,

5 iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 10 1 or 2 substituents R^p ,

iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 15 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional 20 heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^p ,

25 v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^p ;

R^a is, independently, selected from the group consisting of -C₁₋₆alkyl,

-C₂₋₆alkenyl, -C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl,

-OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, -SH, -SC₁₋₆alkyl,

-SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, -CN, -NO₂, -N(R^y)R^z (wherein R^y and

30 R^z are independently selected from H, C₁₋₄alkyl or C₁₋₆cycloalkyl/C₁₋₄alkyl),

-(C=O)C₁₋₄alkyl, -SCF₃, halo, -CF₃, -OCF₃, and -COOC₁₋₄alkyl, or,


alternatively, two adjacent R^a, may be taken together with the carbons of

attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;

R^b is, independently, selected from the group consisting of $-C_{1-4}$ alkyl and halogen;

5 and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.

32. A method for treating or preventing pancreatic adenocarcinoma, pain, gastro-esophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors and gastric tumors
10 comprising administering to a mammal in need of such treatment or prevention an effective dose of a compound of formula (I):



15 wherein

R^1 and R^2 are each independently selected from the group consisting of

a) H, C_{1-7} alkyl, C_{2-7} alkenyl, C_{2-7} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl,

benzo-fused C_{4-7} cycloalkyl where the point of attachment is a carbon atom adjacent to the ring junction, C_{3-7} cycloalkyl C_{1-7} alkyl,

20 b) naphthyl- (CR^s_2) -, benzoyl C_{0-3} alkyl- (CR^s_2) -, phenyl, said phenyl optionally fused at two adjacent carbon atoms to R^f , phenyl- (CR^s_2) -, said phenyl optionally fused at two adjacent carbon atoms to R^f ,

R^f is a linear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a
25 carbonyl,

- c) $\text{Ar}^6-(\text{CR}^s_2)-$, where Ar^6 is a 6-membered heteroaryl having carbon as a point of attachment, having 1 or 2 heteroatom members which are $-\text{N}=\text{}$ and optionally benzo fused or pyrido fused,
- 5 d) $\text{Ar}^5-(\text{CR}^s_2)-$, where Ar^5 is a 5-membered heteroaryl having carbon as a point of attachment, having 1 heteroatom member selected from the group consisting of O, S, $>\text{NH}$ or $>\text{NC}_{1-4}\text{alkyl}$, having 0 or 1 additional heteroatom member which is $-\text{N}=\text{}$ and optionally benzo fused or pyrido fused,
- 10 e) $\text{Ar}^{6-6}-(\text{CR}^s_2)-$, where Ar^{6-6} is phenyl having the point of attachment and fused to a 6-membered heteroaryl having 1 or 2 heteroatom members which are $-\text{N}=\text{}$,
- f) $\text{Ar}^{6-5}-(\text{CR}^s_2)-$, where Ar^{6-5} is phenyl having the point of attachment and fused to a 5-membered heteroaryl having 1 heteroatom member selected from the group consisting of O, S, $>\text{NH}$ or $>\text{NC}_{1-4}\text{alkyl}$ and
- 15 having 0 or 1 additional heteroatom member which is $-\text{N}=\text{}$,
- g) $\text{C}_{1-4}\text{alkylO}-$ and $\text{HSC}_{1-4}\text{alkyl}$,
- where R^1 and R^2 are not simultaneously H and, except in positions where R^s is indicated, each of a) to g) is substituted with 0, 1, 2, or 3 of R^q , R^q is independently selected from the group consisting of $\text{C}_{1-4}\text{alkyl}$,
- 20 hydroxy, fluoro, chloro, bromo, iodo, trifluoromethyl, amino $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkyl}$, di $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkyl}$, $\text{HO-C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylO-C}_{1-4}\text{alkyl}$, $\text{HS-C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylS-C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxy}$ and $\text{C}_{1-4}\text{alkylS}-$,
- R^s is independently selected from the group consisting of hydrogen,
- 25 $\text{C}_{1-4}\text{alkyl}$, trifluoromethyl, amino $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkyl}$, di $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkyl}$, $\text{HO-C}_{1-4}\text{alkyl}$, $\text{HS-C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylS-C}_{1-4}\text{alkyl}$ and phenyl;
- or, alternatively,
- R^1 and R^2 may be taken together with the nitrogen to which they are attached
- 30 and are selected from the group consisting of
- i) 10-Oxa-4-aza-tricyclo[5.2.1.0^{2,6}]dec-4-yl, optionally mono- or di-substituted with R^p ,

R^p is independently selected from the group consisting of hydroxy, C_{1-4} alkyl, hydroxy C_{1-4} alkyl, phenyl, mono-, di- or tri-halo substituted phenyl and hydroxyphenyl,

5 ii) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge and having 0, 1 or 2 substituents R^p,

10 iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 15 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R^p,

20 iv) a 4-7 membered heterocyclic ring said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered hydrocarbon ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR^p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R^p;

30 v) 8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, optionally having 0, 1 or 2 substituents R^p;

- R^a is, independently, selected from the group consisting of $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{3-6}$ cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, $-OH$, $-OC_{1-6}$ alkyl, $-OC_{3-6}$ cycloalkyl, $-O$ phenyl, $-O$ benzyl, $-SH$, $-SC_{1-6}$ alkyl, $-SC_{3-6}$ cycloalkyl, $-S$ phenyl, $-S$ benzyl, $-CN$, $-NO_2$, $-N(R^y)R^z$ (wherein R^y and R^z are independently selected from H , C_{1-4} alkyl or C_{1-6} cycloalkyl C_{1-4} alkyl), $-(C=O)C_{1-4}$ alkyl, $-SCF_3$, halo, $-CF_3$, $-OCF_3$, and $-COOC_{1-4}$ alkyl, or, alternatively, two adjacent R^a , may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl, pyridyl and pyrimidinyl;
- 5
- 10 R^b is, independently, selected from the group consisting of $-C_{1-4}$ alkyl and halogen;
- and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.